Patent Grant
10117812
This invention relates to foamable pharmaceutical and cosmetic compositions.
Foams and, in particular, foam emulsions are complicated systems which do not form under all circumstances. Changes in foam emulsion composition, such as by the addition of active ingredients may destabilize the foam. There is therefore a need for a foam composition which provides desirable properties to the skin and can remain stable whilst accommodating a variety of active ingredients.
U.S. Pat. No. 6,126,920 (“the '920 patent”) discloses treatment of various skin diseases, and in particular, scalp psoriasis, using a foamable pharmaceutical composition containing a corticosteroid active substance, an aliphatic alcohol, water, a fatty alcohol, a surface-active agent, a propellant and a buffering agent. The foamable composition contains 40-90% w/w composition of an aliphatic alcohol. The '920 patent is typical of many compositions that use aliphatic alcohols in the foam composition. The alcohol promotes fast drying and thereby attempts to address the sticky feeling left by many topical formulations after application; however, alcohols, and in particular the methyl, ethyl and isopropyl alcohols preferred in the '920 patent, are defatting agents and may cause skin to become dry and cracked. U.S. Pat. Application Pub. No. US2004/0151671 provides pharmaceutical compositions in a pressurized container, comprising a quick breaking alcoholic foaming agent. U.S. Pat. No. 5,783,202 provides a pediculicidal mousse composition containing a pediculicidal agent containing (a) from about 0.1 to about 10% w/w of a pediculicidal agent (b) about 70 to about 97% w/w of a foaming agent, which is preferably a quick breaking alcoholic foaming agent; and (c) from about 3 to about 20% w/w of an aerosol propellant. U.S. Pat. No. 6,730,288 teaches a pharmaceutical foam composition including (a) an active ingredient; (b) an occlusive agent; (c) an aqueous solvent; and (d) an organic cosolvent; wherein the active ingredient is insoluble in water and insoluble in both water and the occlusive agent; and wherein there is enough occlusive agent to form an occlusive layer on the skin.
A few dermatological foam products are available on the market.
Olux™ Foam, produced by Connetics, Inc., contains clobetasol propionate. Each gram of Olux™ Foam contains 0.5 mg clobetasol propionate, USP, in a thermolabile foam, which consists of ethanol (60%), purified water, propylene glycol, cetyl alcohol, stearyl alcohol, polysorbate 60, citric acid, and potassium citrate. It is dispensed from an aluminum can pressurized with a hydrocarbon propellant (propane/butane). Luxiq™ corticosteroid foam medication contains 1.2 mg betamethasone valerate per gram, in a vehicle, comprising ethanol (60.4%), purified water, propylene glycol, cetyl alcohol, stearyl alcohol, polysorbate 60, citric acid, and potassium citrate, and pressurized with a hydrocarbon propellant. Alcohol is known to impair the integrity of the skin barrier, dry the skin and cause skin irritation. The incidence skin irritation (burning, itching and stinging) as detailed the package inserts of the above mentioned products is very high (54%), probably due to the high alcohol content. Moreover, the respective incidence of skin irritation caused by the vehicle of these foams is 75%.
Thus, while alcohol is useful in solubilizing an active agent and enabling effective dermal penetration of an active agent is desirable, the development of a safe foam vehicle, which will overcome the evident skin drying and irritation caused by alcohol, is warranted.
Furthermore, foam compositions that possess a lesser degree of thermal sensitivity, thus being more useful for the treatment of large skin areas are desired.
The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition comprising:
(1) an organic carrier, at a concentration of about 10% to about 70% by weight, wherein said organic carrier concurrently comprises:
(2) at least one surface-active agent;
(3) water; and
(4) at least one liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
The present invention further relates to said composition comprising an active agent.
In some embodiments, the foamable cosmetic or pharmaceutical composition is non-flammable, wherein said gas propellant contains hydrofluorocarbon.
The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering a therapeutically effective amount of the above-mentioned compositions to an afflicted target site.
The present invention further provides use of a therapeutically effective amount of the above-mentioned compositions in the manufacture of a medicament.
The present invention further provides a therapeutically effective amount of the above-mentioned compositions for use in the manufacture of a medicament.
The present invention provides a safe and effective foamable cosmetic or pharmaceutical vehicle or composition. The vehicle or composition contains a polar solvent, which can optionally be a short-chain alcohol, which possesses (as such) skin drying and skin irritation properties; however, the composition also contains a hydrophobic carrier, which counteracts these undesirable effects and overcomes these drawbacks.
In one or more embodiments, the foamable cosmetic or pharmaceutical vehicle includes:
(1) an organic carrier, at a concentration of about 10% to about 70% by weight, wherein said organic carrier concurrently comprises:
(i) at least one hydrophobic organic carrier and
(ii) at least one polar solvent
(2) at least one surface-active agent;
(3) water; and
(4) at least one liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
In one or more embodiments the foamable cosmetic or pharmaceutical vehicle includes:
(1) an organic carrier, at a concentration of about 10% to about 70% by weight, wherein said organic carrier concurrently comprises
(i) at least one hydrophobic organic carrier, and
(ii) at least one polar solvent;
(2) about 0.1% to about 5% by weight of at least one surface-active agent;
(3) Water; and
(4) at least one liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
In one or more embodiments a foamable cosmetic or pharmaceutical vehicle is provided wherein the ratio of the hydrophobic organic carrier and the polar solvent are selected to provide a selected pharmacological or safety property;
In one or more embodiments a foamable cosmetic or pharmaceutical vehicle is provided also incorporating a polymeric agent.
In one or more embodiments the polymeric agent is selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent and can be from about 0.01% to about 5% by weight
In one or more embodiments, a pharmaceutical or cosmetic foamable product is provided, wherein a pharmaceutical or a cosmetic active agent is incorporated in a foamable vehicle, which contains a polar solvent and a hydrophobic organic carrier.
Thus, in one or more embodiments, the pharmaceutical or cosmetic foamable product comprises:
(1) an effective concentration of at least one pharmaceutical or cosmetic active agent;
(2) an organic carrier, at a concentration of about 10% to about 70% by weight, wherein said organic carrier concurrently comprises
(i) at least one hydrophobic organic carrier
(ii) at least one polar solvent;
(3) about 0.1% to about 5% by weight of at least one surface-active agent; and
(4) at least one liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
In one or more embodiments of the pharmaceutical or cosmetic foamable product is non-flammable.
Water and optional ingredients are added to complete the total mass to 100%.
All % values are provided on a weight (w/w) basis.
Polar Solvent
A “polar solvent” is an organic solvent, typically soluble in both water and oil. Certain polar solvents posses the beneficial property of a humectant, being a substance, which helps retain moisture, for example propylene glycol and glycerin.
In one or more embodiments, the polar solvent is a humectant.
According to one or more embodiments, the polar solvent comprises a short chain alcohol. Short chain alcohols, having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butanol, isobutanol, t-butanol and pentanol. In one or more embodiments the concentration of the short chain alcohols is from about 5% to about 70%, preferably from about 10% to about 60%.
In one or more embodiments, the polar solvent is a polyol. Polyols are organic substances that contain at least two hydroxy groups in their molecular structure.
In one or more embodiments, the polar solvent contains an diol (a compound that contains two hydroxy groups in its molecular structure), such as propylene glycol (e.g., 1,2-propylene glycol and 1,3-propylene glycol), butanediol (e.g., 1,4-butanediol), butanediol (e.g., 1,3-butanediol and 1,4-butenediol), butynediol, pentanediol (e.g., 1,5-pentanediol), hexanediol (e.g., 1,6-hexanediol), octanediol (e.g., 1,8-octanediol), neopentyl glycol, 2-methyl-1,3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol and dibutylene glycol.
In one or more embodiments, the polar solvent contains a triol (a compound that contains three hydroxy groups in its molecular structure), such as glycerin and 1,2,6-Hexanetriol.
Other non-limiting examples of polar solvents include pyrrolidones, (such as N-methyl-2-pyrrolidone and 1-methyl-2-pyrrolidinone), dimethyl isosorbide, 1,2,6-hexapetriol, dimethyl sulfoxide (DMSO), ethyl proxitol, dimethylacetamide (DMAc) and alpha hydroxy acids, such as lactic acid and glycolic acid.
According to still other embodiments, the polar solvent is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature, including PEG200 (MW (molecular weight) about 190-210 kD), PEG300 (MW about 285-315 kD), PEG400 (MW about 380-420 kD), PEG600 (MW about 570-630 kD) and higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
Polar solvents are known to enhance the penetration of active agent into the skin and through the skin, and therefore, their inclusion in the composition of the present invention is desirable, despite their undesirable skin drying and irritation potential. There is at one level a commonality between the different polar solvents and their penetration enhancement properties. However, lower molecular weight alcohols can sometimes be more potent as a solvent, for example by extracting lipids from the skin layers more effectively, which characteristic can adversely affect the skin structure and cause dryness and irritation. Therefore the selection of the hydrophobic carrier to counteract these negative effects may be of more importance when using the lower molecular weight alcohols.
Hydrophobic Solvent
A “hydrophobic organic carrier” as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL.
The identification of a hydrophobic organic carrier or “hydrophobic solvent”, as used throughout this specification synonymously, is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition. Rather, such information is provided to aid in the identification of materials suitable for use as a hydrophobic carrier in the foamable compositions described herein.
In one or more embodiments, the hydrophobic organic carrier is a high-melting point hydrocarbon, such as, petrolatum.
In one or more other embodiments the use of high melting point hydrocarbons, such as petrolatum in concentrations of more than 10%, are not desirable since they have a waxy feeling when applied to the skin; yet, in certain additional embodiments, when an extensive refatting effect is required, then petrolatum in concentrations of more than 10%, for example between about 10% and about 50% is included in the composition of the present invention.
According to one or more embodiments, hydrophobic solvents are liquid oils originating from vegetable, marine or animal sources. Suitable liquid oil includes saturated, unsaturated or polyunsaturated oils. By way of example, the unsaturated oil may be olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils or mixtures thereof, in any proportion.
Suitable hydrophobic solvents also include polyunsaturated oils containing poly-unsaturated fatty acids. In one or more embodiments, the unsaturated fatty acids are selected from the group of omega-3 and omega-6 fatty acids. Examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Such unsaturated fatty acids are known for their skin-conditioning effect, which contribute to the therapeutic benefit of the present foamable composition. Thus, the hydrophobic solvent can include at least 6% of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof.
In the context of the present invention, oils that possess therapeutically beneficial properties are termed as “therapeutically active oil.”
Another class of hydrophobic solvents is the essential oils, which are also considered therapeutically active oils, and which contain active biologically occurring molecules and, upon topical application, exert a therapeutic effect. Non-limiting examples of essential oils include rosehip oil, which contain retinoids and is known to reduce acne and post-acne scars, and tea tree oil, which possess antibacterial, antifungal and antiviral properties. Other examples of essential oils are oils of anise, basil, bergemont, camphor, cardamom, carrot, canola, cassia, catnip, cedarwood, citronella, clove, cypress, eucalyptus, frankincense, garlic, ginger, grapefruit, hyssop, jasmine, jojova, lavender, lavandin, lemon, lime, mandarin, marjoram, myrrh, neroli, nutmeg, orange, peppermint, petitgrain, rosemary, sage, spearmint, star anise, tangerine, thyme vanilla, verbena and white clover.
Another class of therapeutically active oils includes liquid hydrophobic plant-derived oils, which are known to possess therapeutic benefits when applied topically.
Silicone oils also may be used and are desirable due to their known skin protective and occlusive properties. Suitable silicone oils include non-volatile silicones, such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenyl-siloxane) copolymers. Silicone oils are also considered therapeutically active oil, due to their barrier retaining and protective properties.
A further class of hydrophobic carriers includes hydrophobic liquids, selected from the family of organic liquids described as “emollients.” Emollients possess a softening or soothing effect, especially when applied to body areas, such as the skin and mucosal surfaces. Examples of suitable emollients include isopropyl myristate, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, cetyl acetate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, octyl dodecanol, sucrose esters of fatty acids and octyl hydroxystearate.
The foamable composition of the present invention can be an emulsion, or microemulsion, including an aqueous phase and an organic carrier phase.
One non-limiting benefit of combining a polar solvent and a hydrophobic carrier is apparent in the resulting conservation of skin barrier properties.
Another non-limiting benefit of combining a polar solvent and a hydrophobic carrier is further apparent in the reduction of skin irritation.
Another non-limiting benefit of the vehicle or composition of the present invention is to provide increased penetration of the active or beneficial agent whilst replenishing the skin for example by moisturizing or adding fats or oils.
The ratio between the polar solvent and the hydrophobic carrier is determined according to the desirable pharmacologic and safety properties of the product. Typically, the polar solvent to hydrophobic carrier ranges between about 1:4 and about 4:1, for example, about 1:4, about 1:2, about 3:4, about 1:1, about 5:4, about 4:2, about 2:1, about 3:1 and about 4:1. When high solubilization and/or enhanced dermal or transdermal delivery of a drug is desirable, the polar solvent to hydrophobic carrier is selected within the range of about 1:1 and about 4:1, for example, about 1:1, about 5:4. about 6:4, about 7:4, about 2:1, about 3:1 and about 4:1 Yet, in other case, when the need of enhanced skin protection and skin barrier build-up is more pronounced, the polar solvent to hydrophobic carrier is selected within the range of about 2:8 and about 1:1, for example, about 1:4, about 1:2, about 3:4 and about 1:1.
The following table, Table 1 exemplifies, in a non-limiting manner, pairs of polar solvent and the hydrophobic carrier, as provided in the present invention. The examples of the previous paragraph are incorporated herein by reference.
In one or more embodiments, the polar solvent consists of a single polar solvent. Yet, in additional embodiments, the polar solvent consists of a combination of two or more polar solvents.
In one or more embodiments, the hydrophobic carrier consists of a single polar solvent. Yet, in additional embodiments, the hydrophobic carrier consists of a combination of two or more hydrophobic carriers.
In order to derive a composition which is readily foamable upon release from a pressurized container, additional components are required, as provided hereinbelow.
Surface Active Agent
Surface-active agents (also termed “surfactants”) include any agent linking oil and water in the composition, in the form of emulsion. A surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics. Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions. The HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average). The surface-active agent according to the present invention has an HLB value, suitable for stabilizing an emulsion comprising the aqueous phase and the organic carrier of the composition.
According to one or more embodiments of the present invention, the surface-active agent has a hydrophilic lipophilic balance (HLB) between about 9 and about 14, which is the required HLB (the HLB required to stabilize an O/W emulsion of a given oil) of most oils and hydrophobic solvents. Thus, in one or more embodiments, the composition contains a single surface active agent having an HLB value between about 9 and about 14 (e.g., about 9, about 10, about 11, about 12, about 13 and about 14), and in one or more embodiments, the composition contains more than one surface active agent and the weighted average of their HLB values is between about 9 and about 14 (e.g. about 9, about 10, about 11, about 12, about 13 and about 14). Yet, in other embodiments, when a water-in-oil emulsion is desirable, the composition contains one or more surface-active agents, having an HLB value between about 2 and about 9 (e.g., about 2, about 3, about 4, about 5, about 6, about 7, about 8 and about 9).
The surface-active agent is selected from anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants. Such surfactants are well known to those skilled in the therapeutic and cosmetic formulation art. Non-limiting examples of possible surfactants include polysorbates, such as polyoxyethylene (20) sorbitan monostearate (Tween 60) and poly(oxyethylene) (20) sorbitan monooleate (Tween 80); poly(oxyethylene) (POE) fatty acid esters, such as Myrj 45, Myrj 49, Myrj 52 and Myrj 59; poly(oxyethylene) alkylyl ethers, such as poly(oxyethylene) cetyl ether, poly(oxyethylene) palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1; sucrose esters, partial esters of sorbitol and its anhydrides, such as sorbitan monolaurate and sorbitan monolaurate; mono or diglycerides, isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
In one or more embodiments of the present invention, the surface-active agent includes a non-ionic surfactant. Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. We have surprisingly found that non-ionic surfactants alone provide foams of excellent quality, i.e. a score of “E” according to the grading scale discussed herein below.
In one or more embodiments, the surface-active agent includes a mixture of a non-ionic surfactant and an ionic surfactant in a ratio in the range of about 100:1 to about 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1, or greater than about 8:1; or greater than about 14:1, or greater than about 16:1, or greater than about 20:1.
In one or more embodiments of the present invention, a combination of a non-ionic surfactant and an ionic surfactant (such as sodium lauryl sulphate and cocamidopropylbetaine) is employed, at a ratio of between 1:1 and 20:1, for example, about 1:1, about 4:1, about 8:1, about 12:1, about 16:1 and about 20:1 or at a ratio of 4:1 to 10:1, for example, about 4:1, about 6:1, about 8:1 and about 10:1. The resultant foam has a low specific gravity, e.g., less than 0.1 g/ml.
Thus, in an exemplary embodiment, a combination of an non-ionic surfactant having HLB of less than about 9 and an non-ionic surfactant having HLB of equal or more than about 9 is employed, at a ratio of between about 1:8 and about 8:1, or at a ratio of about 4:1 to about 1:4, wherein the HLB of the combination of emulsifiers is between about 9 and about 14.
In one or more embodiments of the present invention, the surface-active agent includes mono-, di- and trimesters of sucrose with fatty acids (sucrose esters), prepared from sucrose and esters of fatty acids or by extraction from sucro-glycerides. Suitable sucrose esters include those having high monoester content, which have higher HLB values.
The total surface-active agent is in the range of about 0.1 to about 5% of the composition, and is occasionally less than about 2% or less than about 1%.
Polymeric Agent
In one or more embodiments, the foamable composition contains a polymeric agent. The polymeric agent serves to stabilize the foam composition and to control drug residence in the target organ. Exemplary polymeric agents are classified below in a non-limiting manner. In certain cases, a given polymer can belong to more than one of the classes provided below.
In one or more embodiments, the composition of the present invention includes a gelling agent. A gelling agent controls the residence of a therapeutic composition in the target site of treatment by increasing the viscosity of the composition, thereby limiting the rate of its clearance from the site. Many gelling agents are known in the art to possess mucoadhesive properties.
The gelling agent can be a natural gelling agent, a synthetic gelling agent and an inorganic gelling agent. Exemplary gelling agents that can be used in accordance with one or more embodiments of the present invention include, for example, naturally-occurring polymeric materials, such as locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g. hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, carboxymethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxypropylmethyl cellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose and carboxymethylhydroxyethylcellulose), guar gum, hydroxypropyl guar gum, soluble starch, cationic celluloses, cationic guars, and the like, and synthetic polymeric materials, such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like. Mixtures of the above compounds are also contemplated.
Further exemplary gelling agents include the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers. Non-limiting examples include Carbopol® 934, Carbopol® 940, Carbopol® 950, Carbopol® 980, Carbopol® 951 and Carbopol® 981.
Yet, in other embodiments, the gelling agent includes inorganic gelling agents, such as silicone dioxide (fumed silica).
Mucoadhesive/bioadhesion has been defined as the attachment of synthetic or biological macromolecules to a biological tissue. Mucoadhesive agents are a class of polymeric biomaterials that exhibit the basic characteristic of a hydrogel, i.e. swell by absorbing water and interacting by means of adhesion with the mucous that covers epithelia. Compositions of the present invention may contain a mucoadhesive macromolecule or polymer in an amount sufficient to confer bioadhesive properties. The bioadhesive macromolecule enhances the delivery of biologically active agents on or through the target surface. The mucoadhesive macromolecule may be selected from acidic synthetic polymers, preferably having an acidic group per four repeating or monomeric subunit moieties, such as poly(acrylic)- and/or poly(methacrylic) acid (e.g., Carbopol®, Carbomer®), poly(methylvinyl ether/maleic anhydride) copolymer, and their mixtures and copolymers; acidic synthetically modified natural polymers, such as carboxymethylcellulose (CMC); neutral synthetically modified natural polymers, such as (hydroxypropyl)methylcellulose; basic amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources, such as alginic acid, hyaluronic acid, pectin, gum tragacanth, and karaya gum; and neutral synthetic polymers, such as polyvinyl alcohol or their mixtures. An additional group of mucoadhesive polymers includes natural and chemically modified cyclodextrin, especially hydroxypropyl-β-cyclodextrin. Such polymers may be present as free acids, bases, or salts, usually in a final concentration of about 0.01% to about 0.5% by weight. Many mucoadhesive agents are known in the art to also possess gelling properties.
In one or more embodiments, the polymeric agent contains a film-forming component. The film-forming component may include a water-insoluble alkyl cellulose or hydroxyalkyl cellulose. Exemplary alkyl cellulose or hydroxyalkyl cellulose polymers include ethyl cellulose, propyl cellulose, butyl cellulose, cellulose acetate, hydroxypropyl cellulose, hydroxybutyl cellulose, and ethylhydroxyethyl cellulose, alone or in combination. In addition, a plasticizer or a cross-linking agent may be used to modify the polymer's characteristics. For example, esters such as dibutyl or diethyl phthalate, amides such as diethyldiphenyl urea, vegetable oils, fatty acids and alcohols such as oleic and myristyl acid may be used in combination with the cellulose derivative.
In one or more embodiments, the polymeric agent includes a phase change polymer, which alters the composition behavior from fluid-like prior to administration to solid-like upon contact with the target mucosal surface. Such phase change results from external stimuli, such as changes in temperature or pH and exposure to specific ions (e.g., Ca2+). Non-limiting examples of phase change polymers include poly(N-isopropylamide) and Poloxamer 407®.
The polymeric agent is present in an amount in the range of about 0.01% to about 5.0% by weight of the foam composition. In one or more embodiments, it is typically less than about 1 wt % of the foamable composition.
Preferably, a therapeutically effective foam adjuvant is included in the foamable compositions of the present invention to increase the foaming capacity of surfactants and/or to stabilize the foam. In one or more embodiments of the present invention, the foam adjuvant agent includes fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof). Other examples of fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50). Fatty alcohols, derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvant agents. The amount of the fatty alcohol required to support the foam system is inversely related to the length of its carbon chains. Foam adjuvants, as defined herein are also useful in facilitating improved spreadability and absorption of the composition.
In one or more embodiments of the present invention, the foam adjuvant agent includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof. As for fatty alcohols, the amount of fatty acids required to support the foam system is inversely related to the length of its carbon chain.
In one or more embodiments, a combination of a fatty acid and a fatty ester is employed.
Optionally, the carbon atom chain of the fatty alcohol or the fatty acid may have a double bond. A further class of foam adjuvant agent includes a branched fatty alcohol or fatty acid. The carbon chain of the fatty acid or fatty alcohol also can be substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
A property of the fatty alcohols and fatty acids used in context of the composition of the present invention is related to their therapeutic properties per se. Long chain saturated and mono unsaturated fatty alcohols, e.g., stearyl alcohol, erucyl alcohol, arachidyl alcohol and behenyl alcohol (docosanol) have been reported to possess antiviral, antiinfective, antiproliferative and antiinflammatory properties (see, U.S. Pat. No. 4,874,794). Longer chain fatty alcohols, e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc., are also known for their metabolism modifying properties and tissue energizing properties. Long chain fatty acids have also been reported to possess anti-infective characteristics.
In one or more embodiments, the active agent is encapsulated in particles, microparticles, nanoparticles, microcapsules, spheres, microspheres, nanocapsules, nanospheres, liposomes, niosomes, polymer matrix, nanocrystals or microsponges.
The composition of the present invention may further optionally include a variety of formulation excipients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and modify their consistency. Such excipients may be selected, for example, from stabilizing agents, antioxidants, humectants, preservatives, colorant and odorant agents and other formulation components, used in the art of formulation.
Aerosol propellants are used to generate and administer the foamable composition as a foam. The total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable carrier. The propellant makes up about 3% to about 25% (w/w) of the foamable carrier or composition. Examples of suitable propellants include volatile hydrocarbons such as butane, propane, isobutane or mixtures thereof, and fluorocarbon gases.
Non-Flammable Stable Foam Compositions
Alcohol and organic solvents render foams inflammable. It has been surprisingly discovered that fluorohydrocarbon propellants, other than chloro-fluoro carbons (CMCs), which are non-ozone-depleting propellants, are particularly useful in the production of a non-flammable foamable composition. A test according to European Standard prEN 14851, titled “Aerosol containers-Aerosol foam flammability test” revealed that compositions containing an organic carrier that contains a hydrophobic organic carrier and/or a polar solvent, which are detected as inflammable when a hydrocarbon propellant is used, become non-flammable, while the propellant is an HFC propellant.
Such propellants include, but are not limited to, hydrofluorocarbon (HFC) propellants, which contain no chlorine atoms, and as such, fall completely outside concerns about stratospheric ozone destruction by chlorofluorocarbons or other chlorinated hydrocarbons. Exemplary non-flammable propellants according to this aspect of the invention include propellants made by DuPont under the registered trademark Dymel, such as 1,1,1,2 tetrafluoroethane (Dymel 134), and 1,1,1,2,3,3,3 heptafluoropropane (Dymel 227). HFCs possess Ozone Depletion Potential of 0.00 and thus, they are allowed for use as propellant in aerosol products.
Notably, the stability of foamable emulsions including HFC as the propellant is improved in comparison with the same composition made with a hydrocarbon propellant.
Active Agents
It is to be understood that the active agents useful herein can in some instances provide more than one benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active agent to that particular application or applications listed.
The composition of the present invention comprises an active agent that provides therapeutic or cosmetic activity.
Non-limiting examples of active agents include an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, a steroid, a vasoactive agent, a vasoconstrictor, a vasodilator, vitamin A, a vitamin A derivative, a retinoid, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin D, a vitamin D derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a burn healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, an allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, an insecticide, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, an anti-wrinkle agent, a radical scavenger, a metal oxide (e.g., titanium dioxide, zinc oxide, zirconium oxide, iron oxide), silicone oxide, talc, an anti-acne agent, a skin whitening agent, a self tanning agent, an anti-cellulite agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof at any proportion. The concentration of the active agent can be adapted to exert a therapeutic effect on a disease when applied to an afflicted area. Various different therapeutic effects of the herbs and their extracts are, for example, illustrated in the above-mentioned references.
In one or more embodiments the active agent may be an extract or tincture of one or more beneficial agents that have beneficial properties, for example, when applied to the skin, a body surface, a body cavity or a mucosal surface. The extract can be, for example, alcoholic, hydroalcoholic, propylene glycol, glycerine, dry, press, cold, hot, liquid carbon dioxide, oil or other process known in the art. The extract or tincture may comprise of substances of animal, plant, (such as herb, fruit, vegetable) mineral or other origin. Nonlimiting examples are proteins, polypeptides, sugars, hyularonic acid, and coal tar. Herbal extracts may be from any known therapeutic herb, as listed for example in Herbal Medicines, London: Pharmaceutical Press Electronic Version 2006 or in the American Herbal Association electronic publication Herbal gram or in German Commission E., such as, angelica, calendula, celery, coltsfoot, comfrey, dandelion, jamaica dogwood, kava, marshmallow, prickly ash, northem prickly ash, southern senna, valerian, agrimony, aloe vera, alfalfa, artichoke, avens, bayberry, bloodroot, blue flag, bogbean, boldo, boneset, broom, buchu, burdock, burnet, calamus, calendula, cascara, centaury, cereus, chamomile, german chamomile, roman chamomile, cinnamon, clivers, cohosh, black, cohosh, blue, cola, corn silk, couchgrass, cowslip, damiana, devil's claw, drosera, echinacea, elder, elecampane, euphorbia, eyebright, figwort, frangula, fucus, fumitory, garlic, golden seal, gravel root, ground ivy, guaiacum, hawthorn, holy thistle, hops, horehound black, horehound white, horse chestnut hydrangea, ispaghula, juniper, lady's lipper, liferoot, lime flower, liquorice, lobelia, maté, meadowsweet, mistletoe, motherwort, myrrh, nettle, parsley, parsley piert, passionflower, pennyroyal, pilewort, plantain, pleurisy root, pokeroot, poplar, pulsatilla, queen's delight, raspberry, red clover, rosemary, sage, sarsaparilla, sassafras, scullcap, senega, shepherd's purse, skunk cabbage, slippery elm, squill, St. john's wort, stone root, tansy, thyme, uva-ursi, vervain, wild carrot, wild lettuce, willow, witch hazel, yarrow and yellow dock.
When the extract is dissolved in a polar solvent, such as a short chain alcohol (e.g., ethanol and isopropyl alcohol), propylene glycol and glycerin, then the polar solvent of the extract can also comprise part or all of the “polar solvent” component of the foamable composition, as specified throughout this specification and likewise the polar solvent of the foamable composition can also comprise as part or all of the “polar solvent” component of the extract.
In one or more embodiments, the active agent is an anti-infective agent, selected from an antibiotic agent, an antibacterial agent, an anti-fungal agent, an anti-viral agent and an anti-parasite agent.
The antibacterial drug can be active against gram positive and gram-negative bacteria, protozoa, aerobic bacteria and unaerobic ones.
In one or more embodiments, the antibiotic agent is selected from the classes consisting of beta-lactam antibiotics, synthetic and semi-synthetic penicillins, aminoglycosides, ansa-type antibiotics, anthraquinones, antibiotic azoles, antibiotic glycopeptides, macrolides, antibiotic nucleosides, antibiotic peptides, antibiotic polyenes, antibiotic polyethers, quinolones, fluoroquinolones, antibiotic steroids, cyclosporines, sulfonamides, tetracycline, chloramphenicol, dicarboxylic acids, such as azelaic acid, salicylates, antibiotic metals, oxidizing agents, substances that release free radicals and/or active oxygen, cationic antimicrobial agents, quaternary ammonium compounds, biguanides, triguanides, bisbiguanides and analogs and polymers thereof and naturally occurring antibiotic compounds.
Additional antibacterial agents, which are non-specific, include strong oxidants and free radical liberating compounds, such as hydrogen peroxide, bleaching agents (e.g., sodium, calcium or magnesium hydochloride and the like), iodine, chlorohexidine and benzoyl peroxide.
The antifungal agent can be an azole compound. Exemplary azole compounds include azoles selected from the group consisting of azoles, diazoles, triazoles, miconazole, ketoconazole, clotrimazole, econazole, mebendazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, thiabendazole, tiaconazole, fluconazole, itraconazole, ravuconazole and posaconazole.
Additional exemplary antifungal agents include griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B, potassium iodide, flucytosine (5FC) and any combination thereof at a therapeutically effective concentration.
In one or more embodiments, the active agent is an anti-viral agent. Any known antiviral agent, in a therapeutically effective concentration, can be incorporated in the foam composition of the present invention. Exemplary antiviral agents include, but not limited to, acyclovir, famciclovir, gancyclovir, valganciclovir and abacavir.
In another embodiment according to the present invention, the active agent is an anti-inflammatory or anti-allergic agent. Anti-inflammatory agents can be selected from the group of corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-histamines, immunosuppressant agents, immunomodulators; and any combination thereof at a therapeutically effective concentration.
Non-limiting examples of corticosteroids include hydrocortisone, hydrocortisone acetate, desonide, betamethasone valerate, clobetasone-17-butyrate, fluocinonide, fluocinolone acetonide, alcometasone dipropionate, mometasone furoate, prednicarbate, triamcinolone acetonide, betamethasone-17-benzoate, methylprednisolone aceponate, betamethasone dipropionate, halcinonide, triamcinolone acetonide, halobetasol and clobetasol-17-propionate.
A second class of anti-inflammatory agents, which is useful in the foam of the present invention, includes the nonsteroidal anti-inflammatory agents (NSAIDs). The variety of compounds encompassed by this group is well known to those skilled in the art. Specific non-steroidal anti-inflammatory agents useful in the composition invention include, but are not limited to, oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam; salicylates, such as salicylic acid, ethyl salicylate, methyl salycilate, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; scetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac; fenamates, such as mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acids; propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indopropfen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic; and pyrazoles, such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, and trimethazone.
Any further steroidal and nonsteroidal compounds, having the capacity to prevent, alleviate the symptoms of, treat or cure inflammation processes, are generally included, as possible anti-inflammatory agents, according to the present invention.
Antiallergic active agents include antihistamine compounds, including, in a non limiting manner, thylenediamines, such as pyrilamine (mepyramine), antazoline and methapyrilene; tripelennamine phenothiazines, such as promethazine, methdilazine and trimeprazine; ethanolamines, such as diphenhydramine, bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenylpyraline, doxylamine and phenyltoxamine; piperazines, such as cyclizine, buclizine, chlorcyclizine, hydroxyzine, meclizine and thiethylperazine; alkylamines, such as brompheniramine, pyrrobutamin, desbrompheniramine, tripolidine, dexchlorpherniramine, chlorpheniramine; dimethindene and pheniramine; and piperidines, such as cyproheptadine and azatadine. These active agents, as well as additional antihistamines can also be incorporated in the composition of the present invention.
The composition of the present invention may also comprise an anti-inflammatory or antiallergic agent, wherein said agent reduces the occurrence of pro-inflammatory cytokines or inhibits the effect of pro-inflammatory cytokines.
Immunosuppressant agents, immunoregulating agents and immunomodulators are chemically or biologically derived agents that modify the immune response or the functioning of the immune system (as by the stimulation of antibody formation or the inhibition of white blood cell activity). Immunosuppressant agents and immunomodulators include, among other options, cyclic peptides, such as cyclosporine, tacrolimus, tresperimus, pimecrolimus, sirolimus (rapamycin), verolimus, laflunimus, laquinimod and imiquimod.
In one or more embodiments, the active agent is a topical anesthetic. Examples of topical anesthetic drugs include, but not limited to, benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, and phenol. Mixtures of such anesthetic agents may be synergistically beneficial.
In one or more embodiments, the active agent is a “keratolytically active agent.” The term “keratolytically active agent” refers herein to a compound which loosens and removes the stratum corneum of the skin, or alters the structure of the keratin layers of the skin.
Suitable keratolytically active agents include phenol and substituted phenolic compounds. Such compounds are known to dissolve and loosen the intracellular matrix of the hyperkeratinized tissue. Dihydroxy benzene and derivatives thereof have been recognized as potent keratolytic agents. Resorcinol (m-dihydroxybenzene) and derivatives thereof are used in anti-acne preparations. Hydroquinone (p-dihydroxybenzene), besides its anti-pigmentation properties, is also keratolytic.
Vitamin A and its derivatives, such as retinoic acid, isoretinoic acid, retinol and retinal are another preferred class of keratolytically active agents.
Another group of keratolytically active agents include alpha-hydroxy acids, such as lactic acid and glycolic acid and their respective salts and derivatives; and beta-hydroxy acids, such as Salicylic acid (o-hydroxybenzoic acid) and its salts and pharmaceutically acceptable derivatives, which typically possess anti-inflammatory, as well as keratolytic, activity. Yet, another class of preferred keratolytically active agents includes urea and its derivatives.
In one or more embodiments, the active agent is a retinoid. Retinoids include, for example, retinol, retinal, all-trans retinoic acid and derivatives, isomers and analogs thereof. Etretinate, actiretin, isotretinoin, adapalene and tazarotene are further examples of said retinoid isomers and analogs.
In one or more embodiments, the active agent is an insecticide or an insect repellent agent.
In one or more embodiments, the active agent is an anti cancer agent.
In one or more embodiments, the active agent is a photodynamic therapy (PDT) agent. By way of example, such PDT agents can be modified porphyrins, chlorins, bacteriochlorins, phthalocyanines, naphthalocyanines, pheophorbides, purpurins, m-THPC, mono-L-aspartyl chlorin e6, bacteriochlorins, phthalocyanines, benzoporphyrin derivatives, as well as photosensitizer precursors, such as aminolevulinic acid (ALA).
In one or more embodiments, the active agent is an agent useful in the treatment of burns, wounds, cuts and ulcers. The foam compositions of the present invention may comprise a combination of anti-infective agents (against bacteria, fungi and/or viruses), anti-inflammatory agents (steroidal and/or NSAIDs) and pain relieving components.
The foam compositions of the present invention, with or without further active ingredients, are suitable for the further application as “cosmeceutical” preparation (cosmetic products with therapeutic benefit), to treat “cosmetic” skin disorders, such as aging skin, wrinkles, hyperpigmentation (melasma, chloasma, freckles, etc.), scaly skin and other skin undesirable properties.
Any cosmetically active agent is considered an active agent in the context of the present invention. The CTFA Cosmetic Ingredient Handbook describes a wide variety of non-limiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention. Examples of these ingredient classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, astringents, etc. (e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate), anti-acne agents, anti-caking agents, antifoaming agents, anti-microbial agents (e.g., iodopropyl butylcarbamate), antioxidants, binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film-forming properties and substantivity of the composition (e.g., copolymer of eicosene and vinyl pyrrolidone), opacifying agents, pH adjusters, propellants, reducing agents, sequestrants, skin bleaching and lightening agents (e.g., hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl glucosamine), skin-conditioning agents (e.g., humectants, including miscellaneous and occlusive), skin soothing and/or healing agents (e.g., panthenol and derivatives (e.g., ethyl panthenol), aloe vera, pantothenic acid and its derivatives, allantoin, bisabolol, and dipotassium glycyrrhizinate), skin treating agents, and vitamins and derivatives thereof.
In one or more embodiments, the active agent is an agent useful in the treatment of acne, wrinkles and scars. Examples of useful anti-acne actives include resorcinol, sulfur, salicylic acid and salicylates, alpha-hydroxy acids, nonsteroidal anti-inflammatory agents, benzoyl peroxide, retinoic acid, isoretinoic acid and other retinoid compounds, adapalene, tazarotene, azelaic acid and azelaic acid derivatives, antibiotic agents, such as erythromycin and clyndamycin, zinc salts and complexes, and combinations thereof, in a therapeutically effective concentration. Exemplary anti-wrinkle/anti-atrophy active agents suitable for use in the compositions of the present invention include sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives; thiols; hydroxy acids (e.g., alpha-hydroxy acids such as lactic acid and glycolic acid and their derivatives and salts; or beta-hydroxy acids such as salicylic acid and salicylic acid salts and derivatives), urea, hyaluronic acid, phytic acid, lipoic acid; lysophosphatidic acid, skin peel agents (e.g., phenol, resorcinol and the like), vitamin B3 compounds (e.g., niacinamide, nicotinic acid and nicotinic acid salts and esters, including non-vasodilating esters of nicotinic acid (such as tocopheryl nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide), vitamin B5 and retinoids (e.g., retinol, retinal, retinoic acid, retinyl acetate, retinyl palmitate, retinyl ascorbate). In the case of dry, scaly skin (xerosis) and ichthyosis such agents can alleviate the symptoms by temporary relief of itching associated with these conditions.
In one or more embodiments, the active agent is an anti-oxidant or a radical scavenger. Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid and its salts, lycine pidolate, arginine pilolate, nordihydroguaiaretic acid, bioflavonoids, curcumin, lysine, methionine, proline, superoxide dismutase, silymarin, tea extracts, grape skin/seed extracts, melanin, and rosemary extracts may be used.
It is further pointed out that polyunsaturated fatty acids, containing omega-3 and omega-6 fatty acids (e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are beneficial in the treatment of psoriasis and other skin inflammation conditions. Likewise, emollients and silicone oils exert moisture-retaining and skin protective effects on the skin. Thus, in a preferred embodiment, a skin protective foam is provided, wherein the hydrophobic carrier comprises in full or in part, an organic liquid selected from the group consisting of emollients, silicone oil and oils rich in unsaturated fatty acids.
In one or more embodiments, the active agent is a self-tanning active Agent, such as dihydroxyacetone.
According to another embodiment, the active agent comprises solid matter or particulate matter, i.e., material that is not soluble in the liquid carrier composition of the foamable composition. For definition purposes, solid matter shall mean material that is not soluble in the foamable composition more than 10% of the concentration intended to be included in said foamable composition. By way of example, the following classes of solid matter substances are presented: metallic oxides, such as titanium dioxide, zinc oxide, zirconium oxide, iron oxide; silicon containing materials such as silicone oxide and talc; carbon, for example in the form of amorphous carbon or graphite; insoluble oxidizing agents, such as benzoyl peroxide, calcium and magnesium hypochlorite; metallic Silver; cosmetic scrub materials, including, for example meals of strawberry seeds, raspberry seeds, apricot seeds, sweet almond, cranberry seeds; and pigments.
According to certain embodiments, the active agent is selected from the group of solvent, surface active agent, foam adjuvant and gelling agent, which are, on a case-by-case basis, known to possess a therapeutic benefit.
In one or more embodiments at least one or at least two active agents are included in the composition.
Composition and Foam Physical Characteristics and Advantages
A pharmaceutical or cosmetic composition manufactured using the foamable carrier of the present invention is very easy to use. When applied onto the afflicted body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
The foamable composition can be in the state of (1) solutions; (2) a readily dispersable suspension; or (3) an emulsion. It is stable, having an acceptable shelf life of a year, or at least two years at ambient temperature, as revealed in accelerated stability tests. Polar solvents, hydrophobic carriers and propellants, which are a mixture of low molecular weight hydrocarbons, tend to impair the stability of emulsions and to interfere with the formation of a stable foam upon release from a pressurized container. It has been observed, however, that the foamable compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
The composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam. Compositions containing semi-solid hydrophobic solvents, e.g., white petrolatum, as the main ingredients of the oil phase of the emulsion, exhibit high viscosity and poor flowability and are inappropriate candidates for a foamable composition.
Foam quality can be graded as follows:
Grade E (excellent): very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
Grade G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
Grade F (fair): very little creaminess noticeable, larger bubble structure than a “fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery.
Grade P (poor): no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
Grade VP (very poor): dry foam, large very dull bubbles, difficult to spread on the skin.
Topically administrable foams are typically of quality grade E or G, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
As a further aspect of the foam is breakability. The breakable foam is thermally stable, yet breaks under sheer force. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
The foam of the present invention has several advantages, when compared with hydroalcoholic foam compositions, such as described in U.S. Pat. Nos. 6,126,920 and 5,783,202:
In terms of usability, the foamable composition is most advantageous, as revealed by clinical trials:
(i) Ease of Application.
(ii) The Foam is Drip-Free
Another property of the foam is specific gravity, as measured upon release from the aerosol can. Typically, foams have specific gravity of less than 0.12 g/mL; or less than 0.12 g/mL; or less than 0.08 g/mL, depending on their composition and on the propellant concentration.
For the purpose of the specification the external limits of the various ranges given are approximate as will be appreciated by those skilled in the art. Therefore, for the purpose of interpreting the outer limits of the range the limits shall be deemed to include up to a 20% leeway outside the range, preferably a 10% leeway.
Fields of Applications
According to one or more embodiments of the present invention, the foamable carrier and the foamable pharmaceutical or cosmetic composition of the present invention are intended for administration to an animal or a human subject. In one or more embodiments, the composition is intended to treat the skin, a body surface, a body cavity or a mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum.
By including an appropriate active agent in the compositions of the present invention, the composition are useful in treating a patient having any one of a variety of dermatological disorders, which include inflammation as one or their etiological factors (also termed “dermatoses”), such as classified in a non-limiting exemplary manner according to the following groups:
Dermatitis including contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis; lichen simplex chronicus; diaper rash;
Bacterial infections including cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, and erythrasma;
Fungal Infections including dermatophyte infections, yeast Infections; parasitic Infections including scabies, pediculosis, creeping eruption;
Viral Infections;
Disorders of hair follicles and sebaceous glands including acne, rosacea, perioral dermatitis, hypertrichosis (hirsutism), alopecia, including male pattern baldness, alopecia areata, alopecia universalis and alopecia totalis; pseudofolliculitis barbae, keratinous cyst;
Scaling papular diseases including psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris;
Benign tumors including moles, dysplastic nevi, skin tags, lipomas, angiomas, pyogenic granuloma, seborrheic keratoses, dermatofibroma, keratoacanthoma, keloid;
Malignant tumors including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, paget's disease of the nipples, kaposi's sarcoma;
Reactions to sunlight, including sunburn, chronic effects of sunlight, photosensitivity;
Bullous diseases including pemphigus, bullous pemphigoid, dermatitis herpetiformis, linear immunoglobulin A disease;
Pigmentation disorders including hypopigmentation such as vitiligo, albinism and postinflammatory hypopigmentation and hyperpigmentation such as melasma (chloasma), drug-induced hyperpigmentation, postinflammatory hyperpigmentation;
Disorders of cornification including ichthyosis, keratosis pilaris, calluses and corns, actinic keratosis;
Pressure sores, open wounds, chronic wounds, open ulcers and burns;
Disorders of sweating; and
Inflammatory reactions including drug eruptions, toxic epidermal necrolysis, erythema multiforme, erythema nodosum, and granuloma annulare.
The same advantage is expected when the composition is topically applied to a body cavity or mucosal surfaces, including, but not limited to the cranial cavity, the thoratic cavity, the abdominal cavity, the venteral cavity, the vagina, the rectum and penile cavities, the urinary tract, the nasal cavity, the mouth, the eye, the ear the peritoneum, the large and small bowel, the caecum, bladder, and stomach, the cavity between the uterus and the fallopian tubes, the ovaries and other body areas, which may accept topically-applied products. The composition of the present invention is suitable to treat conditions of a body cavity and a mucosal membrane, such as post-surgical adhesions, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum.
According to one or more embodiments of the present invention, the compositions are also useful in the therapy of non-dermatological disorders by providing transdermal or trans-mucosal delivery of an active agent that is effective against non-dermatological disorders.
In one or more embodiments, the disorder is a health abnormality that responds to treatment with a hormone. A typical example of such abnormality is sexual dysfunction in men and women whereby androgen therapy is successfully used to restore sexual function. Other non-limiting examples of disorders/medical indications that are in the scope of treatment with a hormone according to the present invention are androgen deficiency, estrogen deficiency, growth disorders, hypogonadism, cancer, vasomotor symptoms, menopausal disorders, vulvar and vaginal atrophy, urethritis, hypoestrogenism, osteoarthritis, osteoporosis, uterine bleeding, Hirsutism, Virilization, ovarian tumors, hypothalamic pituitary unit diseases, testicular tumors, prostate cancer, hypopituitarism, Klinefelter's syndrome, testicular feminisation, orchitectomy, vasomotor symptoms (such as “hot flashes”) associated with the menopause, metabolic abnormalities and mood disturbances.
The following examples further exemplify the, foamable carrier, the pharmaceutical and cosmetic compositions of the present invention, methods for preparing the same, and therapeutic uses of the compositions. The examples are for the purposes of illustration only and are not intended to be limiting of the invention. Many variations may be carried out by one of ordinary skill in the art and are contemplated within the full scope of the present invention.
A general procedure for preparing foamable compositions is set out in WO 2004/037225 which is incorporated herein by reference. Moreover, with respect to using one or more polar solvents, the polor solvent is added to the aqueous phase mixture in the course of preparation.
The following compositions were tested for inflammability according to European Standard prEN 14851: (1) Foam F; (2) Foam I; (3) Foam J; and (4) Foam K.
Procedure: Approximately 5 g of foam, mousse gel or paste is sprayed from the aerosol container on to a watchglass. An ignition source (a lighter) was placed at the base of the watchglass and any ignition and sustained combustion of the foam, mousse, gel or paste was observed. The test was carried out in a draught-free environment capable of ventilation, with the temperature controlled at 20° C.±5° C. and relative humidity in the range of 30% to 80%. According to the standard, appearance of a stable flame which is at least 4 cm high and which is maintained for at least 2 seconds defines a product as “inflammable”.
Results:
Foam F and Foam I were found “inflammable”.
Foam J and Foam K were found “non-flammable”.
Exemplary concentrations of active agents in foamable compositions are set out in Table 2. Each active agent is added into, for example, any of the carriers listed in any of Examples 1 to 5 above in a therapeutically effective concentration and amount. The methodology of addition is well known to those of the art. The composition is adjusted in each case so that it is made up to 100% w/w appropriate by purified water.
The above examples represent different drug classes and it is to be understood that other drugs belonging to each of the classes represented above may be included and used in the compositions of the present invention in a safe and effective amount.
This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 60/700,702, filed on Jul. 19, 2005, entitled “Foamable Composition Combining a Polar Solvent and a Hydrophobic Carrier,” which is herein incorporated by reference in its entirety. This application is a continuation-in-part application of co-pending U.S. application Ser. No. 11/124,676, filed on May 9, 2005, entitled “Vasoactive Kit and Compositions and Uses Thereof,” which is a continuation-in-part application of co-pending International Patent Application No. IB03/005527, designating the United States and filed on Oct. 24, 2003, which claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Patent Application Ser. No. 60/429,546, filed on Nov. 29, 2002, both entitled “Cosmetic and Pharmaceutical Foam,” and which claims the benefit of priority under 35 U.S.C. § 119(a) to Israeli Patent Application No. 152486, filed Oct. 25, 2002, all of which are hereby incorporated in their entirety by reference. This application is also a continuation-in-part application of co-pending U.S. patent application Ser. No. 10/911,367, filed on Aug. 4, 2004, which claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Patent Application Ser. No. 60/492,385, filed on Aug. 4, 2003, both entitled “Foam Carrier Containing Amphiphilic Copolymer Gelling Agent” and both hereby incorporated in their entirety by reference. This application is also a continuation-in-part application of co-pending U.S. patent application Ser. No. 10/835,505, filed on Apr. 28, 2004, which claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Patent Application Ser. No. 60/530,015, filed on Dec. 16, 2003, and U.S. Patent Application Ser. No. 60/492,385, filed on Aug. 4, 2003, all entitled “Oleaginous Pharmaceutical and Cosmetic Foam” and all hereby incorporated in their entirety by reference. This application is also a continuation-in-part application of co-pending U.S. patent application Ser. No. 10/922,358, filed Aug. 20, 2004, entitled “Penetrating Pharmaceutical Foam,” which claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Patent Application Ser. No. 60/497,648, filed on Aug. 25, 2003, both of which are incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1159250 | Moulton | Nov 1915 | A |
| 1666684 | Carstens | Apr 1928 | A |
| 1924972 | Beckert | Aug 1933 | A |
| 2085733 | Bird | Jul 1937 | A |
| 2390921 | Clark | Dec 1945 | A |
| 2524590 | Boe | Oct 1950 | A |
| 2586287 | Apperson | Feb 1952 | A |
| 2617754 | Neely | Nov 1952 | A |
| 2767712 | Waterman | Oct 1956 | A |
| 2968628 | Reed | Jan 1961 | A |
| 3004894 | Johnson et al. | Oct 1961 | A |
| 3062715 | Reese | Nov 1962 | A |
| 3067784 | Gorman | Dec 1962 | A |
| 3092255 | Hohman | Jun 1963 | A |
| 3092555 | Horn | Jun 1963 | A |
| 3141821 | Compeau | Jul 1964 | A |
| 3142420 | Gawthrop | Jul 1964 | A |
| 3144386 | Brighttenback | Aug 1964 | A |
| 3149543 | Naab | Sep 1964 | A |
| 3154075 | Weckesser | Oct 1964 | A |
| 3178352 | Erickson | Apr 1965 | A |
| 3236457 | Kennedy et al. | Feb 1966 | A |
| 3244589 | Sunnen | Apr 1966 | A |
| 3252859 | Silver | May 1966 | A |
| 3261695 | Sienciewicz | Jul 1966 | A |
| 3263867 | Lehmann | Aug 1966 | A |
| 3263869 | Corsette | Aug 1966 | A |
| 3298919 | Charles et al. | Jan 1967 | A |
| 3301444 | Wittke | Jan 1967 | A |
| 3303970 | Breslau et al. | Feb 1967 | A |
| 3330730 | Hernaadez | Jul 1967 | A |
| 3333333 | Noack | Aug 1967 | A |
| 3334147 | Brunelle et al. | Aug 1967 | A |
| 3342845 | Sayigh et al. | Sep 1967 | A |
| 3346451 | Collins et al. | Oct 1967 | A |
| 3366494 | Bower | Jan 1968 | A |
| 3369034 | Chalmers | Feb 1968 | A |
| 3377004 | Wittke | Apr 1968 | A |
| 3383280 | Kuehns | May 1968 | A |
| 3384541 | Clark et al. | May 1968 | A |
| 3395214 | Mummert | Jul 1968 | A |
| 3395215 | Warren | Jul 1968 | A |
| 3401849 | Weber, III | Sep 1968 | A |
| 3419658 | Amsdon | Dec 1968 | A |
| 3456052 | Gordon | Jul 1969 | A |
| 3527559 | Sliwinski | Sep 1970 | A |
| 3540448 | Sunnen | Nov 1970 | A |
| 3559890 | Brooks et al. | Feb 1971 | A |
| 3561262 | Borocki | Feb 1971 | A |
| 3563098 | Weber, III | Feb 1971 | A |
| 3574821 | Pfirrmann | Apr 1971 | A |
| 3577518 | Shepherd | May 1971 | A |
| 3667461 | Zamarra | Jun 1972 | A |
| 3751562 | Nichols | Aug 1973 | A |
| 3770648 | Mackes | Nov 1973 | A |
| 3787566 | Gauvreau | Jan 1974 | A |
| 3819524 | Schubert et al. | Jun 1974 | A |
| 3824303 | Lanzet et al. | Jul 1974 | A |
| 3841525 | Siegel | Oct 1974 | A |
| 3849569 | Mead | Nov 1974 | A |
| 3849580 | Weinstein et al. | Nov 1974 | A |
| 3865275 | De Nunzio | Feb 1975 | A |
| 3866800 | Schmitt | Feb 1975 | A |
| 3878118 | Watson | Apr 1975 | A |
| 3882228 | Boncey et al. | May 1975 | A |
| 3886084 | Vassiliades | May 1975 | A |
| 3890305 | Weber et al. | Jun 1975 | A |
| 3912665 | Spitzer et al. | Oct 1975 | A |
| 3912667 | Spitzer et al. | Oct 1975 | A |
| 3923970 | Breuer | Dec 1975 | A |
| 3929985 | Webb, Jr. | Dec 1975 | A |
| 3952916 | Phillips | Apr 1976 | A |
| 3953591 | Snyder | Apr 1976 | A |
| 3959160 | Horsler et al. | May 1976 | A |
| 3962150 | Viola | Jun 1976 | A |
| 3963833 | DeSalva et al. | Jun 1976 | A |
| 3966090 | Prussin et al. | Jun 1976 | A |
| 3966632 | Colliopoulos et al. | Jun 1976 | A |
| 3970219 | Spitzer et al. | Jul 1976 | A |
| 3970584 | Hart et al. | Jul 1976 | A |
| 3993224 | Harrison | Nov 1976 | A |
| 3997467 | Jederstrom et al. | Dec 1976 | A |
| 4001391 | Feinstone et al. | Jan 1977 | A |
| 4001442 | Stahlberger et al. | Jan 1977 | A |
| 4018396 | Showmaker et al. | Apr 1977 | A |
| 4019657 | Spitzer et al. | Apr 1977 | A |
| 4052513 | Kaplan | Oct 1977 | A |
| 4083974 | Turi | Apr 1978 | A |
| 4100426 | Baranowski et al. | Jul 1978 | A |
| 4102995 | Hebborn | Jul 1978 | A |
| 4110426 | Barnhurst et al. | Aug 1978 | A |
| 4124149 | Spitzer et al. | Nov 1978 | A |
| 4145411 | Mende | Mar 1979 | A |
| 4151272 | Geary et al. | Apr 1979 | A |
| 4160827 | Cho et al. | Jul 1979 | A |
| 4178373 | Klein et al. | Dec 1979 | A |
| 4213979 | Levine | Jul 1980 | A |
| 4214000 | Papa | Jul 1980 | A |
| 4226344 | Booth et al. | Oct 1980 | A |
| 4229432 | Geria | Oct 1980 | A |
| 4230701 | Holick et al. | Oct 1980 | A |
| 4241048 | Durbak et al. | Dec 1980 | A |
| 4241149 | Labes et al. | Dec 1980 | A |
| 4252787 | Sherman et al. | Feb 1981 | A |
| 4254104 | Suzuki et al. | Mar 1981 | A |
| 4268499 | Keil | May 1981 | A |
| 4271149 | Winicov et al. | Jun 1981 | A |
| 4278206 | Prussin | Jul 1981 | A |
| 4292250 | DeLuca et al. | Sep 1981 | A |
| 4292326 | Nazzaro-Porro et al. | Sep 1981 | A |
| 4299826 | Luedders | Nov 1981 | A |
| 4305936 | Klein | Dec 1981 | A |
| 4309995 | Sacco | Jan 1982 | A |
| 4310510 | Sherman et al. | Jan 1982 | A |
| 4323582 | Siegel et al. | Apr 1982 | A |
| 4323694 | Scala, Jr. | Apr 1982 | A |
| 4325939 | Shah | Apr 1982 | A |
| 4329990 | Sneider | May 1982 | A |
| 4335120 | Holick et al. | Jun 1982 | A |
| 4338211 | Stiros | Jul 1982 | A |
| 4352808 | Rane et al. | Oct 1982 | A |
| 4363806 | Bergström et al. | Dec 1982 | A |
| 4385161 | Caunt et al. | May 1983 | A |
| 4386104 | Nazzaro-Porro | May 1983 | A |
| 4393066 | Garrett et al. | Jul 1983 | A |
| 4427670 | Ofuchi et al. | Jan 1984 | A |
| 4439416 | Cordon et al. | Mar 1984 | A |
| 4439441 | Hallesy et al. | Mar 1984 | A |
| 4440320 | Wernicke | Apr 1984 | A |
| 4447486 | Hoppe et al. | May 1984 | A |
| 4469674 | Shah et al. | Sep 1984 | A |
| 4508705 | Chaudhuri et al. | Apr 1985 | A |
| 4522948 | Walker | Jun 1985 | A |
| 4529601 | Broberg et al. | Jul 1985 | A |
| 4529605 | Lynch et al. | Jul 1985 | A |
| 4552872 | Cooper et al. | Nov 1985 | A |
| 4574052 | Gupte et al. | Mar 1986 | A |
| 4576961 | Lorck et al. | Mar 1986 | A |
| 4595526 | Lai | Jun 1986 | A |
| 4603812 | Stoesser et al. | Aug 1986 | A |
| 4607101 | Bernstein | Aug 1986 | A |
| 4612193 | Gordon et al. | Sep 1986 | A |
| 4627973 | Moran et al. | Dec 1986 | A |
| 4628063 | Haines et al. | Dec 1986 | A |
| 4661340 | Nagy née Kricsfalussy et al. | Apr 1987 | A |
| 4661524 | Thomson et al. | Apr 1987 | A |
| 4672078 | Sakai et al. | Jun 1987 | A |
| 4673569 | Shernov et al. | Jun 1987 | A |
| 4678463 | Millar | Jul 1987 | A |
| 4701320 | Hasegawa et al. | Oct 1987 | A |
| 4725609 | Kull, Jr. et al. | Feb 1988 | A |
| 4738396 | Doi et al. | Apr 1988 | A |
| 4741855 | Grote et al. | May 1988 | A |
| 4752465 | Mackles | Jun 1988 | A |
| 4770634 | Pellico | Sep 1988 | A |
| 4772427 | Dawson et al. | Sep 1988 | A |
| 4780309 | Geria et al. | Oct 1988 | A |
| 4784842 | London et al. | Nov 1988 | A |
| 4792062 | Goncalves | Dec 1988 | A |
| 4798682 | Ansmann | Jan 1989 | A |
| 4804674 | Curtis-Prior et al. | Feb 1989 | A |
| 4806262 | Snyder | Feb 1989 | A |
| 4808388 | Beutler et al. | Feb 1989 | A |
| 4822613 | Rodero | Apr 1989 | A |
| 4822614 | Rodero | Apr 1989 | A |
| 4826048 | Skorka et al. | May 1989 | A |
| 4827378 | Gillan et al. | May 1989 | A |
| 4828837 | Uster et al. | May 1989 | A |
| 4836217 | Fischer et al. | Jun 1989 | A |
| 4837019 | Georgalas et al. | Jun 1989 | A |
| 4837378 | Borgman | Jun 1989 | A |
| 4844902 | Grohe | Jul 1989 | A |
| 4847068 | Dole et al. | Jul 1989 | A |
| 4849117 | Bronner et al. | Jul 1989 | A |
| 4849211 | Schrauzer | Jul 1989 | A |
| 4851154 | Grollier et al. | Jul 1989 | A |
| 4855294 | Patel et al. | Aug 1989 | A |
| 4863900 | Pollock et al. | Sep 1989 | A |
| 4867967 | Crutcher | Sep 1989 | A |
| 4873078 | Edmundson et al. | Oct 1989 | A |
| 4874794 | Katz | Oct 1989 | A |
| 4876083 | Grollier et al. | Oct 1989 | A |
| 4877805 | Kligman | Oct 1989 | A |
| 4885282 | Thornfeldt | Dec 1989 | A |
| 4897262 | Nandagiri et al. | Jan 1990 | A |
| 4902281 | Avoy | Feb 1990 | A |
| 4906453 | Tsoucalas | Mar 1990 | A |
| 4913893 | Varco et al. | Apr 1990 | A |
| 4919934 | Deckner et al. | Apr 1990 | A |
| 4933330 | Jorgensen et al. | Jun 1990 | A |
| 4950420 | Svarz | Aug 1990 | A |
| 4954487 | Cooper et al. | Sep 1990 | A |
| 4956049 | Bernheim et al. | Sep 1990 | A |
| 4957732 | Grollier et al. | Sep 1990 | A |
| 4963351 | Weston | Oct 1990 | A |
| 4965063 | Casey et al. | Oct 1990 | A |
| 4966779 | Kirk | Oct 1990 | A |
| 4970067 | Panandiker et al. | Nov 1990 | A |
| 4975466 | Bottcher et al. | Dec 1990 | A |
| 4981367 | Brazelton | Jan 1991 | A |
| 4981677 | Thau | Jan 1991 | A |
| 4981679 | Briggs et al. | Jan 1991 | A |
| 4981845 | Pereira et al. | Jan 1991 | A |
| 4985459 | Sunshine et al. | Jan 1991 | A |
| 4992478 | Geria | Feb 1991 | A |
| 4993496 | Riedle et al. | Feb 1991 | A |
| 4996193 | Hewitt et al. | Feb 1991 | A |
| 5002540 | Brodman et al. | Mar 1991 | A |
| 5002680 | Schmidt et al. | Mar 1991 | A |
| 5007556 | Lover | Apr 1991 | A |
| 5013297 | Cattanach | May 1991 | A |
| 5015471 | Birtwistle et al. | May 1991 | A |
| 5019375 | Tanner et al. | May 1991 | A |
| 5034220 | Helioff et al. | Jul 1991 | A |
| 5035895 | Shibusawa et al. | Jul 1991 | A |
| 5053228 | Mori et al. | Oct 1991 | A |
| 5071648 | Rosenblatt | Dec 1991 | A |
| 5071881 | Parfondry et al. | Dec 1991 | A |
| 5073371 | Turner et al. | Dec 1991 | A |
| 5082651 | Healey et al. | Jan 1992 | A |
| 5087618 | Bodor | Feb 1992 | A |
| 5089252 | Grollier et al. | Feb 1992 | A |
| 5091111 | Neumiller | Feb 1992 | A |
| 5094853 | Hagarty | Mar 1992 | A |
| 5100917 | Flynn et al. | Mar 1992 | A |
| 5104645 | Cardin et al. | Apr 1992 | A |
| 5112359 | Murphy et al. | May 1992 | A |
| 5114718 | Damani | May 1992 | A |
| 5122519 | Ritter | Jun 1992 | A |
| 5130121 | Kopolow et al. | Jul 1992 | A |
| 5133972 | Ferrini et al. | Jul 1992 | A |
| 5135915 | Czarniecki et al. | Aug 1992 | A |
| 5137714 | Scott | Aug 1992 | A |
| 5143717 | Davis | Sep 1992 | A |
| 5156765 | Smrt | Oct 1992 | A |
| 5160665 | Owada et al. | Nov 1992 | A |
| 5164357 | Bartman et al. | Nov 1992 | A |
| 5164367 | Pickart | Nov 1992 | A |
| 5167950 | Lins | Dec 1992 | A |
| 5171577 | Griat et al. | Dec 1992 | A |
| 5196405 | Packman | Mar 1993 | A |
| 5204090 | Han | Apr 1993 | A |
| 5204093 | Victor | Apr 1993 | A |
| 5208031 | Kelly | May 1993 | A |
| 5217707 | Szabo et al. | Jun 1993 | A |
| 5219877 | Shah et al. | Jun 1993 | A |
| 5221534 | DesLauriers et al. | Jun 1993 | A |
| 5221696 | Ke et al. | Jun 1993 | A |
| 5230897 | Griffin et al. | Jul 1993 | A |
| 5236707 | Stewart, II | Aug 1993 | A |
| 5252246 | Ding et al. | Oct 1993 | A |
| 5254334 | Ramirez et al. | Oct 1993 | A |
| 5262407 | Leveque et al. | Nov 1993 | A |
| 5266592 | Grub et al. | Nov 1993 | A |
| 5279819 | Hayes | Jan 1994 | A |
| 5286475 | Louvet et al. | Feb 1994 | A |
| 5294365 | Welch et al. | Mar 1994 | A |
| 5300286 | Gee | Apr 1994 | A |
| 5301841 | Fuchs | Apr 1994 | A |
| 5308643 | Osipow et al. | May 1994 | A |
| 5314904 | Egidio et al. | May 1994 | A |
| 5318774 | Alban et al. | Jun 1994 | A |
| 5322683 | Mackles et al. | Jun 1994 | A |
| 5326557 | Glover et al. | Jul 1994 | A |
| 5344051 | Brown | Sep 1994 | A |
| 5346135 | Vincent | Sep 1994 | A |
| 5352437 | Nakagawa et al. | Oct 1994 | A |
| 5369131 | Poli et al. | Nov 1994 | A |
| 5378451 | Gorman et al. | Jan 1995 | A |
| 5378730 | Lee et al. | Jan 1995 | A |
| 5380761 | Szabo Anna Z. et al. | Jan 1995 | A |
| 5384308 | Henkin | Jan 1995 | A |
| 5385943 | Nazzaro-Porro | Jan 1995 | A |
| 5389305 | Repinec et al. | Feb 1995 | A |
| 5389676 | Michaels | Feb 1995 | A |
| 5397312 | Rademaker et al. | Mar 1995 | A |
| 5398846 | Corba et al. | Mar 1995 | A |
| 5399205 | Shinohara et al. | Mar 1995 | A |
| 5411992 | Eini et al. | May 1995 | A |
| 5422361 | Munayyer et al. | Jun 1995 | A |
| 5429815 | Faryniarz et al. | Jul 1995 | A |
| 5435996 | Glover et al. | Jul 1995 | A |
| 5439670 | Purewal et al. | Aug 1995 | A |
| 5439682 | Wivell et al. | Aug 1995 | A |
| 5447725 | Damani et al. | Sep 1995 | A |
| 5449520 | Frigerio et al. | Sep 1995 | A |
| 5451404 | Furman | Sep 1995 | A |
| 5482965 | Rajadhyaksha | Jan 1996 | A |
| 5491245 | Gruning et al. | Feb 1996 | A |
| 5500211 | George et al. | Mar 1996 | A |
| 5508033 | Briand et al. | Apr 1996 | A |
| 5512555 | Waldstreicher | Apr 1996 | A |
| 5514367 | Lentini et al. | May 1996 | A |
| 5514369 | Salka et al. | May 1996 | A |
| 5520918 | Smith | May 1996 | A |
| 5523078 | Baylin | Jun 1996 | A |
| 5527534 | Myhling | Jun 1996 | A |
| 5527822 | Scheiner | Jun 1996 | A |
| 5529770 | McKinzie et al. | Jun 1996 | A |
| 5531703 | Skwarek et al. | Jul 1996 | A |
| 5534261 | Rodgers et al. | Jul 1996 | A |
| 5536743 | Borgman | Jul 1996 | A |
| 5540853 | Trinh et al. | Jul 1996 | A |
| 5545401 | Shanbrom | Aug 1996 | A |
| 5547989 | Chamness | Aug 1996 | A |
| 5558872 | Jones et al. | Sep 1996 | A |
| 5560859 | Hartmann et al. | Oct 1996 | A |
| 5567420 | McEleney et al. | Oct 1996 | A |
| 5576016 | Amselem et al. | Nov 1996 | A |
| 5578315 | Chien et al. | Nov 1996 | A |
| 5585104 | Ha et al. | Dec 1996 | A |
| 5589157 | Hatfield | Dec 1996 | A |
| 5589515 | Suzuki et al. | Dec 1996 | A |
| 5597560 | Bergamini et al. | Jan 1997 | A |
| 5603940 | Candau et al. | Feb 1997 | A |
| 5605679 | Hansenne et al. | Feb 1997 | A |
| 5608119 | Amano et al. | Mar 1997 | A |
| 5611463 | Favre | Mar 1997 | A |
| 5612056 | Jenner et al. | Mar 1997 | A |
| 5613583 | Kono et al. | Mar 1997 | A |
| 5613623 | Hildebrandt | Mar 1997 | A |
| 5614171 | Clavenna et al. | Mar 1997 | A |
| 5614178 | Bloom et al. | Mar 1997 | A |
| 5618516 | Clavenna et al. | Apr 1997 | A |
| 5635469 | Fowler et al. | Jun 1997 | A |
| 5641480 | Vermeer | Jun 1997 | A |
| 5643600 | Mathur | Jul 1997 | A |
| 5645842 | Gruning et al. | Jul 1997 | A |
| 5648380 | Martin | Jul 1997 | A |
| 5650554 | Moloney | Jul 1997 | A |
| 5658575 | Ribier et al. | Aug 1997 | A |
| 5658749 | Thornton | Aug 1997 | A |
| 5658956 | Martin et al. | Aug 1997 | A |
| 5663208 | Martin | Sep 1997 | A |
| 5672634 | Tseng et al. | Sep 1997 | A |
| 5679324 | Lisboa et al. | Oct 1997 | A |
| 5683710 | Akemi et al. | Nov 1997 | A |
| 5686088 | Mitra et al. | Nov 1997 | A |
| 5693258 | Tonomura et al. | Dec 1997 | A |
| 5695551 | Buckingham et al. | Dec 1997 | A |
| 5695747 | Forestier et al. | Dec 1997 | A |
| 5700396 | Suzuki et al. | Dec 1997 | A |
| 5705472 | Hayes et al. | Jan 1998 | A |
| 5716611 | Oshlack et al. | Feb 1998 | A |
| 5716621 | Bello | Feb 1998 | A |
| 5719122 | Chiodini et al. | Feb 1998 | A |
| 5719197 | Kanios et al. | Feb 1998 | A |
| 5725872 | Stamm et al. | Mar 1998 | A |
| 5725874 | Oda | Mar 1998 | A |
| 5730964 | Waldstreicher | Mar 1998 | A |
| 5733558 | Breton et al. | Mar 1998 | A |
| 5733572 | Unger et al. | Mar 1998 | A |
| 5747049 | Tominaga | May 1998 | A |
| 5753241 | Ribier et al. | May 1998 | A |
| 5753245 | Fowler et al. | May 1998 | A |
| 5753270 | Beauchamp et al. | May 1998 | A |
| 5759520 | Sachetto | Jun 1998 | A |
| 5759579 | Singh et al. | Jun 1998 | A |
| 5767104 | Bar-Shalom et al. | Jun 1998 | A |
| 5773410 | Yamamoto | Jun 1998 | A |
| 5783202 | Tomlinson et al. | Jul 1998 | A |
| 5788664 | Scalise | Aug 1998 | A |
| 5792448 | Dubief et al. | Aug 1998 | A |
| 5792922 | Moloney | Aug 1998 | A |
| 5797955 | Walters | Aug 1998 | A |
| 5804546 | Hall et al. | Sep 1998 | A |
| 5807571 | List | Sep 1998 | A |
| 5817322 | Xu et al. | Oct 1998 | A |
| 5824650 | De Lacharriere et al. | Oct 1998 | A |
| 5833960 | Gers-Barlag et al. | Nov 1998 | A |
| 5833961 | Siegfried et al. | Nov 1998 | A |
| 5837270 | Burgess | Nov 1998 | A |
| 5840744 | Borgman | Nov 1998 | A |
| 5840771 | Oldham et al. | Nov 1998 | A |
| 5843411 | Hernandez et al. | Dec 1998 | A |
| 5846983 | Sandborn et al. | Dec 1998 | A |
| 5849042 | Lim et al. | Dec 1998 | A |
| 5854246 | Francois et al. | Dec 1998 | A |
| 5856452 | Moloney et al. | Jan 1999 | A |
| 5858371 | Singh et al. | Jan 1999 | A |
| 5865347 | Welschoff | Feb 1999 | A |
| 5866040 | Nakama et al. | Feb 1999 | A |
| 5869529 | Sintov et al. | Feb 1999 | A |
| 5871720 | Gutierrez et al. | Feb 1999 | A |
| 5877216 | Place et al. | Mar 1999 | A |
| 5879469 | Avram et al. | Mar 1999 | A |
| 5881493 | Restive | Mar 1999 | A |
| 5885581 | Massand | Mar 1999 | A |
| 5889028 | Sandborn et al. | Mar 1999 | A |
| 5889054 | Yu et al. | Mar 1999 | A |
| 5891458 | Britton et al. | Apr 1999 | A |
| 5902574 | Stoner et al. | May 1999 | A |
| 5902789 | Stoltz | May 1999 | A |
| 5905092 | Osborne et al. | May 1999 | A |
| 5910382 | Goodenough et al. | Jun 1999 | A |
| 5911981 | Dahms et al. | Jun 1999 | A |
| 5912007 | Pan et al. | Jun 1999 | A |
| 5914122 | Otterbeck et al. | Jun 1999 | A |
| 5914310 | Li et al. | Jun 1999 | A |
| 5919830 | Gopalkrishnan et al. | Jul 1999 | A |
| 5922331 | Mausner | Jul 1999 | A |
| 5925669 | Katz et al. | Jul 1999 | A |
| 5939376 | Durbut et al. | Aug 1999 | A |
| 5948682 | Moloney | Sep 1999 | A |
| 5951544 | Konwitz | Sep 1999 | A |
| 5951989 | Heymann | Sep 1999 | A |
| 5951993 | Scholz et al. | Sep 1999 | A |
| 5952373 | Lanzendorfer et al. | Sep 1999 | A |
| 5952392 | Katz et al. | Sep 1999 | A |
| 5955414 | Brown et al. | Sep 1999 | A |
| 5959161 | Kenmochi et al. | Sep 1999 | A |
| 5961957 | McAnalley | Oct 1999 | A |
| 5961998 | Arnaud et al. | Oct 1999 | A |
| 5972310 | Sachetto | Oct 1999 | A |
| 5976555 | Liu et al. | Nov 1999 | A |
| 5980904 | Leverett et al. | Nov 1999 | A |
| 5990100 | Rosenberg et al. | Nov 1999 | A |
| 5993846 | Friedman et al. | Nov 1999 | A |
| 6001341 | Genova et al. | Dec 1999 | A |
| 6006948 | Auer | Dec 1999 | A |
| 6017912 | Bussell | Jan 2000 | A |
| 6019967 | Breton et al. | Feb 2000 | A |
| 6024942 | Tanner et al. | Feb 2000 | A |
| 6030630 | Fleury et al. | Feb 2000 | A |
| 6033647 | Touzan et al. | Mar 2000 | A |
| 6039936 | Restle et al. | Mar 2000 | A |
| 6042848 | Lawyer et al. | Mar 2000 | A |
| 6045779 | Mueller et al. | Apr 2000 | A |
| 6060041 | Candau et al. | May 2000 | A |
| 6071536 | Suzuki et al. | Jun 2000 | A |
| 6071541 | Murad | Jun 2000 | A |
| 6075056 | Quigley, Jr. et al. | Jun 2000 | A |
| 6080394 | Lin et al. | Jun 2000 | A |
| 6087310 | Henkel | Jul 2000 | A |
| 6087317 | Gee | Jul 2000 | A |
| 6090772 | Kaiser et al. | Jul 2000 | A |
| 6093408 | Hasenoehrl et al. | Jul 2000 | A |
| 6096756 | Crain et al. | Aug 2000 | A |
| 6110477 | Hernandez et al. | Aug 2000 | A |
| 6110966 | Pollock | Aug 2000 | A |
| 6113888 | Castro et al. | Sep 2000 | A |
| 6116466 | Gueret et al. | Sep 2000 | A |
| 6121210 | Taylor | Sep 2000 | A |
| 6126920 | Jones et al. | Oct 2000 | A |
| 6133327 | Kimura et al. | Oct 2000 | A |
| 6140355 | Egidio et al. | Oct 2000 | A |
| 6146645 | Deckers et al. | Nov 2000 | A |
| 6146664 | Siddiqui | Nov 2000 | A |
| 6162834 | Sebillotte-Arnaud et al. | Dec 2000 | A |
| 6165455 | Torgerson et al. | Dec 2000 | A |
| 6168576 | Reynolds | Jan 2001 | B1 |
| 6171347 | Kunz et al. | Jan 2001 | B1 |
| 6180662 | Lanzendörfer et al. | Jan 2001 | B1 |
| 6180669 | Tamarkin | Jan 2001 | B1 |
| 6183762 | Deckers et al. | Feb 2001 | B1 |
| 6186367 | Harrold | Feb 2001 | B1 |
| 6187290 | Gilchrist et al. | Feb 2001 | B1 |
| 6189810 | Nerushai et al. | Feb 2001 | B1 |
| 6190365 | Abbott et al. | Feb 2001 | B1 |
| 6204285 | Fabiano et al. | Mar 2001 | B1 |
| 6210656 | Touzan et al. | Apr 2001 | B1 |
| 6210742 | Deckers et al. | Apr 2001 | B1 |
| 6214318 | Osipow et al. | Apr 2001 | B1 |
| 6214788 | Velazco et al. | Apr 2001 | B1 |
| 6217887 | Beerse et al. | Apr 2001 | B1 |
| 6221381 | Shelford et al. | Apr 2001 | B1 |
| 6221823 | Crisanti et al. | Apr 2001 | B1 |
| 6224888 | Vatter et al. | May 2001 | B1 |
| 6231837 | Stroud et al. | May 2001 | B1 |
| 6232315 | Shafer et al. | May 2001 | B1 |
| 6241971 | Fox et al. | Jun 2001 | B1 |
| 6251369 | Stoltz | Jun 2001 | B1 |
| 6258374 | Friess et al. | Jul 2001 | B1 |
| 6261544 | Coury et al. | Jul 2001 | B1 |
| 6264964 | Mohammadi | Jul 2001 | B1 |
| 6270781 | Gehlsen | Aug 2001 | B1 |
| 6271295 | Powell et al. | Aug 2001 | B1 |
| 6274150 | Simonnet et al. | Aug 2001 | B1 |
| 6283336 | Dwyer et al. | Sep 2001 | B1 |
| 6284802 | Bissett et al. | Sep 2001 | B1 |
| 6287546 | Reich et al. | Sep 2001 | B1 |
| 6294550 | Place et al. | Sep 2001 | B1 |
| 6299023 | Arnone | Oct 2001 | B1 |
| 6299032 | Hamilton | Oct 2001 | B1 |
| 6299900 | Reed et al. | Oct 2001 | B1 |
| 6305578 | Hildebrandt et al. | Oct 2001 | B1 |
| 6306841 | Place et al. | Oct 2001 | B1 |
| 6308863 | Harman | Oct 2001 | B1 |
| 6319913 | Mak et al. | Nov 2001 | B1 |
| 6328950 | Franzke et al. | Dec 2001 | B1 |
| 6328982 | Shiroyama et al. | Dec 2001 | B1 |
| 6333362 | Lorant | Dec 2001 | B1 |
| 6335022 | Simonnet et al. | Jan 2002 | B1 |
| 6341717 | Auer | Jan 2002 | B2 |
| 6344218 | Dodd et al. | Feb 2002 | B1 |
| 6348229 | Eini et al. | Feb 2002 | B1 |
| 6352727 | Takahashi | Mar 2002 | B1 |
| 6355230 | Gers-Barlag et al. | Mar 2002 | B2 |
| 6358541 | Goodman | Mar 2002 | B1 |
| 6358924 | Hoffmann | Mar 2002 | B1 |
| 6364854 | Ferrer et al. | Apr 2002 | B1 |
| 6372234 | Deckers et al. | Apr 2002 | B1 |
| 6375936 | Allard et al. | Apr 2002 | B1 |
| 6375960 | Simonnet et al. | Apr 2002 | B1 |
| 6383471 | Chen et al. | May 2002 | B1 |
| 6395258 | Steer | May 2002 | B1 |
| 6395300 | Straub et al. | May 2002 | B1 |
| 6403061 | Candau et al. | Jun 2002 | B1 |
| 6403069 | Chopra et al. | Jun 2002 | B1 |
| 6410036 | De Rosa et al. | Jun 2002 | B1 |
| 6423323 | Neubourg | Jul 2002 | B2 |
| 6423329 | Sine et al. | Jul 2002 | B1 |
| 6428772 | Singh et al. | Aug 2002 | B1 |
| 6433003 | Bobrove et al. | Aug 2002 | B1 |
| 6433024 | Popp et al. | Aug 2002 | B1 |
| 6433033 | Isobe et al. | Aug 2002 | B1 |
| 6433068 | Morrison et al. | Aug 2002 | B1 |
| 6437006 | Yoon et al. | Aug 2002 | B1 |
| 6440429 | Torizuka et al. | Aug 2002 | B1 |
| 6447801 | Salafsky et al. | Sep 2002 | B1 |
| 6451777 | Bradbury et al. | Sep 2002 | B1 |
| 6455076 | Hahn et al. | Sep 2002 | B1 |
| 6468989 | Chang et al. | Oct 2002 | B1 |
| 6479058 | McCadden | Nov 2002 | B1 |
| 6479060 | Jones et al. | Nov 2002 | B1 |
| 6479532 | Kamimura et al. | Nov 2002 | B1 |
| 6482810 | Brem et al. | Nov 2002 | B1 |
| 6486168 | Skwierczynski et al. | Nov 2002 | B1 |
| 6488947 | Bekele | Dec 2002 | B1 |
| 6511655 | Muller et al. | Jan 2003 | B1 |
| 6514487 | Barr | Feb 2003 | B1 |
| 6524594 | Santora et al. | Feb 2003 | B1 |
| 6531118 | Gonzalez et al. | Mar 2003 | B1 |
| 6534455 | Maurin et al. | Mar 2003 | B1 |
| 6536629 | van der Heijden | Mar 2003 | B2 |
| 6544530 | Friedman | Apr 2003 | B1 |
| 6544562 | Singh et al. | Apr 2003 | B2 |
| 6547063 | Zaveri et al. | Apr 2003 | B1 |
| 6548074 | Mohammadi | Apr 2003 | B1 |
| 6551604 | Beck et al. | Apr 2003 | B1 |
| 6562355 | Renault | May 2003 | B1 |
| 6566350 | Ono et al. | May 2003 | B2 |
| 6582679 | Stein et al. | Jun 2003 | B2 |
| 6582710 | Deckers et al. | Jun 2003 | B2 |
| 6589509 | Keller et al. | Jul 2003 | B2 |
| 6596287 | Deckers et al. | Jul 2003 | B2 |
| 6599513 | Deckers et al. | Jul 2003 | B2 |
| 6607716 | Smith et al. | Aug 2003 | B1 |
| 6610315 | Scholz et al. | Aug 2003 | B2 |
| 6620773 | Stork et al. | Sep 2003 | B1 |
| 6638981 | Williams et al. | Oct 2003 | B2 |
| 6649571 | Morgan | Nov 2003 | B1 |
| 6649574 | Cardis et al. | Nov 2003 | B2 |
| 6672483 | Roy | Jan 2004 | B1 |
| 6682726 | Marchesi et al. | Jan 2004 | B2 |
| 6682750 | Loeffler et al. | Jan 2004 | B2 |
| 6691898 | Hurray et al. | Feb 2004 | B2 |
| 6706290 | Kajander et al. | Mar 2004 | B1 |
| 6709663 | Espinoza | Mar 2004 | B2 |
| 6723309 | Deane | Apr 2004 | B1 |
| 6730288 | Abram | May 2004 | B1 |
| 6736860 | Patel et al. | May 2004 | B2 |
| 6753000 | Breton et al. | Jun 2004 | B2 |
| 6753013 | Didriksen et al. | Jun 2004 | B1 |
| 6753167 | Moloney et al. | Jun 2004 | B2 |
| 6762158 | Lukenbach et al. | Jul 2004 | B2 |
| 6765001 | Gans et al. | Jul 2004 | B2 |
| 6774114 | Castiel et al. | Aug 2004 | B2 |
| 6777591 | Chaudhary | Aug 2004 | B1 |
| 6790435 | Ma et al. | Sep 2004 | B1 |
| 6796973 | Contente et al. | Sep 2004 | B1 |
| RE38623 | Hernandez et al. | Oct 2004 | E |
| 6811767 | Bosch et al. | Nov 2004 | B1 |
| 6834778 | Jinbo et al. | Dec 2004 | B2 |
| 6841547 | Brown et al. | Jan 2005 | B2 |
| 6843390 | Bristor | Jan 2005 | B1 |
| 6875438 | Kraemer et al. | Apr 2005 | B2 |
| 6881271 | Ochiai | Apr 2005 | B2 |
| 6890567 | Nakatsu et al. | May 2005 | B2 |
| 6897195 | Su et al. | May 2005 | B2 |
| 6902737 | Quemin et al. | Jun 2005 | B2 |
| 6911211 | Eini et al. | Jun 2005 | B2 |
| 6914057 | Ryan et al. | Jul 2005 | B1 |
| 6946120 | Wai-Chiu So et al. | Sep 2005 | B2 |
| 6946139 | Henning | Sep 2005 | B2 |
| 6951654 | Malcolm et al. | Oct 2005 | B2 |
| 6955816 | Klysz | Oct 2005 | B2 |
| 6956062 | Beilfuss et al. | Oct 2005 | B2 |
| 6958154 | Andolino Brandt et al. | Oct 2005 | B2 |
| 6967023 | Eini et al. | Nov 2005 | B1 |
| 6968982 | Burns | Nov 2005 | B1 |
| 6969521 | Gonzalez et al. | Nov 2005 | B1 |
| RE38964 | Shillington | Jan 2006 | E |
| 6994863 | Eini et al. | Feb 2006 | B2 |
| 7002486 | Lawrence | Feb 2006 | B2 |
| 7014844 | Mahalingam et al. | Mar 2006 | B2 |
| 7021499 | Hansen et al. | Apr 2006 | B2 |
| 7029659 | Abram et al. | Apr 2006 | B2 |
| 7060253 | Mundschenk | Jun 2006 | B1 |
| 7078058 | Jones et al. | Jul 2006 | B2 |
| 7083799 | Giacomoni | Aug 2006 | B1 |
| 7137536 | Walters et al. | Nov 2006 | B2 |
| 7195135 | Garcia et al. | Mar 2007 | B1 |
| 7222802 | Sweeton | May 2007 | B2 |
| 7225518 | Eidenschink et al. | Jun 2007 | B2 |
| 7226230 | Liberatore | Jun 2007 | B2 |
| 7235251 | Hamer et al. | Jun 2007 | B2 |
| 7252816 | Angel et al. | Aug 2007 | B1 |
| 7270828 | Masuda et al. | Sep 2007 | B2 |
| 7455195 | Mekata | Nov 2008 | B2 |
| 7497354 | Decottignies et al. | Mar 2009 | B2 |
| 7575739 | Tamarkin et al. | Aug 2009 | B2 |
| 7645803 | Tamarkin et al. | Jan 2010 | B2 |
| 7654415 | van der Heijden | Feb 2010 | B2 |
| 7682623 | Eini et al. | Mar 2010 | B2 |
| 7700076 | Tamarkin et al. | Apr 2010 | B2 |
| 7704518 | Tamarkin et al. | Apr 2010 | B2 |
| 7758888 | Lapidot et al. | Jul 2010 | B2 |
| 7793807 | Goujon et al. | Sep 2010 | B2 |
| 7820145 | Tamarkin et al. | Oct 2010 | B2 |
| 7842791 | Britten et al. | Nov 2010 | B2 |
| 7960416 | Sato et al. | Jun 2011 | B2 |
| 8114385 | Tamarkin et al. | Feb 2012 | B2 |
| 8158109 | Abram et al. | Apr 2012 | B2 |
| 8192749 | Ashley | Jun 2012 | B2 |
| 8211874 | Theobald et al. | Jul 2012 | B2 |
| 8343945 | Tamarkin et al. | Jan 2013 | B2 |
| 8362091 | Tamarkin et al. | Jan 2013 | B2 |
| 8435498 | Tamarkin et al. | May 2013 | B2 |
| 8486375 | Tamarkin et al. | Jul 2013 | B2 |
| 8518376 | Tamarkin et al. | Aug 2013 | B2 |
| 8592380 | Trumbore et al. | Nov 2013 | B2 |
| 8618081 | Tamarkin et al. | Dec 2013 | B2 |
| 8623330 | Gurge et al. | Jan 2014 | B2 |
| 8652443 | Varanasi et al. | Feb 2014 | B2 |
| 8735377 | Sipos | May 2014 | B1 |
| 8778365 | Hardas et al. | Jul 2014 | B1 |
| 8784780 | Gurge et al. | Jul 2014 | B2 |
| 8846039 | Chung et al. | Sep 2014 | B2 |
| 8895536 | Bannister et al. | Nov 2014 | B2 |
| 8992896 | Tamarkin et al. | Mar 2015 | B2 |
| 9050253 | Tamarkin et al. | Jun 2015 | B2 |
| 9101662 | Tamarkin et al. | Aug 2015 | B2 |
| 9192558 | Chen et al. | Nov 2015 | B2 |
| 9265725 | Tamarkin | Feb 2016 | B2 |
| 9265740 | Johnston et al. | Feb 2016 | B2 |
| 9439857 | Tamarkin et al. | Sep 2016 | B2 |
| 9474720 | Yamamoto | Oct 2016 | B2 |
| 9492412 | Tamarkin et al. | Nov 2016 | B2 |
| 9539208 | Tamarkin et al. | Jan 2017 | B2 |
| 9539266 | Mansouri | Jan 2017 | B2 |
| 9549898 | Tamarkin et al. | Jan 2017 | B2 |
| 9572775 | Tamarkin et al. | Feb 2017 | B2 |
| 9592246 | Salman et al. | Mar 2017 | B2 |
| 9622947 | Tamarkin et al. | Apr 2017 | B2 |
| 9636405 | Tamarkin et al. | May 2017 | B2 |
| 9662298 | Tamarkin et al. | May 2017 | B2 |
| 9668972 | Tamarkin et al. | Jun 2017 | B2 |
| 9675700 | Tamarkin et al. | Jun 2017 | B2 |
| 9682021 | Tamarkin et al. | Jun 2017 | B2 |
| 9713643 | Friedman et al. | Jul 2017 | B2 |
| 9795564 | Tamarkin et al. | Oct 2017 | B2 |
| 9849142 | Tamarkin et al. | Dec 2017 | B2 |
| 9884017 | Tamarkin et al. | Feb 2018 | B2 |
| 20010006654 | Cannell et al. | Jul 2001 | A1 |
| 20010027218 | Stern et al. | Oct 2001 | A1 |
| 20010027981 | Yquel | Oct 2001 | A1 |
| 20010033838 | Farmer | Oct 2001 | A1 |
| 20010036450 | Verite et al. | Nov 2001 | A1 |
| 20010054574 | Navarro | Dec 2001 | A1 |
| 20020002151 | Ono et al. | Jan 2002 | A1 |
| 20020004063 | Zhang | Jan 2002 | A1 |
| 20020013481 | Schonrock et al. | Jan 2002 | A1 |
| 20020015721 | Simonnet et al. | Feb 2002 | A1 |
| 20020031478 | Keller et al. | Mar 2002 | A1 |
| 20020032171 | Chen et al. | Mar 2002 | A1 |
| 20020035046 | Lukenbach et al. | Mar 2002 | A1 |
| 20020035070 | Gardlik et al. | Mar 2002 | A1 |
| 20020035087 | Barclay | Mar 2002 | A1 |
| 20020035182 | L'Alloret et al. | Mar 2002 | A1 |
| 20020039591 | Dahle | Apr 2002 | A1 |
| 20020044659 | Ohta | Apr 2002 | A1 |
| 20020045659 | Michelet et al. | Apr 2002 | A1 |
| 20020048798 | Avery et al. | Apr 2002 | A1 |
| 20020058010 | Picard-Lesboueyries et al. | May 2002 | A1 |
| 20020072544 | Miller et al. | Jun 2002 | A1 |
| 20020090386 | Haslwanter et al. | Jul 2002 | A1 |
| 20020098215 | Douin et al. | Jul 2002 | A1 |
| 20020111281 | Vishnupad | Aug 2002 | A1 |
| 20020117516 | Lasserre et al. | Aug 2002 | A1 |
| 20020134376 | Castro et al. | Sep 2002 | A1 |
| 20020136755 | Tyrrell et al. | Sep 2002 | A1 |
| 20020143188 | Garvey et al. | Oct 2002 | A1 |
| 20020153390 | Vlodek | Oct 2002 | A1 |
| 20020165170 | Wilson et al. | Nov 2002 | A1 |
| 20020182162 | Shahinpoor et al. | Dec 2002 | A1 |
| 20020182234 | Riedel et al. | Dec 2002 | A1 |
| 20020187181 | Godbey et al. | Dec 2002 | A1 |
| 20020198136 | Mak et al. | Dec 2002 | A1 |
| 20030006193 | Ikeda et al. | Jan 2003 | A1 |
| 20030013692 | Gullans et al. | Jan 2003 | A1 |
| 20030017181 | Rood et al. | Jan 2003 | A1 |
| 20030031693 | Breton et al. | Feb 2003 | A1 |
| 20030053961 | Eccard | Mar 2003 | A1 |
| 20030077297 | Chen et al. | Apr 2003 | A1 |
| 20030077301 | Maibach et al. | Apr 2003 | A1 |
| 20030078172 | Guiramand et al. | Apr 2003 | A1 |
| 20030082120 | Milstein | May 2003 | A1 |
| 20030108502 | Uchida et al. | Jun 2003 | A1 |
| 20030114520 | Pereira et al. | Jun 2003 | A1 |
| 20030118515 | Jew et al. | Jun 2003 | A1 |
| 20030118527 | Jager et al. | Jun 2003 | A1 |
| 20030129259 | Mahalingam et al. | Jul 2003 | A1 |
| 20030130247 | Gans et al. | Jul 2003 | A1 |
| 20030148949 | Podolsky | Aug 2003 | A1 |
| 20030175232 | Elliott et al. | Sep 2003 | A1 |
| 20030175315 | Yoo et al. | Sep 2003 | A1 |
| 20030180347 | Young et al. | Sep 2003 | A1 |
| 20030185839 | Podolsky | Oct 2003 | A1 |
| 20030185861 | Hori et al. | Oct 2003 | A1 |
| 20030194379 | Brugger et al. | Oct 2003 | A1 |
| 20030195128 | Deckman et al. | Oct 2003 | A1 |
| 20030206955 | Sonneville-Aubrun et al. | Nov 2003 | A1 |
| 20030215418 | Asmus et al. | Nov 2003 | A1 |
| 20030215472 | Bonda et al. | Nov 2003 | A1 |
| 20030235597 | Withiam et al. | Dec 2003 | A1 |
| 20040002550 | Mercurio | Jan 2004 | A1 |
| 20040018228 | Fischell et al. | Jan 2004 | A1 |
| 20040028752 | Kamm et al. | Feb 2004 | A1 |
| 20040038912 | Michelet et al. | Feb 2004 | A1 |
| 20040053797 | Chen et al. | Mar 2004 | A1 |
| 20040058878 | Walker | Mar 2004 | A1 |
| 20040063787 | Villanueva | Apr 2004 | A1 |
| 20040067970 | Foster et al. | Apr 2004 | A1 |
| 20040072638 | Enos et al. | Apr 2004 | A1 |
| 20040076651 | Brocks et al. | Apr 2004 | A1 |
| 20040078896 | Hellyer et al. | Apr 2004 | A1 |
| 20040079361 | Clayton et al. | Apr 2004 | A1 |
| 20040105825 | Henning | Jun 2004 | A1 |
| 20040106688 | Koike et al. | Jun 2004 | A1 |
| 20040120917 | Perrier et al. | Jun 2004 | A1 |
| 20040127554 | Ghisalberti | Jul 2004 | A1 |
| 20040138179 | Goldstein et al. | Jul 2004 | A1 |
| 20040151671 | Abram et al. | Aug 2004 | A1 |
| 20040151756 | Richards et al. | Aug 2004 | A1 |
| 20040161447 | Paul | Aug 2004 | A1 |
| 20040184992 | Abram | Sep 2004 | A1 |
| 20040185123 | Mazzio et al. | Sep 2004 | A1 |
| 20040191196 | Tamarkin | Sep 2004 | A1 |
| 20040192754 | Shapira et al. | Sep 2004 | A1 |
| 20040195276 | Fuchs | Oct 2004 | A1 |
| 20040197276 | Takase et al. | Oct 2004 | A1 |
| 20040197295 | Riedel et al. | Oct 2004 | A1 |
| 20040198706 | Carrara | Oct 2004 | A1 |
| 20040219122 | Masuda et al. | Nov 2004 | A1 |
| 20040219176 | Dominguez | Nov 2004 | A1 |
| 20040220187 | Stephenson et al. | Nov 2004 | A1 |
| 20040229813 | DiPiano et al. | Nov 2004 | A1 |
| 20040234475 | Lannibois-Drean et al. | Nov 2004 | A1 |
| 20040241099 | Popp et al. | Dec 2004 | A1 |
| 20040247531 | Riedel et al. | Dec 2004 | A1 |
| 20040253275 | Eini et al. | Dec 2004 | A1 |
| 20040258627 | Riedel et al. | Dec 2004 | A1 |
| 20040258628 | Riedel et al. | Dec 2004 | A1 |
| 20040265240 | Tamarkin et al. | Dec 2004 | A1 |
| 20050002976 | Wu | Jan 2005 | A1 |
| 20050013853 | Gil-Ad et al. | Jan 2005 | A1 |
| 20050031547 | Tamarkin et al. | Feb 2005 | A1 |
| 20050042182 | Arkin | Feb 2005 | A1 |
| 20050054991 | Tobyn et al. | Mar 2005 | A1 |
| 20050069566 | Tamarkin et al. | Mar 2005 | A1 |
| 20050074414 | Tamarkin et al. | Apr 2005 | A1 |
| 20050075407 | Tamarkin et al. | Apr 2005 | A1 |
| 20050079139 | Jacques et al. | Apr 2005 | A1 |
| 20050079228 | Jaiswal et al. | Apr 2005 | A1 |
| 20050084551 | Jensen et al. | Apr 2005 | A1 |
| 20050085843 | Opolski et al. | Apr 2005 | A1 |
| 20050100517 | Sanzgiri et al. | May 2005 | A1 |
| 20050101936 | Gonzales et al. | May 2005 | A1 |
| 20050106197 | Blin et al. | May 2005 | A1 |
| 20050123494 | Swaile et al. | Jun 2005 | A1 |
| 20050123496 | Shah et al. | Jun 2005 | A1 |
| 20050148552 | Ryan et al. | Jul 2005 | A1 |
| 20050153943 | Ashley | Jul 2005 | A1 |
| 20050164993 | Ashley | Jul 2005 | A1 |
| 20050186142 | Tamarkin et al. | Aug 2005 | A1 |
| 20050186147 | Tamarkin et al. | Aug 2005 | A1 |
| 20050189377 | Lanzendorfer et al. | Sep 2005 | A1 |
| 20050196414 | Dake et al. | Sep 2005 | A1 |
| 20050205086 | Tamarkin et al. | Sep 2005 | A1 |
| 20050207837 | Kosh et al. | Sep 2005 | A1 |
| 20050222090 | Cheng et al. | Oct 2005 | A1 |
| 20050232869 | Tamarkin et al. | Oct 2005 | A1 |
| 20050244342 | Friedman et al. | Nov 2005 | A1 |
| 20050244354 | Speron | Nov 2005 | A1 |
| 20050245902 | Cornish et al. | Nov 2005 | A1 |
| 20050252995 | Westphal et al. | Nov 2005 | A1 |
| 20050255048 | Hirsh et al. | Nov 2005 | A1 |
| 20050258189 | Peterson et al. | Nov 2005 | A1 |
| 20050266035 | Healy et al. | Dec 2005 | A1 |
| 20050268416 | Sommers | Dec 2005 | A1 |
| 20050271596 | Friedman et al. | Dec 2005 | A1 |
| 20050271598 | Friedman et al. | Dec 2005 | A1 |
| 20050276836 | Wilson et al. | Dec 2005 | A1 |
| 20050281749 | Willcox et al. | Dec 2005 | A1 |
| 20050281755 | Zarif et al. | Dec 2005 | A1 |
| 20050281766 | Martin et al. | Dec 2005 | A1 |
| 20050285912 | Delametter et al. | Dec 2005 | A1 |
| 20050287081 | Aust et al. | Dec 2005 | A1 |
| 20060008432 | Scarampi et al. | Jan 2006 | A1 |
| 20060018937 | Friedman | Jan 2006 | A1 |
| 20060018938 | Neubourg | Jan 2006 | A1 |
| 20060029565 | Xu et al. | Feb 2006 | A1 |
| 20060051301 | Galopin et al. | Mar 2006 | A1 |
| 20060054634 | Mekata | Mar 2006 | A1 |
| 20060057168 | Larm | Mar 2006 | A1 |
| 20060088561 | Eini et al. | Apr 2006 | A1 |
| 20060099151 | Neubourg | May 2006 | A1 |
| 20060108377 | Glynn et al. | May 2006 | A1 |
| 20060110415 | Gupta | May 2006 | A1 |
| 20060110418 | Johnson | May 2006 | A1 |
| 20060114745 | Ollmann et al. | Jun 2006 | A1 |
| 20060121073 | Goyal et al. | Jun 2006 | A1 |
| 20060140984 | Tamarkin et al. | Jun 2006 | A1 |
| 20060140990 | Bortz et al. | Jun 2006 | A1 |
| 20060160713 | Sekine et al. | Jul 2006 | A1 |
| 20060165616 | Brock et al. | Jul 2006 | A1 |
| 20060177392 | Walden | Aug 2006 | A1 |
| 20060193789 | Tamarkin et al. | Aug 2006 | A1 |
| 20060193813 | Simonnet | Aug 2006 | A1 |
| 20060204446 | Lulla et al. | Sep 2006 | A1 |
| 20060222675 | Sabnis et al. | Oct 2006 | A1 |
| 20060233721 | Tamarkin et al. | Oct 2006 | A1 |
| 20060239937 | Neubourg | Oct 2006 | A2 |
| 20060251684 | Annis et al. | Nov 2006 | A1 |
| 20060254597 | Thompson | Nov 2006 | A1 |
| 20060263323 | Hoang et al. | Nov 2006 | A1 |
| 20060269485 | Friedman et al. | Nov 2006 | A1 |
| 20060272199 | Licciardello | Dec 2006 | A1 |
| 20060275218 | Tamarkin et al. | Dec 2006 | A1 |
| 20060275221 | Tamarkin et al. | Dec 2006 | A1 |
| 20060285912 | Eini et al. | Dec 2006 | A1 |
| 20060292080 | Abram et al. | Dec 2006 | A1 |
| 20070009607 | Jones | Jan 2007 | A1 |
| 20070010580 | De Paoli Ambrosi | Jan 2007 | A1 |
| 20070015739 | Walker et al. | Jan 2007 | A1 |
| 20070017696 | Lin et al. | Jan 2007 | A1 |
| 20070020213 | Tamarkin | Jan 2007 | A1 |
| 20070020304 | Tamarkin et al. | Jan 2007 | A1 |
| 20070027055 | Koivisto et al. | Feb 2007 | A1 |
| 20070036831 | Baker | Feb 2007 | A1 |
| 20070053943 | Wang et al. | Mar 2007 | A1 |
| 20070059253 | Popp et al. | Mar 2007 | A1 |
| 20070069046 | Eini et al. | Mar 2007 | A1 |
| 20070071688 | Illel et al. | Mar 2007 | A1 |
| 20070098647 | Neubourg | May 2007 | A1 |
| 20070111956 | Matsushima et al. | May 2007 | A1 |
| 20070134174 | Irwin et al. | Jun 2007 | A1 |
| 20070140998 | Kato et al. | Jun 2007 | A1 |
| 20070140999 | Puglia et al. | Jun 2007 | A1 |
| 20070141086 | Ohara et al. | Jun 2007 | A1 |
| 20070142263 | Stahl et al. | Jun 2007 | A1 |
| 20070148112 | Dingley et al. | Jun 2007 | A1 |
| 20070148194 | Amiji et al. | Jun 2007 | A1 |
| 20070154402 | Trumbore et al. | Jul 2007 | A1 |
| 20070160548 | Riccardi et al. | Jul 2007 | A1 |
| 20070166274 | Mazur et al. | Jul 2007 | A1 |
| 20070224143 | Konis | Sep 2007 | A1 |
| 20070237724 | Abram et al. | Oct 2007 | A1 |
| 20070253911 | Tamarkin et al. | Nov 2007 | A1 |
| 20070264317 | Yosha et al. | Nov 2007 | A1 |
| 20070271235 | Frank et al. | Nov 2007 | A1 |
| 20070280891 | Tamarkin et al. | Dec 2007 | A1 |
| 20070281999 | Fox et al. | Dec 2007 | A1 |
| 20070292355 | Tamarkin et al. | Dec 2007 | A1 |
| 20070292359 | Friedman et al. | Dec 2007 | A1 |
| 20070292461 | Tamarkin et al. | Dec 2007 | A1 |
| 20080008397 | Kisilev | Jan 2008 | A1 |
| 20080015263 | Bolotin et al. | Jan 2008 | A1 |
| 20080015271 | Abram et al. | Jan 2008 | A1 |
| 20080031907 | Tamarkin et al. | Feb 2008 | A1 |
| 20080031908 | Aubrun-Sonneville et al. | Feb 2008 | A1 |
| 20080035155 | Dahl | Feb 2008 | A1 |
| 20080044444 | Tamarkin et al. | Feb 2008 | A1 |
| 20080050317 | Tamarkin et al. | Feb 2008 | A1 |
| 20080058055 | LeMay et al. | Mar 2008 | A1 |
| 20080063682 | Cashman et al. | Mar 2008 | A1 |
| 20080069779 | Tamarkin et al. | Mar 2008 | A1 |
| 20080131378 | Keller et al. | Jun 2008 | A1 |
| 20080138293 | Tamarkin et al. | Jun 2008 | A1 |
| 20080138296 | Tamarkin et al. | Jun 2008 | A1 |
| 20080152596 | Friedman et al. | Jun 2008 | A1 |
| 20080153789 | Dmowski et al. | Jun 2008 | A1 |
| 20080166303 | Tamarkin et al. | Jul 2008 | A1 |
| 20080167376 | Bar-Or et al. | Jul 2008 | A1 |
| 20080181854 | Eini et al. | Jul 2008 | A1 |
| 20080188445 | Muldoon et al. | Aug 2008 | A1 |
| 20080188446 | Muldoon et al. | Aug 2008 | A1 |
| 20080193762 | Dubertret et al. | Aug 2008 | A1 |
| 20080206155 | Tamarkin et al. | Aug 2008 | A1 |
| 20080206159 | Tamarkin et al. | Aug 2008 | A1 |
| 20080206161 | Tamarkin et al. | Aug 2008 | A1 |
| 20080241079 | Neubourg | Oct 2008 | A1 |
| 20080253973 | Tamarkin et al. | Oct 2008 | A1 |
| 20080255498 | Houle | Oct 2008 | A1 |
| 20080260655 | Tamarkin et al. | Oct 2008 | A1 |
| 20080292560 | Tamarkin et al. | Nov 2008 | A1 |
| 20080299220 | Tamarkin et al. | Dec 2008 | A1 |
| 20080311167 | Oronsky et al. | Dec 2008 | A1 |
| 20080317679 | Tamarkin et al. | Dec 2008 | A1 |
| 20090017147 | Lintner et al. | Jan 2009 | A1 |
| 20090041680 | Tamarkin et al. | Feb 2009 | A1 |
| 20090053290 | Sand et al. | Feb 2009 | A1 |
| 20090061001 | Hougaz | Mar 2009 | A1 |
| 20090068118 | Eini et al. | Mar 2009 | A1 |
| 20090093514 | Statham et al. | Apr 2009 | A1 |
| 20090130029 | Tamarkin et al. | May 2009 | A1 |
| 20090131488 | Harel et al. | May 2009 | A1 |
| 20090175799 | Tamarkin et al. | Jul 2009 | A1 |
| 20090180970 | Tamarkin et al. | Jul 2009 | A1 |
| 20090214628 | De Rijk | Aug 2009 | A1 |
| 20090291917 | Akama et al. | Nov 2009 | A1 |
| 20090317338 | Tamarkin et al. | Dec 2009 | A1 |
| 20100111879 | Tamarkin et al. | May 2010 | A1 |
| 20100137198 | Eini et al. | Jun 2010 | A1 |
| 20100221194 | Loupenok | Sep 2010 | A1 |
| 20100221195 | Tamarkin et al. | Sep 2010 | A1 |
| 20100266510 | Tamarkin et al. | Oct 2010 | A1 |
| 20100286417 | Mendes et al. | Nov 2010 | A1 |
| 20110002857 | Tamarkin et al. | Jan 2011 | A1 |
| 20110002969 | Serraima et al. | Jan 2011 | A1 |
| 20110008266 | Tamarkin et al. | Jan 2011 | A1 |
| 20110045037 | Tamarkin et al. | Feb 2011 | A1 |
| 20110097279 | Tamarkin et al. | Apr 2011 | A1 |
| 20110207765 | Van Den Bussche et al. | Aug 2011 | A1 |
| 20110212033 | Tamarkin et al. | Sep 2011 | A1 |
| 20110262542 | Ashley | Oct 2011 | A1 |
| 20110268665 | Tamarkin et al. | Nov 2011 | A1 |
| 20110281827 | Tamarkin et al. | Nov 2011 | A1 |
| 20120064136 | Baker, Jr. et al. | Mar 2012 | A1 |
| 20120082632 | Phillips et al. | Apr 2012 | A1 |
| 20120087872 | Tamarkin et al. | Apr 2012 | A1 |
| 20120128598 | Trumbore et al. | May 2012 | A1 |
| 20120141384 | Tamarkin | Jun 2012 | A1 |
| 20120148503 | Tamarkin et al. | Jun 2012 | A1 |
| 20120156144 | Tamarkin et al. | Jun 2012 | A1 |
| 20120164087 | Carter | Jun 2012 | A1 |
| 20120181201 | Heggie | Jul 2012 | A1 |
| 20120195836 | Tamarkin et al. | Aug 2012 | A1 |
| 20120213709 | Tamarkin et al. | Aug 2012 | A1 |
| 20120213710 | Tamarkin et al. | Aug 2012 | A1 |
| 20120237453 | Tamarkin et al. | Sep 2012 | A1 |
| 20130011342 | Tamarkin et al. | Jan 2013 | A1 |
| 20130028850 | Tamarkin et al. | Jan 2013 | A1 |
| 20130053353 | Tamarkin et al. | Feb 2013 | A1 |
| 20130064777 | Tamarkin et al. | Mar 2013 | A1 |
| 20130115173 | Trumbore et al. | May 2013 | A1 |
| 20130161351 | Eini et al. | Jun 2013 | A1 |
| 20130164225 | Tamarkin et al. | Jun 2013 | A1 |
| 20130183250 | Friedman et al. | Jul 2013 | A1 |
| 20130183251 | Tamarkin et al. | Jul 2013 | A1 |
| 20130189191 | Tamarkin et al. | Jul 2013 | A1 |
| 20130189193 | Tamarkin et al. | Jul 2013 | A1 |
| 20130189195 | Tamarkin et al. | Jul 2013 | A1 |
| 20130189196 | Tamarkin et al. | Jul 2013 | A1 |
| 20130195769 | Tamarkin et al. | Aug 2013 | A1 |
| 20130225536 | Tamarkin et al. | Aug 2013 | A1 |
| 20130251644 | Majhi et al. | Sep 2013 | A1 |
| 20130261565 | Wong et al. | Oct 2013 | A1 |
| 20130295022 | Friedman et al. | Nov 2013 | A1 |
| 20130296387 | Saad | Nov 2013 | A1 |
| 20140050673 | Tamarkin et al. | Feb 2014 | A1 |
| 20140066524 | Tamarkin et al. | Mar 2014 | A1 |
| 20140086848 | Tamarkin et al. | Mar 2014 | A1 |
| 20140121188 | Tamarkin et al. | May 2014 | A1 |
| 20140140937 | Gurge et al. | May 2014 | A1 |
| 20140147504 | Salman et al. | May 2014 | A1 |
| 20140182585 | Tamarkin et al. | Jul 2014 | A1 |
| 20140186269 | Tamarkin et al. | Jul 2014 | A1 |
| 20140186442 | Mansouri | Jul 2014 | A1 |
| 20140221320 | Joks et al. | Aug 2014 | A1 |
| 20140227199 | Tamarkin et al. | Aug 2014 | A1 |
| 20140228355 | Kortagere et al. | Aug 2014 | A1 |
| 20140242016 | Binks et al. | Aug 2014 | A1 |
| 20140248219 | Tamarkin et al. | Sep 2014 | A1 |
| 20140271494 | Tamarkin et al. | Sep 2014 | A1 |
| 20150025060 | Tamarkin et al. | Jan 2015 | A1 |
| 20150098907 | Tamarkin et al. | Apr 2015 | A1 |
| 20150118164 | Tamarkin et al. | Apr 2015 | A1 |
| 20150125496 | Yamamoto | May 2015 | A1 |
| 20150141381 | Levy et al. | May 2015 | A1 |
| 20150157586 | Tamarkin et al. | Jun 2015 | A1 |
| 20150164922 | Tamarkin et al. | Jun 2015 | A1 |
| 20150174144 | Bowser et al. | Jun 2015 | A1 |
| 20150190409 | Tamarkin et al. | Jul 2015 | A1 |
| 20150196570 | Tamarkin et al. | Jul 2015 | A1 |
| 20150209296 | Yamamoto | Jul 2015 | A1 |
| 20150374625 | Tamarkin et al. | Dec 2015 | A1 |
| 20160101051 | Tamarkin et al. | Apr 2016 | A1 |
| 20160101184 | Tamarkin et al. | Apr 2016 | A1 |
| 20160128944 | Chawrai et al. | May 2016 | A1 |
| 20160158261 | Friedman et al. | Jun 2016 | A1 |
| 20160213757 | Edelson et al. | Jul 2016 | A1 |
| 20160279152 | Chen et al. | Sep 2016 | A1 |
| 20160287615 | Chan et al. | Oct 2016 | A1 |
| 20160354473 | Tamarkin et al. | Dec 2016 | A1 |
| 20160361252 | Franke | Dec 2016 | A1 |
| 20160361320 | Zhao et al. | Dec 2016 | A1 |
| 20170014517 | Tamarkin | Jan 2017 | A1 |
| 20170049712 | Bhalani et al. | Feb 2017 | A1 |
| 20170119665 | Tamarkin et al. | May 2017 | A1 |
| 20170157175 | Tamarkin et al. | Jun 2017 | A1 |
| 20170172857 | Tamarkin et al. | Jun 2017 | A1 |
| 20170181970 | Tamarkin et al. | Jun 2017 | A1 |
| 20170216334 | Tamarkin et al. | Aug 2017 | A1 |
| 20170231909 | Tamarkin et al. | Aug 2017 | A1 |
| 20170274084 | Friedman et al. | Sep 2017 | A1 |
| 20170340743 | Tamarkin et al. | Nov 2017 | A1 |
| 20170348418 | Tamarkin et al. | Dec 2017 | A1 |
| 20170354597 | Tamarkin et al. | Dec 2017 | A1 |
| 20170360705 | Tamarkin et al. | Dec 2017 | A1 |
| 20180000734 | Tamarkin et al. | Jan 2018 | A1 |
| 20180064638 | Tamarkin et al. | Mar 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 198780257 | Sep 1986 | AU |
| 782515 | Dec 2005 | AU |
| 2010219295 | Sep 2012 | AU |
| 2114537 | Feb 1993 | CA |
| 2154438 | Jan 1996 | CA |
| 2422244 | Sep 2003 | CA |
| 2502986 | Aug 2011 | CA |
| 2534372 | Jan 2012 | CA |
| 2536482 | Jul 2012 | CA |
| 639913 | Dec 1983 | CH |
| 1 882 100 | Nov 1963 | DE |
| 1926796 | Nov 1965 | DE |
| 4140474 | Jun 1993 | DE |
| 10009233 | Aug 2000 | DE |
| 10138495 | Feb 2003 | DE |
| 102004016710 | Oct 2005 | DE |
| 2 608 226 | Sep 2007 | DE |
| 52404 | May 1982 | EP |
| 0156507 | Oct 1985 | EP |
| 0186453 | Jul 1986 | EP |
| 0 211 550 | Feb 1987 | EP |
| 0 213 827 | Mar 1987 | EP |
| 0214865 | Mar 1987 | EP |
| 0 216 856 | Apr 1987 | EP |
| 0270316 | Jun 1988 | EP |
| 297436 | Jan 1989 | EP |
| 0 326 196 | Aug 1989 | EP |
| 0 336 812 | Oct 1989 | EP |
| 0 391 124 | Oct 1990 | EP |
| 0404376 | Dec 1990 | EP |
| 414920 | Mar 1991 | EP |
| 0 454 102 | Oct 1991 | EP |
| 0 485 299 | May 1992 | EP |
| 0484530 | May 1992 | EP |
| 0488089 | Jun 1992 | EP |
| 0 504 301 | Sep 1992 | EP |
| 0 528 190 | Feb 1993 | EP |
| 0535327 | Apr 1993 | EP |
| 0 552 612 | Jul 1993 | EP |
| 0569773 | Nov 1993 | EP |
| 0598412 | Nov 1993 | EP |
| 0 662 431 | Jul 1995 | EP |
| 0676198 | Oct 1995 | EP |
| 0738516 | Oct 1996 | EP |
| 0 757 959 | Feb 1997 | EP |
| 0824911 | Feb 1998 | EP |
| 0 829 259 | Mar 1998 | EP |
| 0 928 608 | Jul 1999 | EP |
| 0 979 654 | Feb 2000 | EP |
| 0993827 | Apr 2000 | EP |
| 1 025 836 | Aug 2000 | EP |
| 1055425 | Nov 2000 | EP |
| 0 506 197 | Jul 2001 | EP |
| 1215258 | Jun 2002 | EP |
| 1287813 | Mar 2003 | EP |
| 1 308 169 | May 2003 | EP |
| 1 375 386 | Jan 2004 | EP |
| 1428521 | Jun 2004 | EP |
| 1438946 | Jul 2004 | EP |
| 1189579 | Sep 2004 | EP |
| 1475381 | Nov 2004 | EP |
| 1 483 001 | Dec 2004 | EP |
| 1 500 385 | Jan 2005 | EP |
| 1 537 916 | Jun 2005 | EP |
| 1 600 185 | Nov 2005 | EP |
| 1 653 932 | May 2006 | EP |
| 1 734 927 | Dec 2006 | EP |
| 1 758 547 | Mar 2007 | EP |
| 1584324 | Nov 2007 | EP |
| 1 889 609 | Feb 2008 | EP |
| 1 902 706 | Mar 2008 | EP |
| 2 129 383 | Dec 2009 | EP |
| 2422768 | Feb 2012 | EP |
| 2494959 | Sep 2012 | EP |
| 2 456 522 | Dec 1980 | FR |
| 2 591 331 | Jun 1987 | FR |
| 2 640 942 | Jun 1990 | FR |
| 2 736 824 | Jan 1997 | FR |
| 2 774 595 | Aug 1999 | FR |
| 2 789 371 | Aug 2000 | FR |
| 2 793 479 | Nov 2000 | FR |
| 2 814 959 | Apr 2002 | FR |
| 2 833 246 | Jun 2003 | FR |
| 2 840 903 | Dec 2003 | FR |
| 2 843 373 | Feb 2004 | FR |
| 2 845 672 | Apr 2004 | FR |
| 2 848 998 | Jun 2004 | FR |
| 2 860 976 | Apr 2005 | FR |
| 2915891 | Nov 2008 | FR |
| 808104 | Jan 1959 | GB |
| 808105 | Jan 1959 | GB |
| 922930 | Apr 1963 | GB |
| 933486 | Aug 1963 | GB |
| 998 490 | Jul 1965 | GB |
| 1026831 | Apr 1966 | GB |
| 1 033 299 | Jun 1966 | GB |
| 1 081 949 | Sep 1967 | GB |
| 1121358 | Jul 1968 | GB |
| 1 162 684 | Aug 1969 | GB |
| 1 170 152 | Nov 1969 | GB |
| 1 201 918 | Aug 1970 | GB |
| 1 347 950 | Feb 1974 | GB |
| 1 351 761 | May 1974 | GB |
| 1 351 762 | May 1974 | GB |
| 1 353 381 | May 1974 | GB |
| 1 376 649 | Dec 1974 | GB |
| 1397285 | Jun 1975 | GB |
| 1 408 036 | Oct 1975 | GB |
| 1 457 671 | Dec 1976 | GB |
| 1 489 672 | Oct 1977 | GB |
| 2 004 746 | Apr 1979 | GB |
| 1 561 423 | Feb 1980 | GB |
| 2114580 | Aug 1983 | GB |
| 2 153 686 | Aug 1985 | GB |
| 2 172 298 | Sep 1986 | GB |
| 2 206 099 | Dec 1988 | GB |
| 2166651 | May 1996 | GB |
| 2337461 | Nov 1999 | GB |
| 2 367 809 | Apr 2002 | GB |
| 2 406 330 | Mar 2005 | GB |
| 2 406 791 | Apr 2005 | GB |
| 2 474 930 | Jul 2012 | GB |
| 49491 | Sep 1979 | IL |
| 0152486 | May 2003 | IL |
| 60001113 | Apr 1978 | JP |
| 55069682 | May 1980 | JP |
| 57044429 | Mar 1982 | JP |
| 56039815 | Apr 1984 | JP |
| 61275395 | Dec 1986 | JP |
| 62241701 | Oct 1987 | JP |
| 63119420 | May 1988 | JP |
| 01100111 | Apr 1989 | JP |
| 01156906 | Jun 1989 | JP |
| 2184614 | Jul 1990 | JP |
| 2255890 | Oct 1990 | JP |
| 4-51958 | Feb 1992 | JP |
| 04282311 | Oct 1992 | JP |
| 4312521 | Nov 1992 | JP |
| 5070340 | Mar 1993 | JP |
| 5213734 | Aug 1993 | JP |
| 6100414 | Apr 1994 | JP |
| H06-263630 | Jun 1994 | JP |
| 6329532 | Nov 1994 | JP |
| 2007155667 | Jun 1995 | JP |
| 7215835 | Aug 1995 | JP |
| 8501529 | Feb 1996 | JP |
| 2008040899 | Feb 1996 | JP |
| 8119831 | May 1996 | JP |
| 8165218 | Jun 1996 | JP |
| 8277209 | Oct 1996 | JP |
| 09 084855 | Mar 1997 | JP |
| 9099553 | Apr 1997 | JP |
| 9110636 | Apr 1997 | JP |
| 10114619 | May 1998 | JP |
| 3050289 | Sep 1998 | JP |
| 2010332456 | Dec 1998 | JP |
| 11501045 | Jan 1999 | JP |
| 11250543 | Sep 1999 | JP |
| 2000017174 | Jan 2000 | JP |
| 2000080017 | Mar 2000 | JP |
| 2000128734 | May 2000 | JP |
| 2000191429 | Jul 2000 | JP |
| 2000239140 | Sep 2000 | JP |
| 2000354623 | Dec 2000 | JP |
| 2000351726 | Dec 2000 | JP |
| 2001002526 | Jan 2001 | JP |
| 2001019606 | Jan 2001 | JP |
| 2001072963 | Mar 2001 | JP |
| 2002012513 | Jan 2002 | JP |
| 2002047136 | Feb 2002 | JP |
| 2002524490 | Aug 2002 | JP |
| 2002302419 | Oct 2002 | JP |
| 2003012511 | Jan 2003 | JP |
| 2003055146 | Feb 2003 | JP |
| 2004047136 | Feb 2004 | JP |
| 2004250435 | Sep 2004 | JP |
| 2004348277 | Dec 2004 | JP |
| 2005314323 | Nov 2005 | JP |
| 2005350378 | Dec 2005 | JP |
| 2006008574 | Jan 2006 | JP |
| 2006036317 | Feb 2006 | JP |
| 2006103799 | Apr 2006 | JP |
| 2006525145 | Nov 2006 | JP |
| 2007131539 | May 2007 | JP |
| 4892282 | Mar 2012 | JP |
| 143232 | Jul 1998 | KR |
| 2001003063 | Jan 2001 | KR |
| 520014 | May 2005 | NZ |
| 540166 | Jun 2007 | NZ |
| 2277501 | Jun 2006 | RU |
| 66796 | Jun 2004 | UA |
| 8201821 | Jun 1982 | WO |
| WO-8605389 | Sep 1986 | WO |
| 8801502 | Mar 1988 | WO |
| WO-8801863 | Mar 1988 | WO |
| 8808316 | Nov 1988 | WO |
| WO-8906537 | Jul 1989 | WO |
| WO-9005774 | May 1990 | WO |
| WO-9111991 | Aug 1991 | WO |
| WO-9200077 | Jan 1992 | WO |
| 9205142 | Apr 1992 | WO |
| 9205763 | Apr 1992 | WO |
| WO-9211839 | Jul 1992 | WO |
| WO 9213602 | Aug 1992 | WO |
| 9325189 | Dec 1993 | WO |
| 9406440 | Mar 1994 | WO |
| WO 9603115 | Feb 1996 | WO |
| WO-9603115 | Feb 1996 | WO |
| WO-9619921 | Jul 1996 | WO |
| WO 9619921 | Jul 1996 | WO |
| 9624325 | Aug 1996 | WO |
| 9626711 | Sep 1996 | WO |
| WO-9627376 | Sep 1996 | WO |
| WO-9639119 | Dec 1996 | WO |
| 9703638 | Feb 1997 | WO |
| 9739745 | Oct 1997 | WO |
| 9817282 | Apr 1998 | WO |
| WO-9818472 | May 1998 | WO |
| WO-9819654 | May 1998 | WO |
| WO-9821955 | May 1998 | WO |
| WO-9823291 | Jun 1998 | WO |
| WO 9831339 | Jul 1998 | WO |
| WO-9836733 | Aug 1998 | WO |
| 9852536 | Nov 1998 | WO |
| WO-9908649 | Feb 1999 | WO |
| WO-9920250 | Apr 1999 | WO |
| WO-9937282 | Jul 1999 | WO |
| 9953923 | Oct 1999 | WO |
| WO-0009082 | Feb 2000 | WO |
| WO-0015193 | Mar 2000 | WO |
| 0023051 | Apr 2000 | WO |
| WO 0062776 | Apr 2000 | WO |
| 0033825 | Jun 2000 | WO |
| 0038731 | Jul 2000 | WO |
| WO-0061076 | Oct 2000 | WO |
| WO 0072805 | Dec 2000 | WO |
| WO-0076461 | Dec 2000 | WO |
| 0105366 | Jan 2001 | WO |
| WO 0101949 | Jan 2001 | WO |
| 0110961 | Feb 2001 | WO |
| WO-0108681 | Feb 2001 | WO |
| 0153198 | Jul 2001 | WO |
| 0154212 | Jul 2001 | WO |
| 0162209 | Aug 2001 | WO |
| WO-0154679 | Aug 2001 | WO |
| WO-0170242 | Sep 2001 | WO |
| WO 200176579 | Oct 2001 | WO |
| 0182880 | Nov 2001 | WO |
| 0182890 | Nov 2001 | WO |
| 0185102 | Nov 2001 | WO |
| 0185128 | Nov 2001 | WO |
| 0195728 | Dec 2001 | WO |
| WO-0200820 | Jan 2002 | WO |
| WO 0207685 | Jan 2002 | WO |
| 0215860 | Feb 2002 | WO |
| 0215873 | Feb 2002 | WO |
| WO 0224161 | Mar 2002 | WO |
| WO-0228435 | Apr 2002 | WO |
| WO-0241847 | May 2002 | WO |
| WO-0243490 | Jun 2002 | WO |
| WO-02062324 | Aug 2002 | WO |
| 02078667 | Oct 2002 | WO |
| 02087519 | Nov 2002 | WO |
| 03000223 | Jan 2003 | WO |
| 03002082 | Jan 2003 | WO |
| WO 03005985 | Jan 2003 | WO |
| 03013984 | Feb 2003 | WO |
| WO 03015699 | Feb 2003 | WO |
| WO-03051294 | Jun 2003 | WO |
| 03055454 | Jul 2003 | WO |
| WO-03053292 | Jul 2003 | WO |
| WO-03055445 | Jul 2003 | WO |
| 03070301 | Aug 2003 | WO |
| 03071995 | Sep 2003 | WO |
| WO-03075851 | Sep 2003 | WO |
| 03097002 | Nov 2003 | WO |
| WO-03092641 | Nov 2003 | WO |
| WO 03094873 | Nov 2003 | WO |
| 2004017962 | Mar 2004 | WO |
| 2004037197 | May 2004 | WO |
| WO-2004037225 | May 2004 | WO |
| 2004003284 | Aug 2004 | WO |
| 2004064769 | Aug 2004 | WO |
| WO-2004064833 | Aug 2004 | WO |
| WO-2004071479 | Aug 2004 | WO |
| 2004078158 | Sep 2004 | WO |
| WO-2004078896 | Sep 2004 | WO |
| 2004093895 | Nov 2004 | WO |
| WO-2004112780 | Dec 2004 | WO |
| WO 2005009416 | Feb 2005 | WO |
| WO-2005011567 | Feb 2005 | WO |
| WO-2005018530 | Mar 2005 | WO |
| WO-2005018530 | Mar 2005 | WO |
| WO-2005032522 | Apr 2005 | WO |
| WO-2005044219 | May 2005 | WO |
| 2005063224 | Jul 2005 | WO |
| WO-2005065652 | Jul 2005 | WO |
| WO-2005076697 | Aug 2005 | WO |
| WO-2005097068 | Oct 2005 | WO |
| WO-2005097068 | Oct 2005 | WO |
| 2005102282 | Nov 2005 | WO |
| 2005102539 | Nov 2005 | WO |
| WO-2005117813 | Dec 2005 | WO |
| WO-2006003481 | Jan 2006 | WO |
| 2006011046 | Feb 2006 | WO |
| 2006020682 | Feb 2006 | WO |
| WO-2006010589 | Feb 2006 | WO |
| 2006028339 | Mar 2006 | WO |
| WO-2006031271 | Mar 2006 | WO |
| 2006045170 | May 2006 | WO |
| 2006079632 | Aug 2006 | WO |
| 2006081327 | Aug 2006 | WO |
| WO-2006091229 | Aug 2006 | WO |
| WO-2006100485 | Sep 2006 | WO |
| 2006121610 | Nov 2006 | WO |
| 2006122158 | Nov 2006 | WO |
| WO-2006120682 | Nov 2006 | WO |
| WO-2006129161 | Dec 2006 | WO |
| WO-2006131784 | Dec 2006 | WO |
| WO-2007007208 | Jan 2007 | WO |
| WO 2007010494 | Jan 2007 | WO |
| WO-2007012977 | Feb 2007 | WO |
| WO-2007023396 | Mar 2007 | WO |
| WO-2007031621 | Mar 2007 | WO |
| WO-2007039825 | Apr 2007 | WO |
| WO-2007050543 | May 2007 | WO |
| WO-2007054818 | May 2007 | WO |
| WO-2007072216 | Jun 2007 | WO |
| WO 2007082698 | Jul 2007 | WO |
| WO-2007085899 | Aug 2007 | WO |
| WO-2007085902 | Aug 2007 | WO |
| WO-2007099396 | Sep 2007 | WO |
| 2007111962 | Oct 2007 | WO |
| 2008010963 | Jan 2008 | WO |
| WO-2008008397 | Jan 2008 | WO |
| 2008041045 | Apr 2008 | WO |
| WO-2008038147 | Apr 2008 | WO |
| WO-2008075207 | Jun 2008 | WO |
| WO-2008087148 | Jul 2008 | WO |
| WO 2008104734 | Sep 2008 | WO |
| WO-2008110872 | Sep 2008 | WO |
| 2008152444 | Dec 2008 | WO |
| WO-2009007785 | Jan 2009 | WO |
| WO-2009069006 | Jun 2009 | WO |
| WO-2009072007 | Jun 2009 | WO |
| 2009090558 | Jul 2009 | WO |
| WO-2009087578 | Jul 2009 | WO |
| WO-2009090495 | Jul 2009 | WO |
| WO-2009090558 | Jul 2009 | WO |
| WO-2009098595 | Aug 2009 | WO |
| WO 2011006026 | Jan 2011 | WO |
| WO 2011013008 | Feb 2011 | WO |
| WO 2011013009 | Feb 2011 | WO |
| WO 2011026094 | Mar 2011 | WO |
| 2011039637 | Apr 2011 | WO |
| 2011039638 | Apr 2011 | WO |
| WO 2011064631 | Jun 2011 | WO |
| WO 2011106026 | Sep 2011 | WO |
| WO 2011138678 | Nov 2011 | WO |
| WO 2013136192 | Sep 2013 | WO |
| WO 2014134394 | Sep 2014 | WO |
| WO 2014134427 | Sep 2014 | WO |
| WO 2014151347 | Sep 2014 | WO |
| WO 2014201541 | Dec 2014 | WO |
| WO 2015075640 | May 2015 | WO |
| WO 2015114320 | Aug 2015 | WO |
| WO 2015153864 | Oct 2015 | WO |
| WO 2017029647 | Feb 2017 | WO |
| WO 2017030555 | Feb 2017 | WO |
| Entry |
|---|
| Machine translation of JP-08165218 (1996). |
| http://www.naturalwellbeing.com/learning-center/Cetearyl_Alcohol (accessed Jan. 13, 2014). |
| Effendy I. et al., “Surfactants and experimental irritant contact dermatitis”, Contact Dermatitis, 33(4), pp. 217-225 (1995) (abstract). |
| Barry, B.W. et al, Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments, British Journal of Dermatology, 93, 563-571, 1975. |
| Martindale, The extra pharmacopoeia [28th] edition, Eds.: Reynolds, J.E.F. and Prasad, A.B., The Pharmaceutical Press, London, pp. 862-864, 1982. |
| Wormser et al., Protective effect of povidone-iodine ointment against skin lesions induced by sulphur and nitrogen mustards and by non-mustard vesicants, Arch. Toxicol., 1997, 71, 165-170. |
| Wormser, Early topical treatment with providone-iodine ointment reduces, and sometimes prevents, skin damage following heat stimulus, Letter to the Editor, Burns 24, pp. 383, 1998. |
| Alcohol SDA 40B.http://www.pharmco-prod.com/pages/MSDS/SDA_40B_200.pdf Accessed Dec. 9, 2008, 2 pages. |
| Ambrose, Ursual et al., “In Vitro Studies of Water Activity and Bacterial Growth Inhibition of Sucrose-Polyethylene Glycol 400-Hydrogen Peroxide and Xylose-Polyethylene Glycol 400-Hydrogen Peroxide Pastes Used to Treat Infected Wounds,” Antimicrobial Agents and Chemotherapy, vol. 35, No. 9, pp. 1799-1803, 1991. |
| Arisan, http://www.arisankimya.com/kozmetik.htm Accessed Dec. 10, 2008. |
| Benet, et al., Application of NMR for the Determination of HLB Values of Nonionic Surfactants, Journal of the American Oil Chemists Society, vol. 49, 1972, 499-500. |
| Bucks, Daniel A.W., et al., “Bioavailability of Topically Administered Steroids: A ‘Mass Balance’ Technique,” Journal of Investigative Dermatology, vol. 91, No. 1, Jul. 1988, pp. 29-33. |
| Carbowax 1000MSDS; http://www.sciencelab.com/xMSDS-Polyethylene_glycol_1000-9926622. Accessed Dec. 13, 2008, 6 pages. |
| Cheshire, et al., Disorders of Sweating, www.medscape.com, Semin Neurol 23(4):399-406, 2003. |
| Coetzee, “Acceptability and Feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides,” Nicol.AIDS 2001, vol. 15, No. 14, pp. 1837-1842. |
| D.W.A. Sharp Dictionary of Chemistry, Penguin Books, 1983, 3 pages. |
| Dalby, “Determination of Drug Solubility in Aerosol Propellants,” Pharmaceutical Research, vol. 8, No. 9, 1991, pp. 1206-1209. |
| Denatonium Benzoate http://www.newdruginfo.com/pharmaceopeia/usp28/v28230/usp28nf23s0_m22790.htm Accessed Dec. 9, 2008. |
| Emulsifiers with HLB values. http://www.theherbarie.com/files/resources-center/formulating/Emulsifiers_HLB_Values.pdf accessed Aug. 5, 2009 (3 pps). |
| Ethanol, Accessed http://www.sigmaaldrich.com/catalog/ProductDetail.do?N4=E7023SIAL&N5=SEARCH_CONCAT_PNOBRAND_KEY&F=SPEC Dec. 9, 2008, 2 pages. |
| European Patent Application No. 06831721, Official Action, dated Feb. 3, 2009, 9 pages. |
| Flick, Cosmetic and Toiletry Formulations, vol. 5, 2nd Edition, Copyright 1996. |
| Fontana, Anthony, J., “Water Activity: Why It Is Important for Food Safety,” International Conference on Food Safety, Nov. 16-18, 1998, 9 pages. |
| Galligan, John et al., “Adhesive Polyurethane Liners for Anterior Restorations,” J. Dent. Res., Jul.-Aug. 1968, pp. 629-632. |
| Gill, A.M, et al., “Adverse Drug Reactions in a Paediatric lntensitve Care Unit,” Acta Paediatr 84:438-441, 1995. |
| Glaser, et al., Hyperhidrosis: A Comprehensive and Practical Approach to Patient Management, Expert Rev. Dermatol. 1(6), 773-775 (2006). |
| Gschnait, F., et al., “Topical Indomethacin Protects from UVB and UVA Irriadiation,” Arch. Dermatol. Res. 276:131-132, 1984. |
| Hall, Karla, “Diaper Area Hemanglomas: A Unique Set of Concerns,” http://members.tripod.com/˜Michelle_G/diaper.html, Dec. 1, 2008, 8 pages. |
| Hashim, et al. “Tinea versicolor and visceral leishmaniasis,” Int J Dermatol., Apr. 1994; 33(4), pp. 258-259 (abstract only). |
| Hepburn, NC., “Cutaneous leishmaniasis,” Clin Exp Dermatol, Jul. 2000; 25(5), pp. 363-370 (abstract only). |
| Hill, Randall M. (Ed.) Silicone Surfactants, Table of Contents and Chapter 7, “Silicone Surfactants: Applicants in the Personal Care Industry,” by David T. Floyd, 1999 (30 Pages). |
| Innocenzi, Daniele et al., “An Open-Label Tolerability and Effacy Study of an Aluminum Sesquichlorhydrate Topical Foam in Axillary and Palmar Primary Hyperhidrosis,” Dermatologic Therapy, vol. 21, S27-S30, 2008. |
| International Search Report and Written Opinion, International Application No. PCT/IB2006/003628, Foamix Ltd., dated Dec. 7, 2007, 15 pages. |
| International Search Report and Written Opinion, International Application No. PCT/US2007/004459, Foamix Ltd., dated Dec. 9, 2008, 2 pages. |
| International Search Report for International Application No. PCT/IB2006/003974, dated Feb. 25, 2008 (3 pages). |
| International Search Report, International Patent Application No. PCT/IB2007/003463, Foamix, Ltd., dated Jul. 18, 2008, 3 pages. |
| International Search Report, International Patent Application No. PCT/IB2007/003759, Foamix Ltd., dated Jul. 8, 2008 (3 pages). |
| Kalkan, et al., The Measurement of Sweat Intensity Using a New Technique, Tr. J. of Medical Sciences 28, 515-517 (1998). |
| Kathon™ CG (product information sheet by Rohm and Haas, Jun. 2006). |
| Kinnunen, Contact Dermatitis Sep. 1989; 21(3): 154-8. |
| Koerber, S., “Humectants and Water Activity,” Water Activity News, 2000, ISSN No. 1083-3943. |
| Licking Vaginal Dryness without a Prescription. Accessed http://www.estronaut.com/a/vag_dryness.htm on Dec. 14, 2008. |
| Material Safety Data Sheet, Progesterone, Apr. 26, 2006, 5 pages. |
| Material Safety Data Sheet, Science Lab.com, Polyethylene Glycol 1000, MSDS, Nov. 6, 2008, 6 pages. |
| Merriam-Webster Online Dictionaary, 2008, “Mousse,” Merriam-Webster Online, Dec. 8, 2008 http://www.merriam-webster.com/dictionary/mousse. |
| Metronidazole. www.usp.org/pdf/EN/veterinary/metronidazole.pdf. accessed Sep. 10, 2009, 4 pages. |
| Morgan, Timothy M., et al., “Enhanced Skin Permeation of Sex Hormones with Novel Topical Spray Vehicles,” Journal of Pharmaceutical Sciences, vol. 87, No. 10, Oct. 1998, pp. 1213-1218. |
| OM Cinnamate. http://www.makingcosmetics.com/sunscreens/OM-Cinnamate-p102.html accessed Sep. 26, 2009. |
| Pendergrass, “The shape and dimensions of the human vagina as seen in three-dimensional vinyl polysiloxane casts,” Gynecol Obstet. Invest. 1996:42(3):178-82 (abstract). |
| Progesterone MSDS. http://www.usp.org.pdf.EN/referenceStandards/msds/1568007.pdf on Dec. 14, 2002, 5 pages. |
| Savin, et al., “Tinea versicolor treated with terbinafine 1% solution,” Int J. Dermatol, Nov. 1999; 38(11), pp. 863-865. |
| Schmidt A., “Malassezia furfur: a fungus belonging to the physiological skin flora and its relevance in skin disorders,” Curtis., Jan. 1997; 59(1), pp. 21-24 (abstract). |
| Scott as Published in Pharmaceutical Dosage Forms; Disperse Systems, vol. 3, Copyright 1998. |
| Shear, et al., “Pharmacoeconomic analysis of topical treatments for tinea infections,” Pharmacoeconomics. Mar. 1995; 7(3); pp. 251-267 (abstract only). |
| Sigma Aldrich, “HLB-Numbers in Lithography Nanopatterning,” http://www.sigmaaldrich.com/materials-science/micro-and-nanoelectronics/lithography-nanopatterning/hlb-numbers.html, accessed: Feb. 2, 2009, pp. 1-3. |
| Sigma-Aldrich, Material Safety Data Sheet, Hydroxyethyl Cellulose, Mar. 3, 2004, 5 pages. |
| Skin Biology, CP Serum—Copper-Peptide Serum for Skin Regeneration and Reducing Wrinkles, Skin Biology, http;//web.archive.org/web/20030810230608/http://www.skinbio.com/cpserum.html, Dec. 1, 2008, 21 pages. |
| Squire. J, “A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis,” Dermatolog Treat. Jun. 2002;13(2):51-60 (abstract only). |
| Tan et al., “Effect of Carbopol and Polyvinylpyrrolidone on the Mechanical, Rheological, and Release Properties of Bioadhesive Polyethylene Glycol Gels,” AAPS PharmSciTech, 2000; 1(3) article 24 (2000), 10 pages. |
| Torres-Rodriguez, JM., “New topical antifungal drugs,” Arch Med Res. 1993 Winter; 24(4), pp. 371-375 (abstract). |
| Toxicology and Carcinogenesis Studies of t-Butyl Alcohol (CAS No. 75-65-0) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies), http://ntp.niehs.nih.gob/?objectid-=0709F73D-A849-80CA-5FB784E866B576D1. Accessed Dec. 9, 2008. |
| Edirisinghe, et al., “Effect of fatty acids on endothelium-dependent relaxation in the rabbit aorta”, Clin Sci (Lond). Aug. 2006; 111(2): 145-51. |
| Encyclopedia of Pharmaceutical Technology, Second Edition, vol. 3, Copyright 2002. |
| Hakan, et al., “The protective effect of fish oil enema in acetic acid and ethanol induced colitis,” The Turkish Journal of Gasroenterology, 2000, vol. 11, No. 2, pp. 155-161. |
| http://ibabydoc.com/online/diseaseeczema.asp., Atopic Dermatitis, Copyright 2000. |
| http://web.archive.org/web/20000106225413/http://pharmacy.wilkes.edu/kibbeweb/lab7.html, Characteristics of Surfactants and Emulsions, Jan. 29, 2010, 5 pages. |
| http://www.agworkshop.com/p3.asp, AG&Co. Essential oil workshop, accessed Jan. 31, 2010. |
| Kanamoto, et al., “Pharmacokinetics of two rectal dosage forms of ketoprofen in patients after anal surgery,” J Pharmacobiodyn., Mar. 1988; 11(3):141-5. |
| Leung, et al., “Bioadhesive Drug Delivery in Water-Soluble Polymers,” American Chemical Society, Chapter 23, 1991, pp. 350-366. |
| Tarumoto, et al., Studies on toxicity of hydrocortisone 17-butyrate 21-propionate-1. Accute toxicity of hydrocortisone 17-butyrate 21-propionate and its analogues in mice, rats and dogs (author's trans), J Toxicol Sci., Jul. 1981; 6 Suppl: 1-16. |
| U.S. Appl. No. 60/789,186, filed Apr. 4, 2006, Tamarkin. |
| U.S. Appl. No. 60/815,948, filed Jun. 23, 2006, Tamarkin. |
| U.S. Appl. No. 60/818,634, filed Jul. 5, 2006, Friedman. |
| U.S. Appl. No. 60/843,140, filed Sep. 8, 2006, Tamarkin. |
| U.S. Appl. No. 61/248,144, filed Oct. 2, 2009, Tamarkin. |
| U.S. Appl. No. 61/322,148, filed Apr. 8, 2010, Tamarkin. |
| U.S. Appl. No. 61/363,577, filed Jul. 12, 2010, Eini. |
| “Burn patients need vitamin D supplements.” Decision News Media, Jan. 23, 2004, http://www.nutraingredients.com/Research/Burn-patients-need-vitamin-D-supplements, Accessed: May 5, 2010. |
| “HLB Systems”, http://pharmcal.tripod.com/ch17.htm, Accessed Sep. 17, 2010, pp. 1-3. |
| “Minocycline” accessed on Oct. 21, 2011 at en.wikipedia.org/wiki/Minocycline, 7 pages. |
| “Reaction Rate” Accessed at en.wikipedia.org/wiki/Reaction_rate on Dec. 18, 2011, 6 pages. |
| ‘Niram Chemicals’ [online]. Niram Chemicals, [retrieved on Jul. 17, 2012]. Retrieved from the Internet: <URL: http://www.indiamart.com/niramchemicals/chemicals.html>, 7 pages. |
| ‘Surfactant’ [online]. Wikipedia, 2010, [retrieved on Oct. 24, 2010]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/Surfactant>, 7 pages. |
| Adachi, Shuji. “Storage and Oxidative Stability of O/W/ Nano-emulsions.” Foods Food Ingredients. J. Jpn. vol. 209, No. 11. 2004. 1 page. |
| Anton, N. et al. “Water-in-Oil Nano-Emulsion Formation by the phase inversion Temperature Method: A Novel and General Concept, a New Template for Nanoencapsulation,” Proceedings of the 33rd Annual Meeting and Exposition of the Controlled Release Society, Jul. 2006, Vienna, Austria, 2 pages. |
| Arct et al., “Common Cosmetic Hydrophilic Ingredients as Penetration Modifiers of Flavonoids”, International Journal of Cosmetic Science, 24(6):357-366 (2002)—Abstract, 1 page. |
| Augsburger, Larry L. et al. “Bubble Size Analysis of High Consistency Aerosol Foams and Its Relationship to Foam Rheology. Effects of Container Emptying, Propellent Type, and Time.” Journal of Pharmaceutical Sciences. vol. 57, No. 4. Apr. 1968. pp. 624-631. |
| Austria, et al., “Stability of Vitamin C Derivatives in Solution and Topical Formulations”, Journal of Pharmaceutical and Biomedical Analysis, 15:795-801 (1997). |
| Barry and Badal, “Stability of minocycline, doxycycline, and tetracycline stored in agar plates and microdilution trays,” Current Microbiology, 1978, 1:33-36. |
| Bernstein, et al., Effects of the Immunomodulating Agent R837 on Acute and Latent Herpes Simplex Virus Type 2 Invections, Antimicrobial Agents and Chemotherapy, 33(9):1511-1515 (1989). |
| Blute, “Phase behavior of alkyl glycerol ether surfacants”, Physical Chemistry Tenside Sur. Det., 35(3):207-212 (1998). |
| Brenes, et al., “Stability of Copigmented Anthocyanins and Asorbics Acid in a Grape Juice Model System”, J. Agric Food Chem, 53(1):49-56 (2005)—Abstrace, 1 page. |
| Bronopol. Revtrieved online on Jun. 4, 2011. <URL:http://chemicalland21.com/specialtychem/perchem/BRONOPOL.html>. Jul. 17, 2006. 4 pages. |
| Buck, et al., “Treatment of Vaginal Intraephithelial Neoplasia (Primarily Low Grade) with Imiquimod 5% Cream”, Journal of Lower Genetial Tract Disease, 7(3):290-293 (2003). |
| Bunker,et al., “Alterations in Scalp Blood Flow after the Epicutaneous Application of 3% Minoxidil and 0.1% Hexyl Nicotinate in Alopecia”, Presented as a poster at the meeting of the British Society for Investigavie Dermatology, York, Sep. 1986 (2 pages). |
| Burton, et al., “Hypertrichosis Due to Minoxidil”, British Journal of Dermatology, 101:593-595 (1979). |
| Campos, et al., “Ascorbic Acid and Its Derivatives in Cosmetic Formulations”, Cosmetics and Toiletries, 115(6):59-62 (2000)—Abstract, 1 page. |
| Carelli, et al., “Effect of Vehicles on Yohimbine Permeation Across Excised Hairless Mouse Skin”, Pharm Acta Helv, 73(3):127-134 (1998)—Abstract, 1 page. |
| Chebil, et al., “Soulbility of Flavonoids in Organic Solvents”, J. Chem. Eng. Data, 52(5):1552-1556 (2007)—Abstract, 1 page. |
| Chiang, et al., “Bioavailability Assessment of Topical Delivery Systems: In Vitro Delivery of Minoxidil from Prototypical Semi-Solid Formulations”, Int. J. Pharm, 49(2):109-114 (1989)—Abstract, 1 page. |
| Chinnian, et al., “Photostability Profiles of Minoxidil Solutions”, PDA J. Pharm Sci Technol., 50(2):94-98 (1996)—Abstract, 1 page. |
| Chollet, et al., “Development of a Topically Active Imiquimod Formulation”, Pharmaceutical Development and Technology, 4(1):35-43 (1999). |
| Chollet, et al., “The Effect of Temperatures on the Solubility of Immiquimod in Isostearic Acid”, Abstract 3031, Pharmaceutical Research, vol. 14, No. 11 Supplemental (November), p. S475 (1997), 2 pages. |
| Colloidal Silica. Retrieved online on Jun. 4, 2011. <URL:http://www.grace.com/engineeredmaterials/materialsciences/colloidalsilica/default.aspx>. Copyright 2011. 4 pages. |
| Croda 2. Croda Cetomacrogol 1000 Product Information Sheet. 2011 (no month given). 1 page. |
| Croda. Aracel 165 Product Summary. 2011 (no month given). 1 page. |
| Dawber, et al., “Hypertrichosis in Females Applying Minoxidil Topical Solution and in Normal Controls”, JEADV, 17:271-275 (2003). |
| Dentinger, et al., “Stability of Nifedipine in an Extemporaneously Compounded Oral Solution”, American Journal of Health-System Pharmacy, 60(10):1019-1022 (2003)—Abstract, 1 page. |
| Disorder. (2007). In the American Heritage Dictionary of the English Language. Retrieved from http://www.credoreference.com/entry/hmdictenglang/disorder. 1 page. |
| Draelos, Z. D. “Antiperspirants and the Hyperhidrosis Patients.” Dermatologic Therapy. 2001. vol. 14. pp. 220-224. |
| Edens, et al., “Storage Stability and Safey of Active Vitamin C in a New Dual-Chamber Dispenser”, Journal of Applied Cosmetology, 17(4):136-143 (1999)—Abstract, 1 page. |
| Edwards, “Imiquimod in Clinical Practice”, J. Am Acad Dermatol., 43(1, Pt 2):S12-S17 (2000)—Abstract, 1 page. |
| Esposito, E. et al. “Nanosystems for Skin Hydration: A Comparative Study.” International Journal of Cosmetic Science. 29. 2007. pp. 39-47. |
| Ethylene Oxide Derivatives: An Essence of Every Industry. A definition of Emulsifier. Http://www.emulsifiers.in/ethylene_oxide_derivatives2.htm. Accessed Jul. 12, 2011. 3 pages. |
| Farahmand, et al., “Formulation and Evaluation of a Vitamin C Multiple Emulsion”, Pharmaceutical Development and Technology, 11(2):255-261 (2006)—Abstract, 1 page. |
| Final Office Action for U.S. Appl. No. 11/430,437, Tamarkin et al., dated Dec. 16, 2008, 24 pages. |
| Gallarate, et al., “On the Stability of Ascorbic Acid in Emulsified Systems for Topical and Cosmetic Use”, International Journal of Pharmaceutics, 188:233-241 (1999). |
| Gelbard et al. “Primary Pediatric Hyperhidrosis: A Review of Current Treatment Options.” Pediatric Dermatology. 2008. 25 (6). pp. 591-598. |
| Gladkikh, “Ascorbic Acid and Methods of Increasing its Stability in Drugs”, Translated from Khimiko-Farmatsevticheskii Zhurnal, 4(12):37-42 (1970)—1 page. |
| Graves, S. et al. “Structure of Concentrated Nanoemulsions.” The Journal of Chemical Physics . . . 122 America Institute of Physics. Published Apr. 1, 2005. 6 pages. |
| Groveman, et al., “Lack of Efficacy of Polysorbate 60 in the Treatment of Male Pattern Baldness”, Arch Intern Med, 145:1454-1458 (1985). |
| Hallstar. Retrieved online on Jun. 4, 2011. <URL:http://www.hallstar.com/pis.php?product=1H022>. 1 page. |
| Hargreaves, “Chemical Formulation, An Overview of Surfactant-Based Preparations Used in Everyday Life”, The Royal Society of Chemistry, pp. 114-115 (2003). |
| Harrison, et al., “Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs”, Antivial Res., 15(4):315-322 (1991). |
| Harrison, et al., “Modification of Immunological Responses and Clinical Disease During Topical R-837 Treatment of Genital HSV-2 Infection”, Antiviral Research, 10:209-224 (1988). |
| Harrison, et al., “Pharmacokinetics and Safety of Iminquimod 5% Cream in the Treatment of Actinic Keratoses of the Face, Scalp, or Hands and Arms”, Arch. Dermatol. Res., 296(1):6-11 (2004)—Abstract, 1 page. |
| Harrison, et al., “Posttherapy Suppression of Genital Herpes Simplex Virus (HSV) Recurrences and Enhancement of HSV-Specific T-Cell Memory by Imiquimod in Guinea Pigs”, Antimicrobial Agents and Chemotherapy, 38(9):2059-2064 (1994). |
| Heart Failure, The Merck Manual, 2008 <<http://www.merck.com/mmhe/sec03/ch025/ch025a.html>> 12 pages. |
| Hormones. Http://www.greenwillowtree.com/Page.bok?file=libido.html. Jan. 2001. |
| Hubbe, Martin. Mini-Encyclopedia of Papermaking Wet-End Chemistry: Additives and Ingredients, their Composition, Functions, Strategies for Use. Retrieved online on Jun. 4, 2011. <URL://http://www4.ncsu.edu/˜hubbe/CSIL.htm>. Feb. 1, 2001. 2 pages. |
| Hydroxyethylcellulose. Http: //terpconnect.umd.edu/-choi/MSDS/Sigma-Aldrich/HYDROXYETHYL%20CELLULOSE, 5 pages, Jan. 14, 2004. |
| ICI Americas Inc. “The HLB System: A Time-Saving Guide to Emulsifier Selection.” Mar. 1980. pp. 1-22. |
| Ikuta, et al., “Scanning Electron Microscopic Observation of Oil/Wax/Water/Surfacant System”, Journal of SCCJ, 34(4):280-291 (2004)—Abstract, 1 page. |
| Indomethacin. Retrieved online on Jun. 3, 2011. <URL:http://it03.net/com/oxymatrine/down/1249534834.pdf>. Aug. 15, 2009. 3 pages. |
| Izquierdo, P. et al. “Formation and Stability of Nano-Emulsions Prepared Using the Phase Inversion Temperature Method.” University of Barcelona. Sep. 17, 2001. 1 page. |
| Jan. “Troubled Times: Detergent Foam.” http://zetatalk.com/health/theall7c.htm. Accessed Feb. 9, 2012. 2 pages. |
| Joseph, “Understanding foams & foaming,” University of Minnesota (1997), at http://www.aem.umn.edu/people/faculty/joseph/archive/docs/understandingfoams.pdf, pp. 1-8. |
| Kang,et al., “Enhancement of the Stability and Skin Penetration of Vitamin C by Polyphenol”, Immune Netw., 4(4):250-254 (2004)—Abstract, 1 page. |
| Karasu, T.B. et al., “Treatment of Patients with Major Depressive Disorder, Second Edition,” pp. 1-78, 2000. |
| Kim, “Stability of Minoxidil in Aqueous Solution”, Yakhak Hoechi, 30(5):228-231 (1986)—Abstract, 1 page. |
| Kleber, M.D., H.D. et al., “Treatment of Patients with Substance Use Disorders, Second Edition,” pp. 1-276, 2006. |
| Kreuter, J. “Nanoparticles and microparticles for drug and vaccine delivery,” J. Anat. (1996) 189, pp. 503-505. |
| Kumar, J. et ak., “Application of Broad Spectrum Antiseptic Povidone Iodine as Powerful Action: A Review,” Journal of Pharmaceutical Science and Technology vol. 1(2), 2009, 48-58. |
| Kwak et al. “Study of Complete Transparent Nano-Emulsions which Contain Oils.” IFSCC Conference 2003, Seoul, Korea, Sep. 22-24, 2003. 3 pages. |
| Lautenschlager, Dr. Hans. “A Closer Look on Natural Agents: Facts and Future Aspects.” Kosmetic Konzept. Kosmetische Praxis. 2006 (no month given). (5), 8-10. 3 pages. |
| Lebwohl et al. “Treatment of Psoriasis. Part 1. Topical Therapy and Phototherapy.” J. Am. Acad. Dermatol. 45:487-498. Oct. 2001. |
| Lebwohl et al., “A randomized, double-blind, placebo-controlled study of clobestasol propionate 0.05% foam in the treatment of nonscalp psoriasis,” International Journal of Dermatology, 2002, 41(5): 269-274. |
| Lee, et al., “The Stabilization of L-Ascorbic Acid in Aqueous Solution and Water-in-Oil-in-Water Double Emulsion by Controlling pH and Electrolyte Concentration”, J. Cosmet. Sci., 55:1-12 (Jan./Feb. 2004). |
| Li, et al., “Solubility Behavior of Imiquimod in Alkanoic Acids”, Abstract 3029, Pharmaceutical Research, vol. 14, No. 11 Supplemental (November), p. S475 (1997), 2 pages. |
| Lippacher, A. et al. “Liquid and Semisolid SLN Dispersions for Topical Application” Rheological Characterization. European Journal of Pharmaceutics and Biopharmaceutics. 58. 2004. pp. 561-567. |
| Lupo, “Antioxidants and Vitamins in Cosmetics”, Clinics in Dermatology, 19:467-473 (2001). |
| Martindale. 33 ed. London, Bath Press, 2002. pp. 1073 and 1473. |
| Merck index, 10th edition, Merck & Co., Inc.: Rahway, NJ, 1983, pp. 39 (entry 242 for allantoin). |
| Merck index, 14th edition, O'Neill, ed., 2006, entry for p-amino benzoic acid. |
| Merck index, 14th edition, O'Neill, ed., 2006, entry for zinc oxide. |
| Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition. O'Neil et al eds. Entries 1058, 2350, 6143, and 8803. 2001. 7 pages. |
| Merck Manual Home Edition. “Excessive Sweating: Sweating Disorders.” Accessed Apr. 14, 2011 at www.merckmanuals.com/home/print/sec18/ch206/ch206c.html. 2 pages. |
| Merriam Webster Online Dictionary [online] retrieved from http://www.merriam-webster.com/cgi-bin/dictionary?book=dictionary&va=derivative on Jul. 5, 2008; 1 page. |
| Messenger, et al., “Minoxidil: Mechanisms of Action on Hair Growth”, British Journal of Dermatology, 150:186-194 (2004). |
| Metz, et al., “A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy”, Clinical Cancer Research, 10:6411-6417 (2004). |
| Meucci, et al., “Ascorbic Acid Stability in Aqueous Solutions”, Acta Vitaminol Enzymol, 7(3-4):147-153 (1985)—Abstract, 1 page. |
| MMP Inc. International Development and Manufacturing, “Formulating specialities,” http://mmpinc.com, 3 pages. Feb. 2, 2010. |
| Molan, Peter Clark, “World Wide Wounds,” Dec. 2001, 13 pages. |
| Neutrogena. Http://www.cosmetoscope.com/2010/04/neutrogea-clinical-with-johnson-johnsons-cytomimic-techology/. Published Apr. 28, 2010. Accessed Sep. 11, 2010, 5 pages. |
| Nietz, “Molecular orientation at surfaces of solids,” J. Phys. Chem., 1928, 32(2): 255-269. |
| No Author Listed. “Opitmization of Nano-Emulsions Production by Microfluidization.” European Food Research and Technology. vol. 225, No. 5-6. Sep. 2007. Abstract. 1 page. |
| Office Action for U.S. Appl. No. 11/430,437, Tamarkin et al., dated May 9, 2008, 27 pages. |
| Office Action received from the U.S. Patent Office, U.S. Appl. No. 11/430,599, dated Jul. 28, 2008 (59 pages). |
| Oil. Dictionary of Chemistry. Editor: DWA Sharp. Copyright 1990. |
| Olsen, et al., “A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of a Novel Formulation of 5% Minoxidil Topical Foam Versus Placebo in the Treatment of Androgenetic Alopecia in Men”, J. Am. Acad Dermatol, 57:767-774 (2007). |
| Padhi et al., “Phospho-olicines as positive-electrode materials for rechargeable lithium batteries,” J. Electrochemical Soc., 1997, 144(4): 1188-1194. |
| Pakpayat, et al., “Formulation of Ascorbic Acid Microemulstions with Alkyl Polyglycosides”, European Journal of Pharmaceutics and Biopharmaceutics, 72:444-452 (2009). |
| Paula. http://ww.cosmeticscop.com/cosmetic-ingredient-dictionary/definition/259/c12-15-alkyl-benzoate.aspx. Printed Oct. 24, 2010. 1 page. |
| Prescription Information for Aldara, Mar. 2007 (29 pages). |
| Prevent. (2007). In the American Heritage Dictionary of the English Language. Retrieved from http://www.credoreference.com/entry/hmdictenglang/prevent. 1 page. |
| Psoriasis, http://www.quickcare.org/skin/causes-of0psoriasis.html. Accessed Sep. 9, 2010—3 pages. |
| Purcell, Hal C. “Natural Jojoba Oil Versus Dryness and Free Radicals.” Cosmetics and Toiletries Manufacture Worldwide. 1988. 4 pages. |
| Raschke, et al., “Topical Activity of Ascorbic Acid: From In Vitro Optimization to In Vivo Efficacy”, Skin Pharmacology and Physiology, 17(4):200-206 (2004)—Abstract, 1 page. |
| Ravet et al., “Electroactivity of natural and synthetic triphylite,” J. of Power Sources, 2001, 97-98: 503-507. |
| Raymond, Iodine as an Aerial Disinfectant, Journal of Hygiene, vol. 44, No. 5 (May 1946), pp. 359-361. |
| Receptacle. Merriam Webster. Http://www.merriam-webster.com/dictionary/receptacle. Accessed Jul. 12, 2011. 1 page. |
| Richwald, “Imiquimod”, Drugs Today, 35(7):497 (1999)—Abstract, 1 page. |
| Rieger and Rhein. “Emulsifier Selection/HLB.” Surfactants in Cosmetics. 1997 (no month given). 1 page. |
| Rosacea, http://clinuvel.com/skin-conditions/common-skin-conditions/rosacea#h0-6-prevention. Accessed Sep. 9, 2010, 5 pages. |
| Schulze, M.D., Harry “Iodine and Sodium Hypochlorite as Wound Disinfectants,” The British Medical Journal, pp. 921-922, 1915. |
| Scientific Discussion for the approval of Aldara, EMEA 2005 (10 pages). |
| Seborrheic Dermatitis, http://www.cumc.columbia.edu/student/health/pdf/R-S/Seborrhea%20Dermatitis.pdf. Access Sep. 9, 2010, 2 pages. |
| Sheu, et al., “Effect of Tocopheryl Polyethylene Glycol Succinate on the Percutaneous Penetration of Minoxidil from Water/Ethanol/Polyethylene Glycol 400 Solutions”, Drug Dev. Ind. Pharm., 32(5):595-607 (2006)—Abstract, 1 page. |
| Shim, et al., “Transdermal Delivery of Mixnoxidil with Block Copolymer Nanoparticles”, J. Control Release, 97(3):477-484 (2004)—Abstract, 1 page. |
| Shrestha et al., Forming properties of monoglycerol fatty acid esters in nonpolar oil systems, Langmuir, 2006, 22: 8337-8345. |
| Silicone. Definition. Retrieved Apr. 19, 2011 from http://www.oxforddictionaries.com/definition/silicone?view=uk. 1 page. |
| Simovic, S. et al., “The influence of Processing Variables on Performance of O/W Emulsion Gels Based on Polymeric Emulsifier (Pemulen ÒTR-2NF),” International Journal of Cosmetic Science, vol. 2(2): abstract only. Dec. 24, 2001, 1 page. |
| Skin Deep Cosmetics. PPG-40-PEG-60 Lanolin Oil http://www.cosmeticsdatabase.com/ingredient/722972/PPG-40-PEG-60_Lanolin_Oil/?ingred06=722972. 3pages. |
| Smith, Anne. “Sore Nipples.” Breastfeeding Mom's Sore Nipples: Breastfeeding Basics. http://breastfeedingbasics.com/articles/sore-nipples. Accessed Feb. 8, 2012. 9 pages. |
| Sonneville-Aubrun, O. et al. “Nanoemulsions: A New Vehicle for Skincare Products.” Advances in Colloid and Interface Science. 108-109.. 2004. pp. 145-149. |
| Sreenivasa, et al., “Preparation and Evaluation of Minoxidil Gels for Topical Application in Alopecia”, Indian Journal of Pharmaceutical Sciences, 68(4):432-436 (2006), 11 pages. |
| Stehle et al., Uptake of minoxidil from a new foam formulation devoid of propylene glycol to hamster ear hair follicles, J. Invest. Dermatol., 2005, 124(4), A101. |
| Sugisaka, et al., “The Physiochemical Properties of Imiquimod, the First Imidazoquinoline Immune Response Modifier”, Abstract 3030, Pharmaceutical Research, vol. 14, No. 11 Supplemental (November), p. S475 (1997), 2 pages. |
| Surfactant. Chemistry Glossary. Http://chemistry.about.com/od/chemistryglossary/g/surfactant.htm, 2012, 1 page. |
| Sweetman, Sean C. Martindale: The Complete Drug Reference. 33rd Edition. London. Pharmaceutical Press. Jun. 21, 2002. pp. 1073 and 1473. 5 pages. |
| Tadros, Tharwat F. “Surfactants in Nano-Emulsions.” Applied Surfactants: Principles and Applications. Wiley-VCH Verlag GmbH & Co. Weinheim. ISBN: 3-527-30629-3. 2005. pp. 285-308. |
| Tanhehco, “Potassium Channel Modulators as Anti-Inflammatory Agents”, Expert Opinion on Therapeutic Patents, 11(7):1137-1145 (2001)—Abstract, 3 pages. |
| Tata, et al., “Penetration of Minoxidil from Ethanol Propylene Glycol Solutions: Effect of Application Volume on Occlusion”, Journal of Pharmaceutical Sciences, 84(6):688-691 (1995). |
| Tata, et al., “Relative Influence of Ethanol and Propylene Glycol Cosolvents on Deposition of Minoxidil into the Skin”, Journal of Pharmaceutical Sciences, 83(10):1508-1510 (1994). |
| Third Party Submission for U.S. Appl. No. 12/014,088, Feb. 4, 2009, 4 pages. |
| Trofatter, “imiquimod in clinical Practice”, European Journal of Dermatology, 8(7 Supp.):17-19 (1998)—Abstract, 1 page. |
| Tsai, et al., “Drug and Vehicle Deposition from Topical Applications: Use of In Vitro Mass Balance Technique with Minosidil Solutions”, J. Pharm. Sci., 81(8):736-743 (1992)—Abstract, 1 page. |
| Tsai, et al., “Effect of Minoxidil Concentration on the Deposition of Drug and Vehicle into the Skin”, International Journal of Pharmaceutics, 96(1-3):111-117 (1993)—Abstract, 1 page. |
| Tsai, et al., “Influence of Application Time and Formulation Reapplication on the Delivery of Minoxidil through Hairless Mouse Skin as Measured in Franz Diffusion Cells”, Skin Pharmacol., 7:270-277 (1994). |
| Tyring, “Immune-Response Modifiers: A New Paradigm in the Treatment of Human Papillomavirus”, Current Therapeutic Research, 61(9):584-596 (2000)—Abstract, 1 page. |
| Tzen, Jason T.C. et al. “Surface Structure and Properties of Plant Seed Oil Bodies.” Department of Botany and Plant Sciences, University of California, Riverside, California 92521. Apr. 15, 1992. 9 pages. |
| Uner, M. et al. “Skin Moisturizing Effect and Skin Penetration of Ascorbyl Palmitate Entrapped in Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) Incorporated into Hydrogel.” Pharmazie. 60. 2005. 5 pages. |
| Veron, et al., “Stability of Minoxidil Topical Formulations”, Ciencia Pharmaceutica, 2(6):411-414 (1992), Abstract, 1 page. |
| Wermuth, C.G. “Similarity in drugs: reflections on analogue design,” Drug Discovery Today, vol. 11, Nos. 7/8, Apr. 2006, pp. 348-354. |
| Williams, “Scale up of an olive/water cream containing 40% diethylene glycol momoethyl ether”, Dev. Ind. Pharm., 26(1):71-77 (2000). |
| Yamada and Chung, “Crystal Chemistry of the Olivine-Type Li(MnyFe1-y)PO4 and (MnyFe1-y)PO4 as Possible 4 V Cathode Materials for Lithium Batteries,” J. Electrochemical Soc., 2001, 148(8): A960-967. |
| “Coal tars and coal-tar pitches,” Report on Carcinogens, Twelfth Edition, 2011, 3 pages. |
| Adisen et al. “Topical tetracycline in the treatment of acne vulgaris,” J Drugs Dermatol., 2008, 7:953-5. |
| Baskaran et al., “Poloxamer-188 improves capillary blood flow and tissue viability in a cutaneous burn wound,” J. Surg. Res., 2001, 101(1):56-61. |
| Bell-Syer et al. “A systematic review of oral treatments for fungal infections of the skin of the feet,” J. Dermatolog. Treat., 2001, 12:69-74. |
| Boehm et al. 1994, “Synthesis of high specific activity [.sup.3 H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties,” J. Med. Chem., 37:408-414. |
| Carapeti et al., “Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects,” Dis Colon Rectum, 2000, 43(10):1359-62. |
| Cook and Mortensen, “Nifedipine for treatment of anal fissures,” Dis Colon Rectum, 2000, 43(3):430-1. |
| Dumortier et al., “A review of poloxamer 407 pharmaceutical and pharmacological characteristics,” Pharmaceutical Res., 2006, 23(12):2709-2728. |
| Ebadi et al., “Healing effect of topical nifedipine on skin wounds of diabetic rats,” DARU, 2003, 11(1):19-22. |
| Effendy and Maibach. “Surfactants and Experimental Irritant Contact Dermatitis.” Contact Dermatol., 1995, 33:217-225. |
| Elias and Ghadially, “The aged epidermal permeability barrier,” Clinical Geriatric Medicine, Feb. 2002, pp. 103-120. |
| Fantin et al., “Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (Quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus,” Antimicrob Agents and Chemothery, 1999, 39:400-405. |
| Fluhr et al., “Glycerol accelerates recovery of barrier function in vivo,” Acta Derm. Venereol,. 1999, 79:418-21. |
| Garti et al. “Sucrose Esters microemulsions,” J. Molec. Liquids, 1999, 80:253-296. |
| Hammer et al. “Anti-Microbial Activity of Essential Oils and other Plant extracts,” J. Applied Microbiology, 1999, 86:985-990. |
| Hwang et al. “Isolation and identification of mosquito repellents in Artemisia vulgaris,” J. Chem. Ecol., 11: 1297-1306, 1985. |
| Knight et al., “Topical diltiazem ointment in the treatment of chronic anal fissure,” Br. J. Surg., 2001, 88(4):553-6. |
| Kucharekova et al., “Effect of a lipid-rich emollient containing ceramide 3 in experimentally induced skin barrier dysfunction,” Contact Dermatitis, Jun. 2002, pp. 331-338. |
| Leive et al, “Tetracyclines of various hydrophobicities as a probe for permeability of Escherichia coli outer membrane,” Antimicrobial Agents and Chemotherapy, 1984, 25:539-544. |
| Luepke and Kemper, “The HET-CAM Test: An Alternative to the Draize Eye Test,” FD Chem. Toxic., 1986, 24:495-196. |
| Osborne and Henke, “Skin Penetration Enhancers Cited in the Technical Literature,” Pharm. Technology, Nov. 1997, pp. 58-86. |
| Padi. “Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms,” Eur J. Pharmacol, 2008, 601:79-87. |
| Palamaras and Kyriakis, “Calcium antagonists in dermatology: a review of the evidence and research-based studies,” Derm. Online Journal, 2005, 11(2):8. |
| Passi et al., Lipophilic antioxidants in human sebum and aging, Free Radical Research, 2002, pp. 471-477. |
| Perrotti et al., “Topical Nifedipine With Lidocaine Ointment vs. Active Control for Treatment of Chronic Anal Fissure,” Dis Colon Rectum, 2002, 45(11):1468-1475. |
| Repa et al. “All-trans-retinol is a ligand for the retinoic acid receptors,” Proc. Natl. Acad Sci, USA, 90: 7293-7297, 1993. |
| Ruledge, “Some corrections to the record on insect repellents and attractants,” J. Am. Mosquito Control Assoc, 1988, 4(4): 414-425. |
| Sakai et al., “Characterization of the physical properties of the stratum corneum by a new tactile sensor,” Skin Research and Technology, Aug. 2000, pp. 128-134. |
| Schaefer, “Silicone Surfactants,” Tenside, Surfactants, Deterg., 1990, 27(3): 154-158. |
| Simoni et al., “Retinoic acid and analogs as potent inducers of differentiation and apoptosis. New promising chemopreventive and chemotherapeutic agents in oncology,” Pure Appl Chem., 2001, 73(9):1437-1444. |
| Smith, “Hydroxy acids and skin again,” Soap Cosmetics Chemical Specialties, 1993, pp. 54-59. |
| Solans et al. “Overview of basic aspects of microemulsions,” Industrial Applications of Microemulsions, Solans et al Eds, New York, 1997, 66:1-17. |
| Squillante et al., “Codiffusion of propylene glycol and dimethyl isosorbide in hairless mouse skin,” European J. Pharm. Biopharm., 1998, 46(3):265-71. |
| Todd et al. “Volatile Silicone Fluids for Cosmetics,” 91 Cosmetics and Toiletries, 1976, 27-32. |
| Torma et al., “Biologic activities of retinoic acid and 3, 4-dehydroretinoic acid in human keratinoacytes are similar and correlate with receptor affinities and transactivation properties,” J. Invest. Dermatology, 1994, 102: 49-54. |
| USP23/NF 18 The United States Pharmacopeia: The National Formulary, US Pharmacopoeia, 1995, p. 10-14. |
| Van Slyke, “On the measurement of buffer values and on the relationship of buffer value to the dissociation constant of the buffer and the concentration and reaction of the buffer solution,” J. Biol. Chem., 1922, 52:525-570. |
| Van Cutsem et al., “The antiinflammatory efects of ketoconazole,” J. Am. Acad. Dermatol.,1991, 25(2 pt 1):257-261. |
| Wang and Chen, “Preparation and surface active properties of biodegradable dextrin derivative surfactants,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2006, 281(1-3):190-193. |
| Weindl et al., “Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects,” Skin Pharmacology and Physiology, 2004, 17: 207-213. |
| Xynos et al., “Effect of nifedipine on rectoanal motility,” Dis Colon Rectum, 1996, 39(2):212-216. |
| Yamada et al., “Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats,” J. Pharmacol. Exp. Ther., 2003, 307(1)17-23. |
| Paragraph E.3.1 of regulation (EC) No. 2003 (See Directive 67/548/EEC OJ 196, 16.8, 1967, p. 1. |
| Tzen et al., Lipids, proteins and structure of seed oil bodies from diverse species; Plant Physiol., 1993, 101:267-276. |
| Brown et al. “Structural dependence of flavonoid interactions with Cu2+ inos: implications for their antioxidant properties,” Biochem. J., 1998, 330:1173-1178. |
| Cloez-Tayarani. et al., “Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors,” Int. Immunol., 2003, 15:233-40. |
| “Mineral oil USP,” Chemical Abstracts Service Registry No. 8012-95-1, 2011, 7 pages. |
| “Tea tree oil,” Chemical Abstract No. 68647-73-4, 2012, 2 pages. |
| Lin et al., “Ferulic acid stabilizes a solution of vitamins c and e and doubles its protoprotection of skin,” J Invest Dermatol, 2005, 125:826-32. |
| “Arquad HTL8-MS,”AkzoNobel Functional Applications, retrieved on Mar. 18, 2013, Retrieved from the Internet: <URL: http://sc.akzonobel.com/en/fa/Pages/product-detail.aspx?prodID=8764>, 1 page. |
| “Can tuberous sclerosis be prevented?,” Sharecare, 2002, retrieved on Aug. 29, 2013, <URL: http://www.sharecare.com/health/autosomal-dominant-genetic-disorders/can-tuberous-sclerosis-be-prevented;jsessionid=850579B60520A907DE75930E061E60E6>, 2 pages. |
| “Crohn's Disease,” Merch Manual Home Edition, retrieved on Jan. 16, 2013, <http://www.merckmanuals.com/home/digestive_disorders/inflammatory_bowel_diseases_ibd/crohn_disease.html?qt=crohn's disease&alt=sh>, 3 pages. |
| “Dacarbazine,” Chemical Book, 2010, retrieved on Oct. 18, 2013, <URL: http://www.chemicalbook.com/ChemicalProductProperty_EN_CB7710656.htm>, 2 pages. |
| “Drug Index (Professional)—Dacarbazine,” BC Cancer Agency, Jun. 2004, retrieved on Oct. 18, 2013, <URL:http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Dacarbazine.htm>, 6 pages. |
| “Fully refined paraffin waxes (FRP Wax),” Industrial Raw Materials LLC, Feb. 21, 2008, retrieved on Aug. 22, 2013, <http://irmwax.com/Wax/Paraffin/fully_refined.asp> 1 page. |
| “Gas Gangrene,” Merch Manual Home Edition, 2008, retrieved on Jan. 16, 2013, <http://www.merckmanuals.com/home/infections/bacterial_infections/gas_gangrene.html?qt=gasgangrene&alt=sh>1 page. |
| “Human Immunodeficiency Virus Infection,” Merch Manual Home Edition, 2008, retrieved on Jan. 16, 2013, <http://www.merckmanuals.com/home/infections/human_immunodeficiency_virus_hiv_infection/human_immunodeficiency_virus_infection.html?qt=human immunodeficiency virus infection&alt=sh>, 11 pages. |
| “Minocycline (DB01017),” DrugBank, Feb 8, 2013, retrieved on Aug. 15, 2013, <http://www.drugbank.ca/drugs/DB01017>, 10 pages. |
| “New Nanomaterials to deliver anticancer drugs to cells developed,” Science Daily, Jun. 2007, retrieved on Oct. 14, 2013, <URL: http://www.sciencedaily.com/releases/2007/06/070607112931.htm>, 3 pages. |
| “Product Data Sheet for Meclocycline,” bioaustralis fine chemicals, Jun. 28, 2013, 1 page. |
| “Shear,” Vocabulary.com, retrieved on Aug. 23, 2013, <URL: https://www.vocabulary.com/dictionary/shear>, 3 pages. |
| “Sheer,” Vocabulary.com, retrieved on Aug. 23, 2013, <URL: https://www.vocabulary.com/dictionary/sheer>, 3 pages. |
| “View of NCT01171326 on Dec. 7, 2010,” ClinicalTrials.gov_archive, Dec. 7, 2010, retrieved on Sep. 9, 2013, <http://clinicaltrials.gov/archive/NCT01171326/2010_12_07>, 4 pages. |
| “View of NCT01362010 on Jun. 9, 2011,” ClinicalTrials.gov_archive, Jun. 9, 2011, retrieved on Sep. 9, 2013, <http://clinicaltrials.gov/archive/NCT01362010/2011_06_09>, 3 pages. |
| “What is TSC?,” Tuberous Sclerosis Alliance, Jan. 1, 2005, retrieved on Feb. 6, 2014, <URL: http://www.tsalliance.org.pages.aspx?content=2>, 3 pages. |
| Abrams et al., “Ciclopirox gel treatment of scalp seborrheic dermatitis,” Hydroxy-Piridones as Antifungal Agents with Special Emphasis on Onychomycosis, 1999, Chapter 8, 45-50. |
| Blaney and Cook, “Topical use of tetracycline in the treatment of acne,” Arch Dermatol, Jul. 1976, 112:971-973. |
| Chevrant-Breton, et al., “Etude du Traitement Capillaire <<Bioscalin>> dans les Alopecies Diffuses de la Femme”, Gazette Medicale, 93(17):75-79 (1986) [English abstract only]. |
| Cunha, “Minocycline versus Doxycycline in the treatment of Lyme Neuroborreliosis,” Clin. Infect. Diseases, 2000, 30: 237-238. |
| Durian et al., “Scaling behavior in shaving cream,” The Americal Physical Society, Dec. 1991, 44(12):R7902-7905. |
| Google search strategy for minocycline solubility, retrieved on Aug. 15, 2013, <http://www.googl.com/search?rls=com.microsoft%3Aen-us%3AIE-SearchBox&q-melocycline+solubility>, 1 page. |
| Harry, “Skin Penetration,” The British Journal of Dermatology and Syphillis, 1941, 53:65-82. |
| Lee et al., “Historical review of melanoma treatment and outcomes,” Clinics in Dermatology, 2013, 31: 141-147. |
| Livingstone and Hubel, “Segregation of form, color, movement, and depth: Anatomy, physiology, and perception,” Science, May 1988, 240:740-749. |
| Molins PLC v. Textron Inc., 48 F.3d 1172, 33 USPQ2d 1823 (Fed. Cir. 1995), 19 pages. |
| Natural Skincare Authority, “Disodium EDTA: Cosmetic Toxin Data,” 2011, retrieved on Nov. 17, 2013, http://www.natural-skincare-authority.com/DISODIUM-EDTA.html, 4 pages. |
| Neves et al., “Rheological Properties of Vaginal Hydrophilic Polymer Gels,” Current Drug Delivery, 2009, 6:83-92. |
| Prud'homme et al., Foams: theory, measurements and applications, Marcel Dekker, Inc., 1996, 327-328. |
| Purdy et al., “Transfusion-transmitted malaria: unpreventable by current donor exclusion guidelines?” Transfusion, Mar. 2004, 44:464. |
| Reregistration Eligibility Decision for Pyrethrins, EPA, Jun. 7, 2006, 108 pages. |
| Schmolka, “A review of block polymer surfactants,” Journal of the American Oil Chemists Society, Mar. 1977, 54: 110-116. |
| Schott, “Rheology,” Remington's Pharmaceutical Sciences, 17th Edition, 1985, 330-345. |
| Sciarra, “Aerosol Technology,” Kirk-Othmer Encyclopedia of Chemical Technology, Jul. 2012, 20 pages. |
| Scully et al., “Cancers of the oral mucosa treatment and management,” Medscape Drugs, Diseases and Procedures, Apr. 20, 2012, retrieved on Oct. 12, 2013, <http://emedicine.medscape.com/article/1075729-treatment>, 10 pages. |
| Sehgal, “ Ciclopirox: a new topical pyrodonium antimycotic agent: A double-blind study in superficial dermatomycoses,” British Journal of Dermatology, 1976, 95:83-88. |
| Softemul-165: Product Data Sheet, Mohini Organics PVT LTD, retrieved Apr. 10, 2014, http://www.mohiniorganics.com/Softemull65.html#, 1 page. |
| Sun Pharmaceutical Industried Ltd. v. Eli Lilly and Co., 611 F.3d 1381, 95 USPQ2d 1797 (Fed. Cir. 2010),7 pages. |
| Tavss et al., “Anionic detergent-induced skin irritation and anionic detergent-induced pH rise of bovine serum albumin,” J. Soc. Cosmet. Chem., Jul./Aug. 1988, 39:267-272. |
| Tirmula et al., “Abstract: D28.00011: Enhanced order in thinfilms of Pluronic (A-B-A) and Brij (A-B) Block copolymers blended with poly (acrylic acid),” Session D28: Block Copolymer Thin Films, Mar. 13, 2006, 1 page, Abstract. |
| “Alcohol,” Wikipedia, the free encyclopeida, retrieved on May 17, 2014, http://en.wikipedia.org/wiki/Alcohol, 17 pages. |
| Cole and Gazewood, “Diagnosis and Treatment of Impetigo,” Am Fam Physician, Mar. 15, 2007, 75(6):859-864. |
| Oranje et al., “Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study,” Dermatology, 2007, 215(4):331-340. |
| Clobetasol Propionate Cream and Ointment, Apr. 2006, retrieved Jul. 3, 2014, http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=994, 7 pages. |
| Gels, UNC, The Pharmaceutics and Compounding Laboratory, retrieved on Aug. 25, 2014, http://pharmlabs.unc.edu/labs/gels/agents/htm, 4 pages. |
| Griffin, “Calculation of HLB Values of Non-Ionic Surfactants,” Journal of the Society of Cosmetic Chemists, May 14, 1954, 249-256. |
| Klucel Hydroxypropylcellulose; Chemical and Physical Properties, Hercules Limited, copyright 1986, retrieved on Aug. 25, 2014, http://legacy.library.ucsf.edu/tid/cnf81a99/pdf, 35 pages. |
| Le Vine et al., “Components of the Goeckerman Regimen,” Journal of Investigative Dermatology, 1979, 73:170-173. |
| Omega-9 Fatty Acids (Oleic Acid), Orthomolecular.org, Dec. 2004, retrieved on Aug. 15, 2014, http://orthomolecular.org/nutrients/omega9.html. 1 page. |
| Polystyrene, Wikipedia the free encyclopedia, retrieved Apr. 21, 2014, http://web.archive.org/web/20060312210423/http://en.wikipedia.org/wiki/Polystyrene, 4 pages. |
| Vera et al., “Scattering optics of Foam,” Applied Optics, Aug. 20, 2001, 40(24):4210-4214. |
| Al-Mughrabi et al., “Effectiveness of Essential Oils and Their Combinations with Aluminum Starch Octenylsuccinate on Potato Storage Pathogens,” TEOP, 2013, 16(1):23-31. |
| Beauty Banter, “Interesting list of comedogenic ingredients!!!!!!!!!!!” QVC blog, Interesting list of comedogenic ingredients, 2014, 1-14. |
| Chemical Characteristics, The Olive Oil Source, © 1998-2015, retrieved on Jun. 12, 2015, http://www.oliveoilsource.com/page/chemical-characteristics, 10 pages. |
| CODEX Standard for Olive Oils and Olive Pomace Oils CODEX Stan 33-1981, Adopted in 1981, recently amended 2013, 8 pages. |
| Communication of a Notice of Opposition in European Application No. 03772600.7, dated Jan. 13, 2015, 36 pages. |
| Cremophor A Grades, BASF The Chemical Company, Jan. 2008, 6 pages. |
| Devos and Miller, “Antisense Oligonucleotides: Treating neurodegeneration at the Level of RNA,” Neurotherapeutics, 2013, 10:486-497. |
| Ellis et al., “The Treatment of Psoriasis with Liquor Carbonis Detergens,” J. Invest Dermatology, 1948, 10:455-459. |
| Luviquat Polymer Grades, BASF The Chemical Company, May 2012, 32 pages. |
| Mailer, “Chemistry and quality of olive oil,” NSW Dept. of Primary Industries, Aug. 2006, Primefact 227, 1-4. |
| Material Safety Data Sheet, Luvitol EHO, Caelo, Nov. 28, 2013, 4 pages. |
| Material Safety Data Sheet, Liquor carbonis detergens, Caelo, Nov. 28, 2013, 5 pages. |
| Material Safety Data Sheet, Mineral Oil, Macron Fine Chemicals, Oct. 24, 2011, 6 pages. |
| Oh et al., “Antimicrobial activity of ethanol, glycerol monolaurate or lactic acid against Listeria moncylogenes,” Int. J. Food Microbiology, 1993, 20:239-246. |
| Permethrin (Insecticide), Wildpro, retrieved on Jun. 4, 2015, http://widlpro.twycrosszoo.org/S/00Chem/ChComplex/perm.htm, 5 pages. |
| Refina, “Viscosity Guide for Paints, Petroleum & Food Products,” accessed Mar. 4, 2015, http://www.refina.co.uk/webpdfs/info_docs/Viscosity_guide_chart.pdf, 2 pages. |
| Rohstoffinformationen, Hoffmann Mineral, 2008, 8 pages (with English translation). |
| Thorgeirsdottir et al., “Antimicrobial activity of monocaprin: a monoglyceride with potential use as a denture disinfectant,” Acta Odontologica Scandinavica, Feb. 2006, 64:21-26 (Abstract only). |
| United States Standards for Grades of Olive Oil and Olive-Pomace Oil, United States Dept. of Agriculture, Oct. 25, 2010, 21 pages. |
| WebMD, “Psoriasis Health Center,” 2014, retrieved Apr. 13, 2015, http://www.webmd.com/skin-problems-and-treatments/psoriasis/psoriasis-symptoms, 3 pages. |
| WebMD, “Understanding Rosacea—the Basics,” 2014, retrieved Apr. 13, 2015, http://www.webmd.com/skin-problems-and-treatments/understanding-rosacea-basics, 5 pages. |
| Williams et al., “Acne vulgaris,” Lancet, 2012, 379:361-372. |
| Ziolkowsky, “Moderne Aerosolschaume in der Kosmetik (Modern Aerosol Foams in Chemical and Marketing Aspects),”, Seifen-Ole-Fette-Wachse, Aug. 1986, 112(13): 427-429 (with English translation). |
| Haw, “The HLB System: A Time Saving Guide to Surfactant Selection,” Presentation to the Midwest Chapter of the Society of Cosmetic Chemists, Mar. 9, 2004, 39 pages. |
| Allantoin, Römpp Online, retrieved on Sep. 23, 2015, https://roempp.thieme.de/roempp4.0/do/data/RD-O 1-01552, 5 pages. |
| Coconut Oil, Wikipedia, the free encyclopedia, retrieved on Jul. 3, 2015, https://en.wikipedia.org/wiki/Coconut_oil, 8 pages. |
| Communication of a Notice of Opposition in European Application No. 03772600.7, dated Sep. 24, 2015, 30 pages. |
| Communication of a Notice of Opposition in European Application No. 03772600.7, dated Sep. 23, 2015, 42 pages. |
| Diethyltoluamid, Wikipedia, the free encyclopedia, retrieved on Sep. 11, 2015, https://de.wikipedia.org/wiki/Diethyltoluamid, 12 pages. |
| Dimethylphthalate, Wikipedia, the free encyclopedia, retrieved on Sep. 11, 2015, http://de.wikipedia.org/wiki/Dimethylphthalat, 8 pages. |
| Everything but the Olive, (the Olive Oil Source 1998-2016). http://www.oliveoilsource.com/pageAchemical-characteristics). |
| Healy, “Gelled Emollient Systems for Controlled Fragrance Release and Enhanced Product Performance,” Cosmetics and toiletries, 2002, 117(2): 47-54. |
| Lamisil, Lamisil.http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm052213.pdf, Published: Apr. 2001. |
| Leunapon-F, Leuna-Tenside, Screenshot, retrieved on Sep. 18, 2015, http://www.leuna-tenside.de/2006_7_14_3143/2006_8_7 5750/2006_8_7 241/cas-68439-49-6, 1 page. |
| Mead, “Electrostatic Mechanisms Underlie Neomycin Block of the Cardiac Ryanodine Receptor Channel (RyR2),” Biophysical Journal, 2004, (87): 3814-3825. |
| Rowe et al., “Glyceryl Monooleate,” Handbook of Pharmaceutical Excipients, 2011, pp. 1-5, retrieved on Dec. 19, 2011, http://www.medicinescomplete.com/mc/excipients/current/1001938996.htm?q=glyceryl%20monooleate&t=search&ss=text&p=1# hit. |
| Rowe et al., “Octyldodecanol,” Handbook of Pharmaceutical Excipients, 2011, pp. 1-4, retrieved on Dec. 19, 2011, URL:http://www.medicinescomplete.com/mc/excipients/current/1001942450.htm?q=octyldodecanol&t=search&ss=text&p=1# hit. |
| Rowe et al., “Sucrose Palmitate,” Handbook of Pharmaceutical Excipients, 2011, pp. 1-5, retrieved on Dec. 19, 2011, URL:http://www.medicinescomplete.com/mc/excipients/current/EXP-TD-c46-mn0001.htm?q=sucrose%20stearate&t=search&ss=text&p=1# hit. |
| Rowe et al., “Sucrose Stearate,” Handbook of Pharmaceutical Excipients, 2011, pp. 1-4, retrieved on Dec. 19, 2011, URL:http://www.medicinescomplete.com/mc/excipients/current/EXP-TD-c11-mnOOO1-mnOOO1.htm?q=sucrose%20stearate&t=search&ss=text&p=3# hit. |
| RSES (Oil in Refrigerator Systems, Service Application Manual, 2009). |
| Security Datasheet, Luvitol EHO, Cetearyloctanoat, Nov. 27, 2013, 10 pages. |
| Sigma-Aldrich. http://www.sigmaaldrich.com/catalog/product/sial/p1754?lang=en® ion=. Published:Mar. 5, 2014. |
| Suppositories?, CareCure, http://sci.rutgers.edu/forum/showthread.php?4176-Suppositories. Published: Apr. 16, 2002. |
| Triethanolamine, haute.de, retrieved on Sep. 14, 2015, http://www.haut.de/service/inci/anzeige&id=16384&query=Triethanolamine&funktio . . . , 3 pages. |
| Valenta, “Effects of Penetration Enhancers on the In-vitro Percutaneous Absorption of Progesterone,” J. Phann Pharrnacol., 1997, 49: 955-959. |
| Wenninger et al., “International Cosmetic Ingredient Dictionary and Handbook,” The Cosmetic, Toiletry, and Fragrance Association, Washington, DC., 1997, vol. 1, 4 pages. |
| Williams et al., “Urea analogues in propylene glycol as penetration enhancers in human skin,” International Journal of Pharmaceutics, 1989, 36, 43-50. |
| Wu et al., “Interaction of Fatty Acid Monolayers with Cobalt Nanoparticles,” Nano Letters, 2004, 4(2): 383-386. |
| Kaur et al., “Formulation Development of Self Nanoemulsifying Drug Delivery System (SNEDDS) of Celecoxib for Improvement of Oral Bioavailability,” Pharmacophore, 2013, 4(4):120-133. |
| Material Safety Data Sheet, Butane, Gas Innovations, Sep. 7, 2007, 3 pages. |
| Material Safety Data Sheet, Carbon Dioxide, Airgas, Feb. 11, 2016, 11 pages. |
| Material Safety Data Sheet, Dimethyl Ether, Airgas, May 14, 2015, 12 pages. |
| Material Safety Data Sheet, N-Butane, Airgas, May 7, 2015, 13 pages. |
| Material Safety Data Sheet, Nitrous Oxide, Airgas, Feb. 11, 2016, 11 pages. |
| Material Safety Data Sheet, Propane, Airgas, Oct. 20, 2015, 12 pages. |
| Sanders et al., “Stabilization of Aerosol Emulsions and Foams,” J. Soc. Cosmet. Chem., 1970, 21:377-391. |
| Albrecht et al., “Topical minocycline foam for moderate to severe acne vulgaris: Phase 2 randomized double-blind, vehicle-controlled study results,” J. Am. Acad. Dermatol., 2016, 74(6):1251-1252. |
| Chapter 1 Meaning of HLB Advantages and Limitations 1980; 4 pages. |
| Material Safety Data Sheet, Squalane, TCI America, 5 pages, https://www.spectrumchemical.com/MSDS/TC1-H0096.pdf. Published: Oct. 6, 2014. |
| Sorbitan Esters, [online] retrieved on Jul. 1, 2016 from: http://www.drugfuture.com/chemdata/sorbitan-esters.html 2 pages. |
| Sreenivasan et al., “Studies on Castor Oil. I. Fatty Acid Composition of Castor Oil,” Journal of the American Oil Chemists Society. 1956, 33:61-66. |
| Abdullah, G.Z. et al. (Jan. 2013) “Carbopol 934, 940 and Ultrez 10 as viscosity modifiers of palm olein esters based nano-scaled emulsion containing ibuprofen” Pak J Pharm Sci, 26(1):75-83. |
| Craig, D.Q.M. et al. (Jul. 1994) “An investigation into the structure and properties of Carbopol 934 gels using dielectric spectroscopy and oscillatory rheometry” J Controlled Rel, 30(3):213-223 (Abstract). |
| European Patent Application No. 03772600.7 (Patent No. 1556009): Interlocutory Decision in Opposition Proceedings, dated Feb. 3, 2017, 54 pages. |
| European Patent Application No. 03772600.7 (Patent No. 1556009): Minutes of Oral Proceedings, dated Feb. 3, 2017, 6 pages. |
| Foamix Pharmaceuticals Ltd. (May 1, 2017) “Foamix Pharmaceuticals Announces Plans for Additional Phase 3 Trial for FMX101 in Moderate to Severe Acne,” Press Release [online]. Retrieved from: http://www.foamix.co.il/news.asp?nodeID=564&itemID=204, on Jun. 12, 2017, 5 pages. |
| Frankel, A.J. et al. (2010) “Coal Tar 2% Foam in Combination with a Superpotent Corticosteroid Foam for Plaque Psoriasis. Case Report and Clinical Implications” J Clin Aesthet Dermatol, 3(10):42-45. |
| Ghica, M.V. et al. (2011) “Design and optimization of some collagen-minocycline based hydrogels potentially applicable for the treatment of cutaneous wound infections” Pharmazie, 66:853-861. |
| Kanicky, J.R. and D.O. Shah (2002) “Effect of Degree, Type, and Position of Unsaturation on the pKa , of Long-Chain Fatty Acids” J Colloid and Interface Science, 256:201-207. |
| Kircik, L.H. and S. Kumar (Aug. 2010) “Scalp Psoriasis” J Drugs Dermatol, 9(8 Suppl):s101-s137. |
| Milton, D.T. et al. (2006) “A Phase I/II Study of Weekly High-Dose Erlotinib in Previously Treated Patients With Nonsmall Cell Lung Cancer” Cancer, 107:1034-1041. |
| Musial, W. and A. Kubis (2004) “Carbopols as factors buffering triethanolamine interacting with artificial skin sebum” Polim Med, 34(4):17-30 (Abstract). |
| Pharmaceutical Benefits Advisory Committee (PBAC) of Australia. PBAC Public Summary Document -Nov. 2014 Meeting(5 pages). |
| Penreco, “Intelligent Gel Technology Product Specifications,” Rev. 06/16 (2 pages). |
| Promius™ Pharma LLC (2012) Scytera™ (coal tar) Foam, 2%. Product Information Sheet, 1 page. |
| Sigma Aldrich, “Surfactants Classified by HLB Numbers” 2017 [online]. Retrieved from the Internet: www.sigmaaldrich.com/materials-science/material-science-products.html?TablePage=22686648, on Jul. 8, 2017 (3 pages). |
| Solodyn® (Minocycline HCl, USP) Prescribing Information; revised Jun. 2016, 2 pages. |
| Sung, J.H. et al. (2010) “Gel characterisation and in vivo evaluation of minocycline-loaded wound dressing with enhanced wound healing using polyvinyl alcohol and chitosan” Intl J Pharmaceut, 392:232-240. |
| Tamarkin, D. (2013) “Foam: A Unique Delivery Vehicle for Topically Applied Formulations” in: Formulating Topical Applications—a Practical Guide. Dayan N, Ed., Carol Stream, IL: CT Books, Chapter 9, pp. 233-260. |
| Tjulandin, S. et al. (2013) “Phase I, dose-finding study of AZD8931, an inhibitor of EGRF (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors” Invest New Drugs, 32(11:145-153. |
| Water Jel Technologies, “Material Safety Data Sheet for Neomycin Antibiotic Ointment,” Dec. 1, 2004, 7 pages. |
| WebMD (2017) “User Reviews & Ratings—Scytera topical” [online]. Retrieved Mar. 1, 2017; retrieved from the Internet: http://www.webmd.com/drugs/drugreview-151502-Scytera+topical.aspx?drugid=151502&drugname=Scyterai+topical&sortby=3 (2 pages). |
| Wrightson, W.R. et al. (1998) “Analysis of minocycline by high-performance liquid chromatography in tissue and serum” J Chromatography B, 706:358-361. |
| Zeichner, J.A. (2010) “Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas” J Clin Aesthet Dermatol, 3(9):37-40. |
| Aslam et al. (2015) “Emerging drugs for the treatment of acne” Expert Opin Emerging Drugs, 20:91-101. |
| Beuchat (Feb. 1983) “Influence of Water Activity on Growth, Metabolic Activities and Survival of Yeasts and Molds” J Food Prot, 46(2):135-141. |
| Brisaert, M. et al. (1996) “Investigation on the chemical stability of erythromycin in solutions using an optimization system” Pharm World Sci, 18(5):182-186. |
| Canavan et al. (2016) “Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review” Dermatol Ther, 6:555-578. |
| Fontana (Apr. 1999) “Pharmaceutical Applications for Water Activity” Pharmaceutical Online [online]. Retrieved from https://www.pharmaceuticalonline.com/doc/pharmaceutical-applications-for-water-activit- . . . , on Jan. 17, 2018 (4 pages). |
| Sarpotdar, P.P. et al. (Jan. 1986) “Effect of Polyethylene Glycol 400 on the Penetration of Drugs Through Human Cadaver Skin in Vitro” J Pharma Sci, 75(1):26-28. |
| Number | Date | Country | |
|---|---|---|---|
| 20070020213 A1 | Jan 2007 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60429546 | Nov 2002 | US | |
| 60492385 | Aug 2003 | US | |
| 60497648 | Aug 2003 | US | |
| 60530015 | Dec 2003 | US | |
| 60700702 | Jul 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10532618 | US | |
| Child | 11124676 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10835505 | Apr 2004 | US |
| Child | 11488989 | US | |
| Parent | 10911367 | Aug 2004 | US |
| Child | 10835505 | US | |
| Parent | 10922358 | Aug 2004 | US |
| Child | 10911367 | US | |
| Parent | 11124676 | May 2005 | US |
| Child | 10922358 | US |
